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ABSTRACT OF THE DISSERTATION
Characterizing the Humoral Response to Flavivirus Infection
by
Estefanía Fernández
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2019
Professor Michael S. Diamond, Chairperson
Flaviviruses are positive (+) sense, single-stranded RNA viruses of the Flaviviridae family
that are transmitted by mosquitoes. For our studies, we focused on Zika virus (ZIKV) and Japanese
encephalitis virus (JEV). Most human infections with ZIKV historically resulted in a mild selflimiting febrile illness. However, since 2013, a worldwide spread and increase in ZIKV infections
has been observed. Notably, ZIKV has been associated with autoimmune ascending paralysis
(Guillain-Barré Syndrome) and ophthalmologic effects in adults and intrauterine growth restriction
and microcephaly in developing fetuses. Current vaccine efforts utilize technologies implemented
for related flaviviruses (yellow fever virus (YFV), Dengue virus (DENV), and JEV) including
subunit-based, chemically inactivated, and live-attenuated vaccines. Furthermore, co-circulation
of flaviviruses, such as DENV and ZIKV in regions of South America, make it desirable to
generate a vaccine that protects against both.
JEV infections are usually clinically asymptomatic or result in a mild self-limiting febrile
illness. However, disseminated infection and viral penetration of the blood-brain barrier into the
central nervous system results in meningitis and encephalitis, which are associated with high

x

morbidity and mortality. Children are especially vulnerable to neuroinvasion due to lack of prior
immunity and the relative immaturity of their immune responses. Although vaccination programs
in endemic countries have decreased the incidence of disease, existing vaccines have limitations
including multiple dose requirements and reactogenicity. Finally, a major issue in vaccine efficacy
is the derivation from genotype III (GIII) strains, the concurrent diversity of JEV worldwide, and
the scarcity of efficacy testing across multiple genotypes. Currently, there are five genotypes of
JEV that encompass approximately 100 unique strains. In addition, the dominant genotypes vary
by country and are not static over time.
We are interested in understanding the immunologic restriction of flavivirus infection by
characterizing the interaction between viruses and the humoral response. We identified a panel of
mouse and human derived anti-ZIKV monoclonal mAbs and found that ZIKV specific mAbs
strongly neutralize multiple strains of ZIKV of Asian and African lineages compared to mAbs that
recognize a cross-reactive determinant. Additionally, we identified a novel conformational interdimer epitope that when bound, results in significant reduction in in vitro infection and in vivo
protection. We tested the prophylactic and therapeutic efficacy of the strongest neutralizing mAbs
in adult male mice for lethality and pregnant female mice for transplacental protection of fetuses.
We also tested a panel of anti-DENV mAbs derived from naturally infected patients. We confirmed
that EDE1 mAbs, which have stronger virus binding in the absence of glycosylation compared to
EDE2 mAbs, are more potent neutralizers of multiple ZIKV strains. We demonstrated that viral
seeding of immune privileged sites, such as testis and fetus, occurs by the second day postinfection and mAb administration after this may reduce but not eliminate viral burden and effects
in the acute and persistent stages of infection. For JEV, we generated a panel of mouse and human
anti-JEV mAbs. We identified a subset of domain I and domain III specific mAbs that can

xi

neutralize JEV strains representative of four different genotypes. Subsequent in vivo testing
demonstrated a broad range of effective doses that protected prior to and following infection with
highly virulent strains of JEV representative of multiple genotypes. We anticipate that further
understanding of epitope specificity for neutralization and protection is essential for understanding
the efficacy of current (for JEV) and future (for ZIKV) vaccines to multiple strains and genotypes.
Moreover, this will improve our understanding of correlates of protection of flavivirus vaccines
which remain poorly understood, apart from YFV.
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Chapter 1:
Introduction to Flaviviruses

This chapter is partially adapted from a review published in Current Opinions in Virology:

Fernandez E and Diamond MS. 2017. Vaccination strategies against Zika virus. Curr Opin Virol.
2017 Apr 19; 23: 59-67.

1

1.1 Overview of Flaviviruses
Flaviviruses, which form a genus in the Flaviviridae, include mosquito and tick-transmitted
arthropod-borne viruses. Flaviviruses with significant impact on human health and disease
include dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), yellow fever virus
(YFV), tick-borne encephalitis virus (TBEV), and Japanese encephalitis virus (JEV)

1–3

.

Historically, Flaviviruses are categorized by different vector transmission or sequence
relatedness

4,5

. By vector analysis, viruses are classified based on tick vectors, mosquito

vectors, and those not transmitted by arthropod vectors 4. Sequencing analysis of structural
(envelope protein) and non-structural proteins (NS3 and NS5) have found the viruses
distribute similarly between the clades distinguished (Figure 1.1) 5. Additionally, the clades
identified by sequencing analysis correspond to those observed by vector transmission 4.
1.2 Flavivirus virology and structure
Flavivirus genomes are organized as one open reading frame (ORF) encoding a single
polyprotein that is co- and post-translationally cleaved into three structural (capsid (C), premembrane/membrane (prM/M), and envelope (E)) and seven non- structural (NS) proteins by
host and viral proteases. The NS proteins are involved in viral replication and immune evasion,
among other functions 6–10.
Multiple copies of C protein bind a single copy of viral RNA and forms the nucleocapsid
(NC) that is contained within an endoplasmic reticulum (ER)-derived membrane 11,12. PrM has
two C-terminal transmembrane helices that anchor to the ER surface and assists in E protein
processing in the ER, folding during maturation, and prevents premature activation that may
otherwise occur at acidic pH 13,14.

2

Pulse-chase data of TBEV glycoproteins indicates that prM and E form a heterodimeric
complex soon after synthesis, and that prM is necessary for proper E protein folding 15. In the
immature state, prM and E form 60 icosahedral spikes that protrude from the membrane
surface and result in a slightly larger viral particle, ~600 Å

16

. The spikes are made up of

trimers of prM-E where prM functions as a cap for the DII-FL at the tip of the E protein16.
Maturation during transit through the trans-golgi network results in furin-mediated cleavage
of prM to M 17 (Figure 1.2). Upon cleavage of the prM and release of pr at neutral pH in the
extracellular space18, the virion rearranges to a mature structure with 90 E protein homodimers
in an anti-parallel orientation in rafts of three to form a herringbone array and a smooth virion
surface 19. The cleavage process is not completely efficient and may result in partially mature
virions. The transitions undergone by viral particles expose different epitopes on the E protein
that are essential for receptor-binding, entry, and fusion.
Potential N-linked glycosylation sites are found in structural and NS1 proteins 20–22, but the
quantity and sites may differ between flaviviruses. N-linked glycosylation may alter overall
protein structure and therefore impact host-range and cellular tropism. For example, DENV E
protein is glycosylated at positions N67 and N153 whereas WNV and JEV E proteins are
modified only at the analogous N154 in some but not all strains 23,24. Cryo-EM studies have
shown interactions between DC-SIGN on host cells and the N67 glycan on DV2

25

; this

interaction functions as an attachment factor to concentrate virus rather than as a bona fide
entry receptor 26,27. Mutations of N67, but not N153, of DV2 demonstrated a decrease in viral
replication in mammalian cells although no difference was observed in mosquito cells 28. In
contrast, mutation of N154 in WNV showed reduced replication in mosquito cells
mosquitoes

23

29

and

as well as decreased neuroinvasiveness 30. Finally, the presence or absence of

3

glycosylation sites may alter antibody binding and neutralization. E-dimer epitope (EDE)
mAbs (discussed in Chapter 4) are human-derived anti-DENV mAbs that have been
subdivided in EDE1 and EDE2 based on their binding affinity for glycosylation site in the 150
loop. EDE1 mAbs bind better in the absence of the glycan versus EDE2 mAbs, which bind
better in the presence of the glycan (discussed in Chapter 4) 2.
1.3 Flavivirus E protein
The E protein (~53 kDa) is the primary surface protein involved in cellular attachment,
fusion, and entry
and host range

26,27,31,32

19,33–35

. A receptor-binding domain is implicated in both cellular tropism

. The E protein also is the principal target for neutralizing antibodies.

Discussed in this section are characteristics common to flaviviruses. Unique features will be
discussed in the corresponding virus-specific sections below.
The E protein is subdivided into three domains: a central β-barrel domain (domain I, DI),
an extended dimerization domain containing a hydrophobic fusion loop (FL) epitope at the
distal end (domain II, DII), and an immunoglobulin-like segment implicated in receptorbinding and entry (domain III, DIII). Exposure to acidic pH in the endosome results in
rearrangement of the E protein, trimerization, and exposure of DII-FL, which facilitates
membrane fusion between the virus and the outer lipid layer of the host cell 36–39. The fusion
loop is highly conserved across flaviviruses and because of this, antibodies generated against
DII-FL are cross-reactive therefore lack type specificity. These anti-DII-FL antibodies
variably neutralize virions in part because of differential exposure of this epitope in the
ensembles of flavivirus structural states 40–43. In vivo studies using murine models have shown
a protective role for DII-FL specific antibodies, possibly through effector functions, but with
limited efficacy40,44.

4

DIII contains the putative receptor-binding domain and is also the region against which
highly effective neutralizing antibodies are made

45

. DIII is a continuous ~100 amino acid

residues that forms a beta (b)-barrel structure made up of six antiparallel strands resembling
an immunoglobulin constant domain 46. Single mutations generated by type-specific antibody
selection to flaviviruses have been mapped to DIII and more specifically, to similar regions
across multiple viruses 47. The lateral ridge (DIII-LR) epitope includes the N-terminal linker
region along with the BC, DE, and FG loops which, when folded, forms a single patch 46,48,49
and the A-strand epitope are primary sites for neutralizing epitopes by the humoral response.
In vivo studies of anti-DIII mAb administration prior to and following infection have shown
significant protection against flavivirus dissemination and subsequent lethality 43,48,50–53.
1.4 Flavivirus entry, replication, and assembly
Flaviviruses bind and enter target cells through clathrin-dependent receptor-mediated
endocytosis facilitated by surface glycoproteins and cellular receptors, including heparin
sulfate34,35, DC-SIGN27,54, and CLEC5A55,56. After low pH-dependent fusion between the
virus and host membranes in the endosome, uncoating of the nucleocapsid, and finally release
of the viral RNA genome into the host cytoplasm 57. The positive-sense RNA of flaviviruses
allows for immediate viral protein translation of the single open reading frame by host
machinery, cleavage of the polypeptide into viral proteins by host and viral proteases, and
subsequent viral replication mediated by NS5, the RNA-dependent RNA polymerase, 1,58,59.
Genome packaging occurs concurrently with RNA replication and immature viral particles
are assembled in the lumen of the ER60. Viral particles then bud from the endoplasmic
reticulum and once in the trans-Golgi, prM undergoes furin-mediated cleavage, and infectious
virus is released by exocytosis (as discussed above). Flaviviruses do not exist in a single

5

homogeneous state and can also be found as subviral particles (SVPs), immature forms, and
variants of the canonical mature form (partially mature virions). Subviral particles have an
outer surface made of E and M proteins and a lipid membrane that is smaller than a mature
viral particle and lacks genome content, and therefore is not subsequently infectious

18,61

.

Recombinant SVPs can be generated using in vitro systems; as they retain immunogenic
properties, they have been applied as vaccine platforms for inducing protective immunity.
Immature viruses exist in a non-infectious spiky configuration. Mature virus exists as the
smooth form often depicted but is also susceptible to variations in temperature and efficiency
of furin-mediated cleavage. For DENV, an increase in temperature from 28°C to 35°C results
in structural reorganization to generate a larger virion with a bumpier surface 62,63 which may
impact virus stability, in the case of ZIKV.
1.5 Antibody-mediated protection against enveloped viruses
Neutralizing antibody titers are commonly used as correlates of protection following
vaccination or natural infection 64. Virus neutralization is defined as antibody binding via the
Fab segment to the respective epitope on the virion and therefore inhibiting subsequent steps
of infection or production of viral progeny65.
Antibodies may also act through effector functions between the Fc segment and Fc
receptors (FcR) or complement proteins to protect against viral infection. Antibody-dependent
cellular cytotoxicity (ADCC) occurs when an antibody, for example HIV-1 mAb A32, detects
a virus-infected cell by the Fab segment and simultaneously engages effector cells, such as
natural killer cells, via the Fc region

66

. The complement system, particularly the classical

complement pathway, is implicated as an antiviral response as well as detrimental to the host
67,68

. Antibody mediated protection in vivo is an interplay of mAb-antigen interaction and the

6

effector functions initiated via Fc-FcR interactions on effector cells. For example, studies on
anti-influenza mAbs (anti-HA head) demonstrated a requirement of Fab-antigen binding to
initiate mAb-FcR interaction

69

. The development and functional testing of mAbs may be

limited by changes in the antigenic makeup of the virus over time, particularly for viruses with
error-prone polymerases, and changes in antigenic availability based on environmental factors,
such as temperature 62,63.
1.5.1

Antibody-defined epitopes in flaviviruses
The antibody response against flaviviruses is categorized by breadth of reactivity to
viruses within and between related serologic groups. DENV is often used to exemplify the
nomenclature as type-specific (a single DENV serotype), subcomplex-specific (more than
one serotype), complex reactive (all serotypes), or reactive to multiple flaviviruses (crossreactive). In many cases, type-specific mAbs most potently neutralize infection of a given
virus and allow distinction between closely related viruses.
Domain I is the central domain within the E monomer and together with DIII, forms a
hydrophobic pocket for the DII-FL from the opposing E monomer. Most antibodies
generated against DI are type-specific with limited in vitro neutralization potential
Within DI, the sites most commonly targeted are the DI-LR (e.g., bound by DV2-106

42

.

70

and WNV mAb E121 42) and the DI-DII linker region (e.g., bound by WNV mAbs CR4353
and 7G5 42,71). In vivo therapeutic studies show 35% survival for animals treated with E121
compared with only 10% survival for those treated with 7G5 42. A chimpanzee-derived
anti-DENV4 mAb, 5H2, mapped to DI by phage display library, neutralized three
independent strains of DENV4, and was able to protect rhesus monkeys from infectioninduced lethality72,73

7

One of the most immunodominant epitopes of the human humoral response to
flaviviruses falls within the DII-FL, residues 98-110. As discussed above, DII-FL is highly
conserved across flaviviruses, is transiently exposed during viral infection, and elicits a
cross-reactive, limited neutralizing humoral response. A single mutation at W101 is
sufficient to abolish binding of most DII-FL specific mAbs, although loss of binding is also
observed at residues G104, G106, and G107 42,74–78.
Studies on DENV, WNV, and YFV have mapped potent neutralizing mAbs to DIII,
specifically, there are two epitopes that have been found to be critical for binding. The DIII
A-strand is a short (~7 amino acid) segment made up of residues 305-313 on DENV that
is bound by complex and subcomplex-specific mAbs. DENV mAb 1A1D-2 is potently
neutralizing (PRNT50 = 0.3 ug/ml) and cross-reacts with DENV-1, DENV-2, and DENV3 79. Mapping studies showed binding of 1A1D-2 was sensitive to mutations at residues
305, 307, and 310 52. The DIII lateral ridge (DIII-LR) is a discontinuous epitope made up
of residues of the BC (330-333), DE (365-368), FG (389-391) loops, and N-termini linker
region. Antibodies that map to this region, such as WNV E16, are type-specific and
neutralize at nanomolar concentration (PRNT50= 4-18 ng/ml) 48,50.
Additional structural, quaternary epitopes have been identified that are comprised of
residues in multiple domains within E protein dimers. The E-dimer epitope (EDE) was first
identified through mapping of monoclonal mAbs generated from a DENV-infected patient
80

. The EDE is made up of DII-FL and additional DII residues along with DI and DIII

amino acids found in the opposite E subunit of the dimer (discussed in Chapter 4).
Additionally, CR4354 is a human mAb that binds a structural hinge region formed between
E-DI and E-DII but is unable to bind a linear epitope 81.

8

1.6 Zika virus
1.6.1

Unique features of the E protein
Since the ZIKV epidemic began, research groups have sought to understand the
cause of its emergence and its unique pathogenesis (i.e., congenital syndrome) that is not
observed for related flaviviruses. Cryo-EM data demonstrates general similarities between
the structures of mature ZIKV, DENV, and WNV. One difference is the protrusions of E
protein glycan seen on ZIKV, not present on related viruses

82

. ZIKV only has a single

glycosylation site (N154) compared to two glycosylation sites (N67 and the analogous
N153) observed on DENV

82

. A second potential difference is the stability of ZIKV E

protein on the virion, however, the data presented thus far has not demonstrated a
conclusive effect of physiologic temperatures on ZIKV E protein stability

83,84

. These

differences, along with differences in genetics (discussed below), have implications in the
development of cross-reactive and cross-neutralizing mAbs.
1.6.2

Vaccination strategies against Zika virus
This section is adapted from a review published in Current Opinions in Virology 85
Introduction Historically, Zika virus (ZIKV) infection caused a mild, self-limiting febrile
illness that was associated with conjunctivitis, rash, headache, myalgia, and arthralgia 86.
However, during the recent epidemics in Asia and the Americas, more severe and unusual
clinical consequences have been observed. Infection of fetuses during pregnancy,
particularly during the first trimester, has been associated with placental insufficiency and
congenital malformations including cerebral calcifications, microcephaly, and miscarriage
87–91

. In adults, ZIKV infection is linked to an increased incidence of Guillain-Barré

syndrome (GBS), an autoimmune disease characterized by ascending paralysis and

9

polyneuropathy 92 that occurs during the acute phase of ZIKV infection or shortly afterward
93–95

.
ZIKV was identified in 1947 from a sentinel Rhesus monkey in the Zika Forest of

Uganda

96,97

. Prior to 2007, seroprevalence studies in Asia and Africa suggested ZIKV

infections occurred periodically without evidence of severe disease

86,98

. Contemporary

outbreaks of ZIKV arose in 2007 on Yap Island in the Federated States of Micronesia
followed by an epidemic in French Polynesia in 2013 99; these events were associated with
a high prevalence of infection, with greater than 11% of people on the islands presenting
with ZIKV-associated symptoms 92,99. A study in French Polynesia of patients diagnosed
with GBS during the outbreak found that all had neutralizing antibodies against ZIKV
compared to 56% of patients presenting to hospitals with non-febrile illnesses 92. The next
ZIKV outbreak began in late 2014 in northeastern Brazil, which was followed by a rapid
spread to many other countries in the Americas in 2015 and 2016, including locallytransmitted infections in Florida and Texas in the United States 100–102. Associated with the
ZIKV epidemic were cases of GBS and congenital defects that correlated temporally with
the growing number of infections 94. Aedes aegypti and Aedes albopictus mosquitoes have
tested positive for ZIKV and are believed to be primary agents of transmission

103,104

. In

addition to mosquito vectors, sexual transmission of ZIKV was established from male-tofemale

105,106

and subsequently from male-to-male and female-to-male

107,108

. Diagnostic

studies have confirmed viral RNA in semen, sperm, and vaginal secretions of symptomatic
patients up to 6 months following the onset of symptoms 109–111.
ZIKV belongs to the Flavivirus genus of the Flaviviridae family of positivestranded, enveloped RNA viruses. ZIKV has an 11 kb RNA genome and one open reading

10

frame. Translation of infectious viral RNA in the cytoplasm generates a polyprotein that is
cleaved into three structural proteins (capsid (C), pre-membrane/membrane (prM/M), and
envelope (E)) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5). ZIKV strains are classified into two genetic lineages, African and
Asian/American. As the African lineage shows greater divergence 112, some studies have
divided them into two African subtypes 113. The existence of multiple lineages, however,
does not impact antibody neutralization significantly and thus, ZIKV has been classified
as a single serotype114. ZIKV is related genetically to several pathogens that cause disease
globally including Dengue (DENV), yellow fever (YFV), West Nile (WNV), Japanese
encephalitis (JEV), and tick-borne encephalitis (TBEV) viruses. Of these viruses, ZIKV is
most closely related to the four serotypes of DENV and shares 54–59% amino acid identity
across the viral E protein

115

. The sequence similarity between ZIKV and DENV poses

unique issues for diagnosis and vaccination, and has implications for disease pathogenesis
due to antibody cross-reactivity 115–118.
Studies on related flaviviruses have shown that antibody responses against the viral
E protein can serve as correlates of protection in animals and humans

43,71,119–121

. The

historical efficacy of the YFV, TBEV, and JEV vaccines in preventing infection and
epidemics suggests that an effective vaccine targeting all strains of ZIKV should be
feasible, especially given the limited (3–5%) amino acid variability between E proteins of
the two lineages 112. In terms of prioritization, pre-pubescent children and men and women
of child-bearing age living within or traveling to endemic areas might be priority recipients
in a ZIKV vaccination campaign (Figure 1.3) 122.
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ZIKV vaccine epitope targets of humoral immunity The ZIKV E protein is composed
of three ectodomains (DI, DII, and DIII), which are displayed on the surface of the virion
and contribute to entry into susceptible cells. A large proportion of anti-ZIKV antibodies
generated during human infection target the fusion loop present in DII (DII-FL), which is
highly conserved across flaviviruses. Animal studies have shown some protective activity
of DII-FL antibodies in the context of flavivirus infection even though they generally have
poor neutralizing capacity in vitro

41,44

. Most DII-FL antibodies are not ideal from a

protection perspective because their epitope is partially inaccessible on the mature virion
123

and they require Fc-dependent effector functions for in vivo activity, the latter of which

also is responsible for antibody dependent enhancement (ADE) of infection (see below)
124

. DIII adopts an immunoglobulin-like fold and is believed to participate in viral

attachment and entry to host cells, which could influence cellular tropism and host range
31,32,125

. The lateral ridge epitope within DIII (DIII-LR) is recognized by type-specific,

strongly neutralizing anti-ZIKV antibodies

117,126,127

(e.g., ZV-67 and Z004) that likely

block infection by preventing E protein rearrangements required for fusion 48,128. A panel
of mAb generated from an infected individual against DII (SMZAb2) and DIII (SMZAb1
and SMZAb5) protected rhesus macaques against heterologous infection, however, the
exact epitopes were unindentified129. Additionally, several classes of conformational antiZIKV antibodies that potently neutralize infection and recognize quaternary epitopes
formed by adjacent E proteins have been described. E-dimer-dependent (EDE) antibodies
(e.g., C10) bind to conserved sites along the E dimer interface to cross-link the E protein
in a prefusion state. Specifically, EDE antibodies bind to DII-FL and additional sites of DII
(b strand and ij loop) of one E subunit along with residues in DI and DIII of the opposite
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E subunit of the dimer2,130. Although originally identified in the context of a humoral
response to DENV

130

, cross-reactive EDE antibodies neutralize ZIKV infection in cell

culture and protect against lethal infection in mice

2,115,131–133

. Another conformational

epitope is recognized by neutralizing antibodies (e.g., ZIKV-117) that bind across two
adjacent ZIKV E protein dimers in DII. These inter-dimer binding antibodies can prevent
fetal infection and disease in pregnancy models of ZIKV in mice 117. A group of protective
human antibodies with distinct binding activity was described recently 118; Z3L1 and Z23
preferentially recognize ZIKV-specific epitopes in DI and DIII, respectively, whereas Z20
binds to an epitope in DII across the E dimer interface but in a distinct pattern from EDE
antibodies

118

. Collectively, these studies define a suite of protective antibodies that bind

distinct epitopes and suggest that vaccines capable of targeting accessible epitopes on the
soluble E protein or conformational epitopes on the virion should elicit polyclonal antibody
responses with broad protective activity against most, if not all, ZIKV strains.
ZIKV vaccine approaches Many approaches have been used for developing flavivirus
vaccines against YFV, DENV, JEV, WNV, and TBEV including subunit-based (protein or
DNA plasmid), chemically inactivated, and live-attenuated vaccines. Moreover, novel
lipid-encapsulated modified mRNA vaccines

134,135

and viral vectored vaccines

136

have

recently been adapted for ZIKV. Remarkably, in less than one year, several of these
vaccines have progressed beyond pre-clinical studies in animals and are advancing into
phase 1 human trials (Table 1.1). Additional platforms (e.g., live-attenuated vaccines) are
in pre-clinical testing and expected to enter human trials in 2017 137.
DNA and adenovirus-vectored vaccines Leading candidates for ZIKV immunization
include DNA plasmid-based and adenovirus-vectored vaccines incorporating the prM and
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E genes to produce a secreted E protein or subviral particle that elicits neutralizing antibody
response. DNA plasmid-based vaccines have utility due to their ease of production, relative
stability, and low reactogenicity

138

. Additionally, they lack risk of reversion, as can be

observed with some live-attenuated virus vaccines. One limitation of DNA plasmid
vaccines is that they must be introduced into cells (e.g., by electroporation) for optimal
protein production

139

. Their low reactogenicity, however, makes this vaccine class a

candidate for use in pregnant women

138,140

. Adenovirus-vectored vaccines share ease of

production and stability with DNA plasmid vaccines; additionally, they have broad cellular
tropism and can be manufactured to high titer, which allows for optimal delivery and
immunogenicity. Limitations for adenovirus vaccines include their ability to induce toxic
inflammatory responses at high doses, the potential for pre-existing immunity to naturally
occurring human adenoviruses that results in accelerated clearance and dampened
immunogenicity, and a size limit on the gene inserted

141

. Reactogenicity has been

circumvented by deletion of genes required for replication, which also allows for larger
inserts

141

. Identification of monkey adenoviruses as vaccine vectors can bypass pre-

existing immunity to human adenoviruses 142.
Full-length prM-E (amino acids 93-794) DNA vaccines from a French Polynesian
ZIKV strain (H/PF/2013) in a cytomegalovirus promoter-driven plasmid vector were
constructed with mutations in the signal sequence or the E protein stem and transmembrane
regions to improve expression 143. Immunization of six rhesus macaques using a prime and
boost scheme induced humoral immunity and protected against viremia independent of the
challenge dose of a heterologous ZIKV strain (PRVABC59) when administered eight
weeks after the boost

144

. Analysis of the pre- and post-challenge serum of immunized
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animals demonstrated an inverse correlation between neutralizing antibody titer and
viremia 144.
Engineering of the M-E genes (amino acids 216-794) of a Brazilian ZIKV isolate
(BeH815744) into a mammalian expression plasmid yielded high levels of humoral and
cellular immunity in BALB/c mice when assessed at three weeks following a single
immunization

143

. Upon challenge of BALB/c mice with homologous or heterologous

strains of ZIKV four weeks following immunization, the M-E plasmid vaccine abrogated
ZIKV viremia. Antibody mediated responses were sufficient to confer protection, as CD4+
or CD8+ T cell depletion did not impact vaccine efficacy and passive transfer of vaccinederived antibody to naïve mice protected against challenge

143

. Intramuscular

immunization of four rhesus macaques with this ME plasmid induced protective humoral
and cellular immune responses against a homologous strain of ZIKV, but only after
boosting 136.
Full-length prM-E (amino acids 93-794) from a ZIKV consensus sequence was
incorporated into a eukaryotic plasmid (pVax1) with the addition of an IgE leader sequence
to improve expression

145

. Serial immunization of wild-type and immunodeficient mice

induced humoral and cellular immunity that protected against challenge with a virulent
American strain of ZIKV (ZIKV-PR209). Notably, vaccination also reduced disease
severity in immunodeficient mice. Primary immunization of five rhesus macaques
promoted a humoral response that was enhanced upon boosting 145.
A rhesus adenovirus serotype 52 (RhAd52) vaccine encoding the M-E genes from
ZIKV BeH815744 induced broadly neutralizing humoral and cellular immunity after a
single dose in four rhesus macaques 136. The M-E sequence also was codon optimized and
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inserted into a replication-defective adenovirus

146

. A single immunization of female

C57BL/6 mice with RhAd52-M-E induced ZIKV-specific neutralizing IgG that was
augmented upon boosting. Immunized female mice were mated with naïve sires, and
neonatal mice were challenged with a heterologous ZIKV strain at day 7 after birth and
followed for 21 days 146. Maternally transmitted vaccine immunity protected suckling mice
against ZIKV-induced weight loss and lethality.
Modified mRNA vaccines Although lipid encapsulated modified mRNA vaccines have
been developed in the oncology field

147

, more recently they have been adapted for viral

vaccines, with two now described for ZIKV

134,135

. Many mRNA vaccines are non-

amplifying and all platforms lack the capacity to integrate into the genome

147

. Modified

mRNA vaccines contain a type I cap, a poly(A) tail, and untranslated regions that optimize
translation efficiency and intracellular stability as well as nucleoside modifications (e.g.,
introduction of pseudouridine bases) to minimize the indiscriminate activation of innate
immunity.
A lipid encapsulated mRNA vaccine encoding full-length prM-E of an Asian
(Micronesia 2007) strain of ZIKV induced robust neutralizing antibody responses in mice
against ZIKV

134

. Challenge studies with a heterologous African ZIKV strain (Dakar

41519) in immunodeficient (AG129) or immunocompetent (C57BL/6 and BALB/c) mice
showed protection against weight loss and lethality when a prime and boost regimen was
administered intramuscularly, and this effect was durable even 18-weeks after initial
vaccination. A modified prM-E mRNA vaccine encoding mutations destroying the
conserved fusion loop epitope in domain II of the E protein protected against ZIKV and
diminished production of antibodies enhancing DENV infection in cells or mice 134.
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A single intradermal dose of nucleoside-modified lipid encapsulated mRNA
vaccine encoding prM-E of ZIKV H/PF/2013 (French Polynesia) induced a strong antibody
response in C57BL/6 and BALB/c mice that persisted for 12- and 20-weeks, respectively
135

. Challenge with a heterologous Asian-American ZIKV (PRVABC59, Puerto Rico) at

2- and 20-weeks post vaccination yielded no detectable viremia. Furthermore, a single
intradermal dose inoculation of rhesus macaques also induced high levels of neutralizing
antibody

135

. Non-human primates challenged with the heterologous ZIKV strain

(PRVABC59) at 5-weeks following mRNA vaccination were protected from developing
viremia compared to placebo-immunized animals

135

. A single intramuscular dose of a

lipid-encapsulated mRNA vaccine showed increased serum neutralization titers and
decreased lethality in a lethal model of infection. The protective effect was particularly
observed when a modified vaccine was generated with an abrogated fusion loop epitope
(IgEsig prM-E FL) or substitution with the JEV signal sequence (JEVsig prM-E)134.
Inactivated virus vaccines Purified, inactivated whole virus vaccines have been
developed to circumvent issues associated with live-attenuated vaccines. This approach
eliminates the possibility of viral replication yet retains, to varying degrees, the antigenicity
of the structural proteins. Inactivated viral vaccines are considered desirable, especially for
populations that are relatively immunocompromised (newborns, elderly, acquired or
genetic immune deficiencies, or pregnant women) where live-attenuated virus vaccines
may be contraindicated

148,149

. Inactivated whole virus vaccines have been used

successfully for several flaviviruses including YFV, JEV, TBEV, and WNV (the latter for
veterinary use only) 150.
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An inactivated ZIKV vaccine (ZPIV) was developed based on a previous vaccine
targeting JEV 151. A Puerto Rican strain (PRVABC59) of ZIKV was cultured to high titer
in Vero cells, purified, and inactivated with formalin treatment 143. A single immunization
of BALB/c mice with alum-adjuvant ZPIV yielded ZIKV specific IgG titers (1/100) that
correlated with protection against challenge with a heterologous strain of ZIKV 143. ZPIV
testing in rhesus macaques also induced neutralizing antibodies and cellular immunity after
two doses

136,152

. Subsequent challenge of nonhuman primates with homologous or

heterologous strains of ZIKV resulted in complete protection against plasma viremia, or
viral RNA in urine, cerebrospinal fluid, colorectal, and cervicovaginal secretions 136.
Live-attenuated vaccines. Arguably, the most successful flavivirus vaccine is YF-17D, a
live-attenuated virus that was generated in the 1930s after 176 serial passages of the parent
YFV Asibi strain in mouse and chicken tissues 153,154. A single YF-17D dose induces high
levels of neutralizing antibodies in most individuals and confers protection in 95% of
recipients, which can last up to 40 years 154. A chimeric vaccine against JEV was developed
by substituting the prM-E genes of JEV into the backbone of the YF-17D capsid and nonstructural protein genes. Immunization of subjects in endemic regions with ChimerVax
JE™ resulted in responses that neutralized JEV strains of multiple genotypes 155,156 and is
available in Australia, Malaysia, Philippines, Thailand, and Myanmar

157

. This chimeric

vaccine platform also was adapted for DENV. Different industry groups have refined
tetravalent formulations incorporating either chimeric DENV-YFV virus strains (approved
as Dengvaxia1) or DENV-DENV chimera (phase 3 trials of TAK-003) to achieve an
attenuated strains for vaccination

158,159

. Although a multi-dose regimen of Dengvaxia1
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protected flavivirus-immune individuals from subsequent symptomatic DENV infection,
it had less efficacy for naïve subjects160,161.
Live-attenuated vaccines are a favored immunization strategy against flaviviruses
because of their ability to induce durable and effective adaptive immunity at relatively low
production cost162. However, they generally are avoided in immunocompromised
populations (including pregnant women) due to possible reversion and pathogenicity. For
YF-17D, there have been rare cases of vaccine associated neurotropic and viscerotropic
disease following immunization, especially in the elderly 148,154. Several groups have stated
an intention of developing live-attenuated ZIKV vaccines although to date, no data
showing immunogenicity or protection has yet been published 137. Recently, a single dose
of live-attenuated ZIKV vaccine lacking the 3’UTR (ZIKV-3’UTR-LAV) was
administered to C57BL/6 female mice 35 days prior to mating and a week later were
challenged with ZIKV. One week after challenge, dams and pups of vaccinated dams had
enhanced antibody titer, reduced viral burden. Furthermore, A129 male mice demonstrated
protection against viremia and testicular damage when challenged 30 days after
immunization. Lastly, a rhesus macaque model showed that immunization with ZIKV3’UTR-LAV was able to protect against challenge up to two months after infection163.
These studies demonstrate that live-attenuated vaccines are highly immunogenic and are
protective in multiple models of infection, including pregnancy but questions remain as to
their relative safety when tested in pregnant women.
ZIKV vaccine challenges Beyond the generation of an immunogenic vaccine that elicits
protective humoral and cell-mediated immunity, there are unique challenges to developing
a ZIKV vaccine: (a) Immune enhancement of heterologous DENV infection. The DENV
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complex is comprised of four genetically related serotypes. Whereas primary infection with
DENV generates a protective antibody response that protects durably against the
homologous serotype, secondary infection with a heterologous DENV serotype can result
in a severe capillary permeability shock syndrome. This disease is attributed in part to
ADE, whereby cross-reactive antibodies from the first DENV infection bind but fail to
neutralize the second DENV serotype, and instead augment infection in myeloid cells
expressing Fc-gamma receptors

124

. This phenomenon could be relevant to ZIKV

vaccination because DENV and ZIKV are related closely to one another, the two viruses
co-circulate, and their infections produce cross-reactive antibodies targeting the highly
conserved DII-FL epitope of the E protein. Indeed, studies in cell culture have confirmed
that ADE can occur reciprocally, with DENV and ZIKV antibodies augmenting infection
of ZIKV and DENV, respectively

115,164–166

. Moreover, anti-ZIKV human monoclonal

antibodies can enhance DENV infection and disease in mice

167

and reciprocally, anti-

DENV and anti-WNV polyclonal antibodies enhanced ZIKV infection and disease in mice
168

. If ZIKV antibody responses are shown to augment DENV infection and disease in

humans, vaccine strategies that minimize the generation of cross-reactive antibodies may
be required to avoid sensitizing ZIKV vaccine recipients to severe DENV infections. In
this case, soluble E protein or virus-like particle (prM-E) antigens that abrogate the DII-FL
epitope but retain other protective epitopes may be useful

31,75,134,169

. (b) Guillain–Barré

syndrome. Currently, there is an epidemiological association between ZIKV infection and
GBS, although a causal link has not yet been established. The pathogenesis of GBS might
be due to direct ZIKV infection of neurons and glial cells in the spinal cord or to
autoimmune-mediated targeting, possibly due to antibodies or T cells that cross react
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between viral and host antigens

95

. Prior to deployment of a ZIKV vaccine, it will be

important to confirm that the elicited humoral or cellular anti-ZIKV responses in humans
do not promote the development of GBS. (c) Pregnancy. Many vaccines are avoided during
pregnancy due to the possible risks of infection or inflammation to the developing fetus.
Indeed, vaccination prior to pregnancy remains the desired approach. Notwithstanding this,
retrospective analysis of administered live-attenuated or inactivated vaccines have failed
to establish conclusively adverse outcomes in fetuses of vaccinated mothers

170,171

. The

current recommendation is to administer vaccines if the disease risk outweighs the potential
of vaccine related effects 172. Several recent studies suggest a relatively high frequency of
adverse neurodevelopmental effects of fetuses of symptomatic and asymptomatic pregnant
women following ZIKV infection

91,173–175

. With current information, it remains difficult

to determine whether the risk of exposure to ZIKV in utero surpasses that associated with
immunization with certain classes of vaccines.
Conclusions The consequences of the ZIKV epidemic highlight the need for rapid
development and introduction of a vaccine. Decades of work on related flaviviruses have
provided mature vaccine technologies and platforms, many of which can be adapted for
use in immunocompromised and susceptible populations including children and pregnant
women. Currently, DNA plasmid, modified mRNA, and purified, inactivated vaccines
have demonstrated immunogenicity and protection in mice and nonhuman primates and
now are entering Phase 1 clinical testing in humans. While optimism remains high for
generating protective vaccines against ZIKV across multiple platforms, questions remain
about their safety because of the unique clinical manifestations of ZIKV and its genetic

21

and serological relatedness to DENV. Parallel discovery and epidemiological efforts are
needed to address these issues prior to widespread implementation of a ZIKV vaccine.
1.7 Japanese encephalitis virus
1.7.1

Virology
Genotypes of JEV are determined by sequence alignment and differences within
prM-E 176. There are 4 historically identified genotypes of JEV (genotype I, II, III, and IV)
differing by a minimum nucleotide divergence of 7%

177–179

and amino acid divergence

from 4.7-6.5%180. A fifth genotype (genotype V) has been identified, from a patient in
Malaysia, which has approximately 20% nucleotide divergence from previously
recognized isolates

178,181–183

. Sequence alignment with other members of the flavivirus

family has shown an ~78% E protein amino acid alignment between JEV and WNV

184

,

the most closely related virus. The variation in sequence likely explains the differential
mosquito vectors, pathogenicity, and immune system response against the two closely
related members.
Structural studies of JEV E protein have identified features that may have a role in
promoting viral stability. The JEV E dimer has less buried surface area compared to related
flaviviruses and different residue interaction between dimers 185. Furthermore, a cryo-EM
structure of JEV reveals spaces present between the E monomers, which may confer virus
stability and impact conformational changes during assembly and infection
1.7.2

186

.

Epidemiology
Encephalitic epidemics attributable to JEV infection have been reported since 1871
and the first large outbreak described in 1924

187

with more than 6,000 cases and 60%

fatality. JEV was originally isolated in 1934 from the brain of a fatal human encephalitic
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case in Tokyo

188

and in 1938 from Culex tritaeniorhynchus mosquitoes

188,189

. JEV,

particularly genotypes (G) II and IV, are known to be endemic in tropical regions of
Southeast Asia

190

where sporadic cases occur throughout the year, mainly affecting

children younger than 15 years of age

191

. Epidemic outbreaks of GI and GIII occur in

temperate and subtropical regions, such as Japan, following the rainy season 191.
Rural areas with open water sources serve as breeding grounds for JEV mosquito
vectors. Pigs 190 and wading birds 192 are considered the major reservoir and amplification
hosts as they develop high-titer viremia that can facilitate mosquito transmission. Wading
birds are commonly referred to as carriers because of their mid-level titers and ability to
travel larger distances and move between locations that have appropriate mosquito vectors
as part of the environment.
Incidence of disease has been reduced substantially in countries that have
implemented immunization and surveillance programs (see Current vaccines against JEV
section below). However, there are still unprotected rural populations in South and
Southeast Asia that are exposed and susceptible to JEV infection and disease due to their
proximity to amplifying hosts and the difficulty in obtaining a full course of vaccination
193

. Even with the implementation of JEV vaccination, 81% of annual JEV infections occur

in countries with vaccination programs 194.
1.7.3

Clinical presentation of disease
The annual incidence of clinical JEV infection worldwide is between <1 to >10 per
100,000, which is approximately 1% of those infected 195. In endemic areas, symptomatic
JEV infection is observed in children between the ages of 3 and 6-years old due to the
absence of previous immunity

196,197

. However, people living in areas of epidemic
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outbreaks or those traveling to endemic areas may be affected irrespective of age due to
the absence of a previous immune response 197.
Initial infection manifests 5-15 days after infection as non-specific febrile illness
accompanied by headache, malaise, and general discomfort. Patients with encephalitis
experience behavioral abnormalities, seizures, or neurological deficits

198,199

. One group

identified a poliomyelitis-like illness in 15% of children subsequent to JEV infection with
pronounced viremia 200, however, upper limb paralysis is more commonly observed 201,202.
Alternatively, older children and adults may present with behavioral abnormalities

203

.

Seizures occur especially among children, although still observed in adults, and when
present, correlate with a negative outcome 204. A combination of Parkinsonian effects and
dystonia are more indicative of a long, protracted illness 199.
1.7.4

Humoral immune response to JEV infection
Epidermal tissue-resident dendritic cell (DC) are among the first cells in humans to
detect JEV following arthropod-mediated transmission

205

. DCs are myeloid-derived

antigen presenting cells (APCs) that serve as a link between the innate and adaptive
immune systems. Skin-resident DCs internalize JEV, migrate to draining lymph nodes
(DLN) where they present antigen to T cells for clonal expansion and activation of effector
functions 206. The internalization of JEV leads to the maturation and migration of DCs to
the DLN and presents the opportunity for viral dissemination and pathogenesis.
The humoral immune response to flaviviruses is classified into primary, if first
exposure, or secondary, following an unspecified infection with an alternate flavivirus.
Primary infection results in early high levels of anti-JEV IgM in the serum and if
symptomatic, they are also present in the cerebrospinal fluid (CSF). The inability to mount
24

a robust IgM response during primary infection is associated with a poor outcome for JEV
and also WNV 207,208. The antibody response restricts viral replication and in its absence,
infectious virus can be isolated from blood of patients for prolonged periods

207

.

Alternatively, secondary infection with JEV following primary infection with a
heterologous flavivirus can result in high levels of cross-reactive anti-flavivirus IgG early
after infection 199,207.
1.7.5

Anti-JEV monoclonal antibodies
Kimuro-Kuroda et al. generated a panel of mAbs against JEV-JaGAr- 01 (GIII) in
BALB/c mice and found that JEV-specific mAbs against the E protein were better able to
neutralize JEV in vitro and protect in vivo 119,207,209. Studies in mice with non-neutralizing
mAbs found partial prophylactic protection though the mechanism was not further studied.
Distinct panels of mAbs from BALB/c mice immunized and boosted with JEV-Nakayama
(GIII) again showed that JEV-specific mAbs were better able to neutralize JEV in vitro
compared to cross-reactive mAbs; however, not all type-specific mAbs had strong
neutralization activity 120,210. One key finding was the identification of the E protein as the
antigenic determinant and specifically a 95 amino acid stretch, residues 303-398, required
for binding of highly neutralizing mAbs. However, administration of the fragment was
unable to confer prophylactic protection in mice infected with a heterologous strain, JEVBeijing (GIII). Specifically, E-DIII was identified as the target of strongly neutralizing
mAbs against JEV. such as E3.3, as has been observed with related flaviviruses46. NMR
spectrometry and alanine scan mutagenesis identified the top of the ß-barrel, and
specifically S331 and N332 to be important for mAb binding46,47. Computer modeling of
E3.3 bound with DIII shows S331 is closely contact with R94 and N332 was closely
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associated with Y27, Y32, and R9447. Distinct but spatially related epitopes are also
targeted by neutralizing mAbs, as judged by competition binding assays 120,211.
The shift in genotypes over time from GIII to GI has prompted investigators to
generate mAbs against GI strains. A group of mAbs were generated with in vitro crossneutralization to multiple genotypes and members of the serocomplex, including WNV and
DENV

212

. The use of humanized mAbs derived from immunized chimpanzees has also

provided a panel of cross-neutralizing mAbs that provide in vivo prophylactic protection
against a heterologous strain of the same genotype 213. To date, 8 panels of mAbs against
JEV have been published (Table 1.2).
1.7.6

Vaccines against JEV
There are currently 4 classes of licensed JEV vaccines used worldwide, depending
on the country. Vaccine trials have been limited to testing efficacy against GIII strains,
from which vaccines are derived due to the high prevalence of GIII strains. The first
vaccine, JE-VAX®, was licensed in Japan and was derived by inoculating young mice
intracranially with Nakayama or Beijing-1, infectious strains of JEV. The brains are
harvested, purified, and formalin inactivated. The recommended regimen is a three-dose
series with subsequent boost doses. The presence of animal products and development of
cell-based vaccine technologies have led to the discontinuation of this vaccine strategy.
Inactivated, cell-based vaccines, such as IXIARO®, are derived by culturing live virus in
immortalized animal cell lines and inactivating using formalin. A two-dose regiment is
required and an adjuvant may be included to further boost the immune response. This class
of vaccines is licensed for infants between 2-6 months old in contrast with remaining
vaccine platforms that may only be used in infants older than 8 months of age. A live-
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attenuated, cell-based vaccine, SA14-14-2, was formulated by passaging a wild-type
virulent strain of JEV, SA-14, in chick embryo cells. A single dose is required, an
advantage over previously described platforms particularly in remote areas where JEV is
endemic. Most recently, a chimeric JEV vaccine (ChimeriVax-JE) was developed based
on the YFV vaccine by replacing the structural genes for those of JEV. ChimeriVax-JEV
is a live, attenuated vaccine that is protective in mouse and non-human primate models
over a range of doses by assessing viremia and clinical signs

156,214,215

and when is

protective as a single dose without a further protection seen with a booster dose 216. Recent
work shows limited efficacy of current GIII-derived vaccine platforms against GV disease
in mouse model of infection

217

, indicating a need to reassess and potentially update the

available vaccines.
1.7.7

Conclusions
Current studies of anti-JEV mAbs are beginning to address the shift in genotype
and the impact of this on efficacy of current vaccine platforms. A key gap in our
understanding is how neutralizing epitopes differ across genotypes

212,213

. Additionally,

although mechanisms of neutralization have been hypothesized, it is important to
characterize the critical steps for infection and determine whether these are unique from
the steps inhibited by mAb binding and neutralization.
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Figure 1.1: Phylogenetic tree of the Flavivirus genus
The distribution of Flaviviruses depending on the proteins utilized for sequence alignment, the structural
envelope (E) amino acid sequence. The serocomplex is shown in the second column. The fourth column
denotes the grouping based on vector for transmission (adapted from Mukopadhyay et al., 2005).
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Figure 1.2: Conformational changes of JEV during maturation
During virus maturation, the E protein rearranges oligomeric conformation. The transition from immature
to mature virion exposes different epitopes that may impact viral binding and entry as well as humoral
immune response (adapted from Li et al., 2008).
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Figure 1.3: ZIKV vaccine candidates, targets, and challenges.
(Left) Current platforms entering Phase 1 clinical trials in humans include purified, inactivated virus
(adapted from Sirohi et al., 2016), DNA plasmid, adenovirus-vectored, and modified mRNA vaccines, all
of which have demonstrated pre-clinical efficacy in mice and non-human primates. The primary target
populations are indicated. (Right, top) Structural analysis of monoclonal antibodies derived from infected
mice and human subjects identified protective epitopes for vaccine targeting: Inter-dimer (adapted from
Sapparapu et al., 2016), Intra-dimer (EDE) (adapted from Barba-Spaeth et al., 2016), DIII-LR (adapted
from Ref. [47]), and DI-DII (adapted from Wang et al., 2016). (Right, bottom) Concerns for ZIKV vaccine
development and deployment include immune-mediated enhancement (ADE) of DENV infection
and Guillain–Barré syndrome (GBS) due to the possible induction of autoreactive antibodies and/or T
cells (latter not shown).
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Table 1.1: ZIKV vaccine candidates entering humans in 2016-2017
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Table 1.2: Summary of mAbs to JEV

mAb

Source

Immunization

Epitope

EC50

Citation

2B4

BALB/c

JEV E, E-DIII

394-397

500 ng/ml

218

7E5

BALB/c

JEV/sw/Chiba/88/2002

52, 276

1:102,400

212

52

1:102,400

212

B cell, TH

1:10

219

E protein

>1:890

220,221

JEV-733913

1:100

211

2.55-7.91 nM

213

3-3H8
P-JEV

Plasmid

Hs-1 to Hs-4

Swiss

NHA

JEV-733913

A3, B2, E3

Chimpanzee

JEVAX

503

BALB/c

JEV-JaGAr-01

E protein

1:32,000

207,209,222

J2

BALB/c

JEV-Nakayama

E-DIII

>1:640

120

E-DIII

>1:5120

120

J3
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Chapter 2:
Structural Basis of Zika Virus-Specific Antibody Protection
This chapter is adapted from a manuscript published in Cell:

Zhao H*, Fernandez E*, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA,
Pierson TC, Diamond MS, Fremont DH. 2016. Structural basis of Zika virus- specific
antibody protection. Cell. 2016 Aug 11; 166(4): 1016- 27.

H.Z., E.F., K.A.D., S.D.S., T.C.P., M.S.D., and D.H.F. designed the experiments. H.Z. generated
Fabs and performed the ELISA experiments. H.Z. and C.A.N. purified the recombinant proteins
and performed the BLI experiments. H.Z. and D.H.F. performed the crystallography
experiments. E.F. and D.J.P. generated the mAbs. E.F., D.J.P., S.D.S., and K.A.D. performed the
neutralization and enhancement assays and tested binding to SVPs. M.J.G. generated the ZIKV.
J.G. and E.F. performed infection studies. H.Z., C.A.N., E.F., K.A.D., T.C.P., and M.S.D.
analyzed the data. M.S.D., T.C.P., and D.H.F. wrote the manuscript with all authors providing
editorial comments.

45

2.1

Summary
Zika virus (ZIKV) infection during pregnancy has emerged as a global public health

problem because of its ability to cause severe congenital disease. Here, we developed six mouse
monoclonal antibodies (mAbs) against ZIKV including four (ZV-48, ZV-54, ZV-64, and ZV-67)
that were ZIKV specific and neutralized infection of African, Asian, and American strains to
varying degrees. X-ray crystallographic and competition binding analyses of Fab fragments and
scFvs defined three spatially distinct epitopes in DIII of the envelope protein corresponding to the
lateral ridge (ZV-54 and ZV-67), C-C’ loop (ZV-48 and ZV-64), and ABDE sheet (ZV-2) regions.
In vivo passive transfer studies revealed protective activity of DIII-lateral ridge specific
neutralizing mAbs in a mouse model of ZIKV infection. Our results suggest that DIII is targeted
by multiple type-specific antibodies with distinct neutralizing activity, which provides a path for
developing prophylactic antibodies for use in pregnancy or designing epitope-specific vaccines
against ZIKV.
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2.2

Introduction
Zika virus (ZIKV), a flavivirus transmitted by Aedes species mosquitoes, was
originally identified in 1947 from a sentinel rhesus monkey in the Zika forest of Uganda1,2.
It is closely related to the four serotypes of dengue (DENV) as well as other globally
relevant viruses including yellow fever (YFV), West Nile (WNV), and Japanese
encephalitis (JEV) viruses3. Since its identification almost 70 years ago, there were few
studies of ZIKV until this past year, when large epidemics in the Americas were
accompanied by unexpectedly severe clinical manifestations. Although in most instances
ZIKV infection results in a mild febrile illness associated with rash and conjunctivitis,
severe neurological phenotypes have been described including Guillain-Barré syndrome
and meningoencephalitis4,5. Infection in pregnant women6 and mice7–9 is now linked
causally to fetal abnormalities including microcephaly, spontaneous abortion, and
intrauterine growth restriction due to placental insufficiency. Like other flaviviruses, ZIKV
is a positive-sense RNA virus with an ~11-kilobase open reading frame flanked by 5’ and
3’ non-coding regions. The genome encodes a single polyprotein that is post-translationally
cleaved by host and viral proteases into three structural proteins (capsid [C], pre-membrane
[prM], and envelope [E]) and seven non-structural proteins. C forms a nucleocapsid when
bound to viral RNA; prM complexes with E shortly after synthesis to facilitate folding and
prevent premature fusion to host membranes; and E mediates viral assembly, attachment,
entry, and fusion. The ZIKV E protein is divided into three domains: a central b-barrel
domain (domain I [DI]), an extended dimerization domain (DII), and an immunoglobulinlike segment (DIII)10. The distal end of DII contains the fusion loop (FL), a hydrophobic
sequence that inserts into the host cell endosomal membrane during pH-dependent
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conformational changes that drive fusion. Two high-resolution cryoelectron microscopic
structures show that, like other flaviviruses, mature ZIKV virions are smooth particles that
incorporate 180 copies each of the E and cleaved M proteins11,12. As in DENV13, the E
proteins of ZIKV pack as antiparallel dimers in a herringbone pattern that lie relatively flat
against the lipid envelope. Neutralizing antibodies have important roles in the protection
against infection by many flaviviruses and are considered correlates of protection for
licensed YFV and tick-borne encephalitis virus (TBEV) vaccines14,15. The E protein is a
primary antigenic target of neutralizing antibodies, which bind epitopes in all three
structural domains, with many type-specific protective antibodies recognizing
determinants in DIII16–19. Potently neutralizing anti-flavivirus antibodies also recognize
complex quaternary epitopes composed of more than one domain or E protein20–22. In
comparison, antibodies that recognize the fusion loop in DII are more cross-reactive and
neutralize flaviviruses less efficiently, although they may still have protective activity in
vivo10,23,24. In this study, we developed six mouse monoclonal antibodies (mAbs) against
ZIKV after immunizing with live virus and boosting with infectious virus or recombinant
E proteins. Four of the mAbs (ZV-48, ZV-54, ZV-64, and ZV-67) neutralized infection of
African, Asian, and American strains of ZIKV to varying degrees, whereas two (ZV-2 and
ZV-13) inhibited infection poorly. High-resolution crystal structures were determined for
three Fabs and one single-chain variable fragment (scFv) bound to DIII, defining three nonoverlapping conformational epitopes: the lateral ridge (LR) (ZV-54 and ZV-67), the C-C’
loop (ZV-48 and ZV-64), and the ABDE sheet (ZV-2). In vivo passive transfer studies in a
lethal mouse model of ZIKV infection revealed protective activity of neutralizing DIII LR
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mAbs. Overall, our results suggest that DIII is targeted by several different type-specific
antibodies with distinct neutralizing activities.
2.3

Results
Generation of mAbs against ZIKV E Protein. To generate a panel of antibodies against
ZIKV, we serially infected Irf3-/- mice 30 days apart with ZIKV MR-766 (Uganda, 1947)
and ZIKV H/PF/2013 (French Polynesia, 2013). Irf3-/- mice were used instead of wildtype (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated
immunity25,26. 3 days before myeloma-splenocyte fusion, mice were boosted intravenously
with ZIKV H/PF/2013 or recombinant DIII (amino acids 299 to 407 of the ZIKV E
protein). After screening ~2,000 hybridomas, we isolated six mAbs that recognized ZIKV
E protein by ELISA (Table 2.1).
We tested the mAbs for their specificity by evaluating reactivity with cells infected
by ZIKV, DENV (all four serotypes), or JEV. Five of the mAbs (ZV-2, ZV-48, ZV-54,
ZV-64, and ZV-67) were ZIKV specific and did not recognize DENV- or JEV-infected
cells by flow cytometry (Figure 2.1A; data not shown); these mAbs all bound to
recombinant ZIKV DIII in a direct ELISA (Figure 2.1B). In contrast, ZV-13 was crossreactive and bound to cells infected with all serotypes of DENV (Figure 2.1A). Consistent
with these data, only ZV- 13 bound to WNV E protein, as detected by ELISA (Figure
2.1B). ZV- 13 recognized the conserved FL in DII, as binding was lost to a ZIKV E protein
with mutations in highly conserved residues within and immediately proximal to the FL
(Figure 2.1B).
Neutralizing Activity against ZIKV In Vitro. We evaluated the mAbs for their ability to
inhibit ZIKV H/PF/2013 infection. Four (ZV-48, ZV-54, ZV-64, and ZV-67) of the six
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mAbs had neutralizing activity, whereas two (ZV-2 and ZV-13) did not inhibit infection
appreciably (Figure 2.1C). To determine the breadth of their activity, the mAbs were
evaluated for inhibition of infection by three other ZIKV isolates including two African
(MR-766, Uganda, 1947 and Dakar 41519, Senegal, 1982) and an American (Paraiba,
Brazil, 2015) strain. Whereas ZV-54 and ZV-67 neutralized all four ZIKV strains, ZV-48
and ZV-64 had reduced inhibitory activity against the other tested strains (Figure 2.1C;
Table 2.1).
Binding Characteristics of Anti-ZIKV mAbs. We next assessed whether the variation in
neutralizing activity among our antibodies could be explained by differences in binding to
the ZIKV E protein derived from H/PF/2013. Based on the ELISA data (Figure 2.1B), we
tested the mAbs for binding to a recombinant DIII produced in E. coli using biolayer
interferometry (BLI) (Figure 2.2A; Table 2.1) or, for the fusion-loop epitope binding ZV13, the monomeric form of the ectodomain of E expressed in mammalian cells (Figure
2.3; Table 2.1). These biophysical analyses showed that mAbs with stronger neutralizing
capacity had greater binding affinities for recombinant proteins. The best neutralizing
antibodies, ZV-54 and ZV-67, had the highest affinities with KD equilibrium values less
than 10 nM. These two mAbs also showed the slowest dissociation rates, with half-lives of
33 and 13.8 min, respectively. The mAbs with intermediate neutralizing capacity, ZV-64
and ZV-48, had lower affinities, with KD equilibrium values around 35 nM, and more rapid
off rates, having half-lives of 1 and 3.2 min, respectively. ZV-2 and ZV-13, which do not
inhibit infection appreciably, showed weaker binding, with KD equilibrium values >250
nM.
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Based on the interactions of individual mAbs with purified ZIKV proteins, we
speculated that differences in the stoichiometry of binding to the viral particle, which also
is a function of epitope accessibility27, might correlate with our neutralization data. To test
this idea, we captured purified ZIKV subviral particles (SVPs, prM-E) on 96-well plates
and analyzed binding of biotinylated detection mAbs over a range of concentrations. There
was an association between the functional avidity of binding and the ability to neutralize
infection: ZV- 67 and ZV-54 bound more avidly than did ZV-2 and ZV-13 (Figure 2.2B).
These data also showed that even at the highest concentrations tested, ZV-2 and ZV-13
failed to saturate binding to the SVPs.
We confirmed these results with pseudo-infectious reporter virus particles (RVPs)
in a functional assay. Antibody-mediated neutralization requires engagement of the virions
by antibody with a stoichiometry sufficient for neutralization. Antibody-dependent
enhancement of infection (ADE) occurs following engagement of the virion by fewer
antibody molecules and thus represents a sensitive functional probe for antibody binding
to an infectious virion. We evaluated the antibody concentration dependence and
magnitude of ADE of ZIKV and DENV by our anti-ZIKV mAbs using an established assay
(Pierson et al., 2007) in Fcg receptor II (FcgRII, CD32A) expressing human K562 cells.
While all ZIKV mAbs enhanced infection to varying degrees, those which bound SVPs
weakly (e.g., ZV-2) only supported FcgRII-mediated infection at high concentrations
(Figure 2.2C). Reciprocally, as described previously for WNV antibodies (Pierson et al.,
2007), the most inhibitory anti-ZIKV mAbs (ZV-54 and ZV-67) exhibited ADE, but this
occurred only at sub-neutralizing concentrations. These experiments also corroborated the
type-specificity of the mAbs, as only ZV-13 supported ADE of DENV. This latter
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observation suggests that at least some ZIKV-specific antibodies generated during natural
infection can enhance DENV infection in vitro.
Structures of ZIKV Antibodies in Complex with DIII. To gain insight into the basis for
differential binding and neutralization of the ZIKV mAbs, we generated Fab fragments or
scFvs and undertook crystal screening using DIII of ZIKV H/PF/2013. X-ray crystal
structures were obtained for four antibody complexes with DIII: ZV-2 Fab to 1.7-A˚
resolution, ZV-48 scFv to 1.7-A˚ resolution, ZV-64 Fab to 1.4-A˚ resolution, and ZV-67
Fab to 1.4-A˚ resolution (Figure 2.4A; data collection and refinement statistics in Table
2.2 and antibody-antigen structural analysis in Tables 2.3, 2.4, and 2.5). In all four
complexes, ZIKV DIII adopts a conserved structure nearly identical to that observed in
soluble E dimers10 as well as mature virions11,12 with variation observed primarily at the
N- and C-terminal regions of the domain. Analysis of antibody contact residues indicates
that ZV-2 and ZV-67 binding is dominated by heavy chain complementarity determining
region (CDR) usage, whereas ZV-48 and ZV-64, which appear to be siblings and engage
DIII in a similar manner, primarily use light-chain CDRs (Tables 2.3, 2.4, and 2.5; Figure
2.5). Notably, 10 of 12 light chain CDR contact residues are identical in ZV-48 and ZV64, whereas only 2 of 11 heavy-chain CDR residues are the same, with the most significant
difference in the short CDRH3 of ZV-48 that makes more contact with DIII than the long
CDR-H3 found in ZV-64 (Figures 2.4A and 2.5). Comparison of the sequences of ZV-67
with ZV-54, for the latter of which we lack structural data, suggests that they bind DIII
very similarly, as only two contact residues differ, CDR-L3 Tyr/PheL96 and CDR-H1
Ser/ThrH31.
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ZIKV mAbs Bind Three Spatially Distinct Epitopes on DIII. Analysis of the docking
of our mAbs onto DIII indicates that ZV-2 and ZV-67 binding should not compete with
ZV-48 or ZV-64 binding, whereas ZV-48 and ZV-64 should compete with each other
(Figure 2.4B). To evaluate this prediction experimentally, we set up a competitive BLI
assay (Figure 2.4C). When ZV-67 was immobilized, we observed that both ZV-64 and
ZV-2 could bind in a DIII-dependent manner. In contrast, ZV-54 binding was excluded,
supporting the idea that ZV-67 and ZV-54 recognize the same DIII determinants.
Analogously, immobilized ZV-48 allowed for the binding of ZV-67 and ZV-2 after DIII
capture, but ZV-64 was blocked competitively. This analysis strongly supports our
structural observations and defines three distinct ZIKV type-specific epitopes on DIII.
ZIKV DIII Epitope Mapping. We examined the precise footprints of our mAbs on ZIKV
DIII (Figure 2.6A and 2.6B). ZV-2 binds to a large, fairly flat surface on the exposed face
of the ABDE b sheet of DIII (Table 2.3). The ABDE sheet epitope is highly conserved
among ZIKV sequences but many of the primary contacts diverge in other flaviviruses.
Previous structural studies of the DENV cross-reactive mAb 2H12 revealed that it contacts
six of the same residue positions, especially near the A-B loop28. ZV-48 and ZV- 64 both
engage the C- and C’-b strands and connecting loop, which project away from the b
sandwich core of DIII. The C-C’ loop epitope recognized by ZV-48 and ZV-64 is
remarkably similar to that engaged by the DENV-1 type-specific antibody E11129, with 9
structurally related positions contacted (Figure 2.6A).
The epitope recognized by ZV-67 is created by four discrete secondary structure
elements: the A-strand, B-C loop, D-E loop, and F-G loop. A total of 21 residues are
contacted by ZV-67, with only one difference between the two ZIKV immunizing strains
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(EE393 in H/PF/2013, DE393 in MR-766). This epitope region has been termed the LR and
was described in relation to the binding of the potently neutralizing E16 mAb to WNV
DIII30. Notably, 13 contact positions of E16 and WNV DIII are shared by ZV-67 (Figure
2.6A). DV1-E106 is another mAb recognizing the LR-epitope31, and it shares 10 contact
positions with ZV-67, four of which are conserved in the B-C loops of WNV and ZIKV.
Another related DIII epitope (termed the A-strand) has been described for two DENVcomplex-specific mAbs, 1A1D-232 and 4E1133 (Figure 2.6A). These A-strand epitope
binding mAbs do not make significant contact with the B-C or F-G loop residues engaged
by LR-epitope mAbs. Collectively, the three distinct ABDE sheet, C-C’ loop, and LR
epitopes recognized by our mAbs represent nearly one half of the total ZIKV DIII surface
area with no overlap in the contact residues.
Exposed and Cryptic ZIKV Epitopes. We docked our mAb-DIII structures onto the
cryoelectron microscopy (cryo-EM)-derived model of the mature ZIKV virion11,12.
Whereas the LR epitope for ZV-67 was accessible on the mature virion (Figure 2.7A), the
C-C’ loop and ABDE sheet epitopes were occluded almost completely in all three
symmetry environments. We next examined the exposure of the ABDE sheet epitope on
the E ectodomain crystal structure10 and found that Fab binding is blocked sterically due
to the adjacent positioning of DI (Figure 2.7B). Furthermore, dimerization of E would
preclude ZV-2 mAb binding as its CDR loops contact several of the same DIII residues
that are contacted by DII residues in the dimer. Examination of the binding of ZV-64
reveals that it likely engages the cryptic C-C’ loop epitope in a manner similar to the
DENV-1 specific mAb DV1-E11129 (Figures 2.7C and 2.7D). Residues on the C-C’ loop
are intimately involved in lateral E protein contacts on the mature virion, so their exposure
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would require substantial reorganization of the particle, which perhaps could occur locally
rather than globally. Our most potent mAbs, ZV-67 and ZV-54, recognize the LR epitope
in a manner similar to WNV-E16, which can bind up to 120 of the 180 copies of DIII on
the mature virion30,34 (Figures 2.7C and 2.7E). This is the same stoichiometry observed
for the binding of the A-strand-specific mAb 1A1D-232, which like 4E1133, can broadly
neutralize multiple DENV serotypes (Figure 2.7F). The clustering of DIII LR epitopes
around the 5-fold axis of symmetry appears to preclude binding at this site (Figure 2.7A),
although minor repacking of the interface could lead to possible binding31.
In Vivo Protection Studies. Recently, we and others have generated in vivo models of
ZIKV pathogenesis in mice deficient in type I IFN signaling25,26. To evaluate whether
neutralizing mAbs protected against ZIKV infection in vivo, we treated 4- to 5-week-old
WT C57BL/6 mice at day 1 with anti-Ifnar (2 mg) and anti-ZIKV or isotype control mAbs
(250 mg) and then infected animals at day 0 with an African ZIKV strain that is more
pathogenic in mice than isolates from Asia or the Americas25. Treatment of mice with antiIfnar mAb and a non-binding isotype control mAb (CHIKV-166) resulted in high levels of
ZIKV RNA in serum at day 3 (Figure 2.8A) and significant weight loss and mortality
(Figures 2.8B and 2.8C). In comparison, treatment with anti-Ifnar mAb and the DIII LR
mAbs ZIKV-54 or ZIKV-67 resulted in reduced viremia and complete clinical protection.
Consistent with a recent vaccine study that showed antibody-mediated protection against
ZIKV viremia in BALB/c mice35, our neutralizing anti-ZIKV mAbs can protect against
lethal ZIKV infection in IFN-deficient C57BL/6 mice. This model is a stringent test of
protection, since in humans, the overwhelming majority of infections does not result in
lethality.
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2.4

Discussion
We set out to develop a panel of mAbs against ZIKV that could provide insight into
epitopes that are recognized by neutralizing antibodies. After inoculating mice with
infectious ZIKV, we generated and characterized a panel of ZIKV-specific mAbs at both
the functional and structural level. Four of the mAbs were ZIKV specific, bound to sites
within DIII, and neutralized infection of a contemporary Asian strain of ZIKV. Whereas
ZV-54 and ZV- 67 neutralized other ZIKV strains efficiently, ZV-48 and ZV-64 showed
reduced inhibitory activity against American and African ZIKV strains. Sequence analysis
of the VL region of ZV-48 and ZV-64 suggest they are sibling clones, although the VH
domains of the IgG heavy chains are distinct and make little contact with DIII. In
comparison, the functionally related ZV-54 and ZV-67 mAbs have highly similar VL and
VH sequences (Figure 2.5). From these analyses, we defined three spatially distinct typespecific epitopes on ZIKV DIII (LR, C-C’ loop, and ABDE sheet) with functionally
different properties. Finally, in vivo passive transfer studies revealed protective activity of
ZV-54 and ZV- 67 against an African ZIKV strain in a lethal challenge model in mice.
Type-specific protective and neutralizing mAbs in DIII have been observed in
studies with other flaviviruses. As no other ZIKV-specific mAbs have been described to
date, it remains uncertain whether the DIII epitopes reported here are immunodominant in
humans. However, antibodies to DIII, which is prominently displayed on the surface of
flaviviruses (Pierson and Diamond, 2013), appear less dominant in the human response
against other flaviviruses36–38. The structures of three other antibodies with reactivity
against ZIKV have been published recently. Dai et al. (2016) described the 3.0-A˚ structure
of ZIKV E protein in complex with a cross-reactive murine antibody, 2A10G6. This
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antibody bound the highly conserved FL in DII and was poorly neutralizing (PRNT50 of
249 mg/mL) yet still protected mice against lethal ZIKV infection. ZV-13 had a similar
neutralizing profile in vitro and also bound to a DII-FL epitope. Barba-Spaeth et al. (2016)
reported 2.4-A˚ and 2.6-A˚ structures of ZIKV E protein complexed with Fab fragments of
C8 or A11 antibodies, both of which recognize EDE dimer epitopes22. Although these
cross-reactive anti-DENV antibodies inhibited ZIKV infection efficiently (FRNT50 of ~14
and 135 ng/mL, respectively, against H/PF/2013), no protection experiments with C8 or
A11 and ZIKV were undertaken in animals.
Three of our mAbs recognized cryptic epitopes in the ABDE sheet (ZV-2) and CC’ loop (ZV-48 and ZV-64) on DIII, which are not predicted to be accessible on the mature
virion11,12. So how were these antibodies generated in vivo? ZV-48 and ZV-64 were the
product of serial infections with two different strains of ZIKV (MR-766 and H/PF/2013)
and a final 3-day boost with purified DIII prior to fusion and hybridoma generation. While
it is possible that ZV-48 and ZV-64 were selected against the recombinant protein during
the last boost, given the extensive somatic hypermutation seen in the sequences (Figure
2.5), it seems more likely that viral breathing (Dowd et al., 2011) allows exposure of the
C-C’ loop, as observed previously for a neutralizing DENV-1 mAb29. For ZV-2, it is more
difficult to comprehend, as this mAb was a product only of prime-boosts with infectious
ZIKV MR-766 and H/PF/2013. Other possible ways to generate antibodies against cryptic
epitopes include exposure of the epitope on partially mature viruses, SVPs, ‘‘broken’’ viral
particles, or cleaved soluble envelope proteins.
The two mAbs (ZV-48 and ZV-64) that bound to the C-C’ loop showed reduced
neutralizing activity against the American and African strains. Sequence alignment of the
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C-C’ loop contact residues in DIII of all four tested strains failed to reveal an explanation
for the loss of inhibitory activity relative to the Asian H/PF/ 2013 ZIKV strain. Only a
single amino acid change (A343V) in the crystallographic footprint was identified in MR766 and Dakar 41671, and this substitution was not present in the Paraiba, 2015 sequence.
This phenotype is similar to a neutralizing mAb (DV1-E111) that bound the C-C’ loop of
DENV-1 DIII, in which we observed a genotype-dependent pattern of neutralization29 that
mapped to a single conservative amino acid substitution in DII remote from the footprint
of the epitope39.
We observed protection in vivo by DIII LR neutralizing mAbs (ZV-54 and ZV-67).
This result is similar to that observed for other DIII LR mAbs against flaviviruses that
protected against lethal infection by WNV17, DENV-118, or DENV-219. Although
mechanistic studies with ZV-54 and ZV-67 remain to be performed, protective mAbs
against WNV and DENV that bound the DIII LR epitope inhibited infection at a postattachment stage including blocking viral fusion from the endosome40.
A key question remains whether neutralizing antibodies will protect pregnant
women and their developing fetuses from ZIKV infection and congenital malformations,
including microcephaly. Although we and others have developed models of infection of
pregnant mice with resultant injury to the fetus7,9, we chose not to perform such protection
studies because mice, in contrast to many other mammalian species, lack expression of the
neonatal Fc receptor (FcRn) on their trophoblasts in the chorioallantoic placenta41. Rather,
FcRn is expressed in the mouse yolk sac endoderm, and thus, the transfer of IgG in mice
is believed to be predominantly postnatal42. As reduced levels of transport of maternal or
exogenous IgG into the fetus occur in mice, protection by a given antibody may be
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underestimated. Passive antibody transfer studies during pregnancy may require
experiments in mammals with more similar placental anatomy that are susceptible to ZIKV
infection (e.g., nonhuman primates).
Our studies identify ZIKV DIII as a potential target of neutralizing antibodies and
thus a possible immunogen for vaccines. DIII has been used previously in the context of
different flavivirus vaccines43,44. Although neutralizing antibodies are generated in several
animal species in response to soluble DIII immunogens, the titers have been lower than
expected, possibly because of immunodominance of regions of DIII that normally are
inaccessible on the viral particle. Alternatively, the mouse VH-CDR3 regions are shorter
and vary in amino acid composition compared to other species (Shi et al., 2014), which
could impact immunodominance against DIII epitopes in a species-specific manner. Our
structural analysis provides a hierarchy of neutralization efficacy associated with distinct
epitopes on DIII. Masking of epitopes that fail to elicit neutralizing antibodies could be
combined with epitope-focused vaccine design approaches45 to generate DIII variants that
induce more protective responses.
In summary, we identified a panel of type-specific ZIKV mAbs, several of which
bind to distinct regions on DIII and have disparate functional activities. Type-specific antiZIKV mAbs could be useful for diagnostic assays that distinguish ZIKV antigens from
closely related flaviviruses, including DENV. Alternatively, their characterization may
provide a path forward for developing prophylactic antibodies for use in pregnancy, for
therapeutic antibodies to potentially prevent viral persistence, or for the design of domain
and minimal epitope-specific vaccines against ZIKV infection.
2.5

Experimental Procedures
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Ethics Statement. This study was carried out in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the NIH. The protocols were
approved by the Institutional Animal Care and Use Committee at the Washington
University School of Medicine.
Viruses. ZIKV strain H/PF/2013 (French Polynesia, 2013) was obtained from X. de
Lamballerie (Aix Marseille Université). ZIKV Brazil Paraiba 2015 was provided by S.
Whitehead (Bethesda) and originally obtained from P.F.C. Vasconcelos (Instituto Evandro
Chagas). ZIKV MR-766 (Uganda, 1947) and Dakar 41519 (Senegal, 1982) were provided
by the World Reference Center for Emerging Viruses and Arboviruses (R. Tesh, University
of Texas Medical Branch). Nicaraguan DENV strains (DENV-1 1254-4, DENV-2 172-08,
DENV-3 N2845-09, and DENV-4 N703-99) were generously provided by E. Harris
(University of California, Berkeley). Virus stocks were propagated in C6/36 Aedes
albopictus cells25. ZIKV Dakar 41519 was passaged in vivo in Rag1-/- mice (M.J.G. and
M.S.D., unpublished data) and a brain homogenate was used. Virus stocks were titrated by
focus-forming assay (FFA) on Vero cells as described46.
mAb Generation. Irf3-/- mice were infected and boosted with 103 FFU of ZIKV (MR-766
and H/ PF/2013, respectively) and given a final intravenous boost with infectious 106 FFU
of ZIKV (H/PF/2013) or purified DIII 3 days prior to fusion with P3X63.Ag.6.5.3 myeloma
cells. Hybridomas secreting antibodies that reacted with ZIKV-infected Vero cells were
cloned by limiting dilution. All mAbs were purified by protein A affinity chromatography.
The VH and VL sequences of mAbs were amplified from hybridoma cell RNA by a 5’
RACE procedure.
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ZIKV mAb Domain Mapping by ELISA. A MAXISORP 96-well plate (Nunc) was
coated with 50 µL of 2 µg/mL of recombinant ZIKV E, ZIKV E-FL (fusion-loop mutant),
ZIKV DIII, WNV-E, or DV4-E overnight at 4°C. Plates were washed three times with PBS
with 0.02% Tween 20 followed by incubation with PBS, 2% BSA, and 0.02% Tween 20
for 1 hr at 37°C. MAbs (0.5 µg/mL) were added for 1 hr at room temperature. Plates were
washed again and then sequentially incubated with 2 mg/mL of HRP-conjugated antimouse IgG and tetramethylbenzidine substrate. The reaction was stopped by the addition
of 1 N H2SO4 to the medium, and emission (450 nm) was read using an iMark microplate
reader (Bio-Rad).
Neutralization Assays. Serial dilutions of mAbs were incubated with 100 FFU of different
ZIKV for 1 hour at 37°C. mAb-virus complexes were added to Vero cell monolayers in
96-well plates. After 90 min, cells were overlaid with 1% (w/v) methylcellulose in MEM
supplemented with 4% FBS. Plates were harvested 40 hr later and fixed with 1% PFA in
PBS. The plates were incubated sequentially with 500 ng/mL of ZV-16 (E.F., unpublished
data) and HRP-conjugated goat anti-mouse IgG in PBS supplemented with 0.1% saponin
and 0.1% BSA. ZIKV-infected foci were visualized using TrueBlue peroxidase substrate
(KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies).
mAb Binding to Flavivirus-Infected Cells. Vero or C6/36 cells were inoculated with
different flaviviruses in DMEM supplemented with 10 mM HEPES, penicillin and
streptomycin, and 10% FBS. At different time points after infection (ZIKV H/PF/2013,
MOI of 5, 24 hr, Vero cells; DENV strains, MOI of 0.01, 120 hr, C6/36 cells), cells were
fixed with 4% PFA diluted in PBS for 20 min at room temperature and permeabilized with
HBSS, 10 mM HEPES, 0.1% saponin (Sigma), and 0.025% NaN3 for 10 min at room
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temperature. Fifty-thousand cells were transferred to a U-bottom plate and incubated for 1
hr at 4°C with 5 µg/mL of anti-ZIKV mAbs or isotype controls (negative, CHK-16647;
positive, WNV E53 [Oliphant et al., 2006]). After washing, cells were incubated with an
Alexa Fluor 647-conjugated goat anti-mouse IgG (Invitrogen), fixed in 1% PFA in PBS,
processed on a FACS Array (BD Biosciences), and analyzed using FlowJo software (Tree
Star).
Biolayer Interferometry Binding Assays. The binding affinity of purified ZIKV E or
ZIKV DIII protein with ZIKV mAbs was monitored by BLI using an Octet-Red96 device
(Pall ForteBio). Briefly, 100 µg of each antibody was mixed with biotin (EZ-Link-NHSPEG4-Biotin, Thermo Fisher) at a molar ratio of 20:1 biotin:protein and incubated at room
temperature for 30 min. The unreacted biotin was removed by passage through a desalting
column (5 mL Zeba Spin 7K MWCO, Thermo Fisher). The antibodies were loaded onto
streptavidin biosensors (ForteBio) until saturation, typically 2 mg/mL for 3 min, in 10 mM
HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.005% P20 surfactant with 3% BSA.
Association and dissociation were measured at 25°C for all mAbs. The real-time data were
analyzed using Biaevaluation 4.1 (GE Healthcare). Association and dissociation profiles,
as well as steady-state equilibrium concentration curves, were fitted using a 1:1 binding
model.
SVP Production and Binding Assay. ZIKV SVPs were generated as described previously
for WNV (Hanna et al., 2005). Briefly, a plasmid encoding the prM-E gene of ZIKV
H/PF/2013 was transfected into HEK293T cells. SVPs were harvested every 24 hr and
stored aliquoted at 80°C. 96-well high-binding plates (Immulon 4HBX; Thermo Scientific)
were coated with 1 mg/mL of ZV-67 in coating buffer (15 mM sodium carbonate, 35 mM
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sodium bicarbonate [pH 9.6]) overnight at 4°C. Plates were blocked with PBS-T + 1.5%
BSA, followed by capture of SVPs diluted in blocking buffer for 1 hr at 37°C. Plates were
incubated with the indicated concentrations of biotin-conjugated mAbs for 30 min at 37°C,
followed by incubation with 30 ng/mL streptavidin-HRP for 30 min at 37°C. The plates
were developed with SureBlue TMB substrate (KPL) and stopped with 1 M HCl. Plates
were analyzed at 450 nm, with a 570 nm correction (BioTek).
ADE Studies. RVP production and ADE assays were performed using approaches detailed
in prior studies with WNV and DENV RVPs27,48 using plasmids expressing the C-prM-E
genes of ZIKV H/PF/2013 or DENV-2 16681 and a plasmid encoding a WNV replicon
expressing GFP. Infection of human K562 cells were carried out at 37°C and GFP-positive
infected cells were detected by flow cytometry 48 hr later.
Mouse Protection Experiments. C57BL/6 mice (4- to 5-week-old, Jackson Laboratories)
were inoculated with ZIKV by subcutaneous (footpad) route with 105 FFU of mouseadapted ZIKV Dakar in a volume of 50 mL. One day prior, mice were treated with 2 mg
of an Ifnar-blocking mAb (MAR1-5A3) by intraperitoneal injection25. ZIKV mAbs were
administered as a single 250 ug dose 1 day before infection via an intraperitoneal route.
Serum samples were obtained at day 3 after ZIKV infection and extracted with the Viral
RNA Mini Kit (QIAGEN). ZIKV RNA levels were determined by TaqMan one-step qRTPCR on an ABI 7500 Fast Instrument using published primers and conditions49.
Statistical Analysis. All virological data were analyzed with GraphPad Prism software.
Kaplan-Meier survival curves were analyzed by the log rank test, and weight losses and
viremia were compared using an ANOVA with a multiple comparisons test. A p value of
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<0.05 indicated statistically significant differences. SVP ELISA data were analyzed by
non-linear regression analysis using a one-site binding model.
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Table 2.1: Characteristic of Anti-ZIKV mAbs
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Figure 2.1: Profile of Neutralizing mAbs Against ZIKV
(A) Cells were infected with DENV-1, DENV-2, DENV-3, DENV-4, or ZIKV (H/PF/2013), and stained
with indicated anti-ZIKV mAbs or isotype controls and processed by flow cytometry. The data are
representative of several independent experiments. Blue arrows indicate binding of cross-reactive mAbs
(ZV-13 or WNV E53) to DENV and ZIKV-infected cells. Red arrows indicate binding of ZIKV mAbs to
ZIKV-infected cells. (B) The indicated flavivirus proteins (ZIKV E, ZIKV E-FL [fusion loop mutant],
ZIKV DIII, WNV E, and DENV-4 E) were incubated with the indicated anti-ZIKV mAbs or controls (WNV
E60 [flavivirus cross-reactive] and WNV E24 [WNV type-specific]). Binding was determined
by ELISA and the results are representative of two independent experiments performed in triplicate. (C)
Focus reduction neutralization tests (FRNT). Different ZIKV strains (H/PF/2013, Paraiba, 2015, Dakar
41519, and MR-766) were incubated with increasing concentrations of mAbs for 1 hr at 37°C prior to
infection of Vero cells. Subsequently, an FRNT assay was performed (Experimental Procedures). The
results reflect pooled data from two or more independent experiments performed in triplicate.
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Figure 2.2: Differential Binding and ADE Activity of Different Anti-ZIKV mAbs
(A) Quantitative analysis of DIII binding to anti-ZIKV mAbs by BLI. Shown in the top panel are binding
curves obtained by passing different concentrations of DIII over biotinylated antiZIKV antibody immobilized on a biosensor surface. The kinetic values were obtained by simultaneously
fitting the association and dissociation responses to a 1:1 Langmuir binding model (KD, kinetic). The lower
panels show the steady-state analysis results (KD, equilibrium). Plotted in the bottom panels (open circles)
is the binding response (nm) versus concentration of DIII offered. In each case, the binding was saturable.
Bottom insets, Scatchard plots suggest a single binding affinity for each interaction. The data are
representative of two independent experiments per mAb. (B) Left: ZIKV SVPs were adsorbed to 96-well
plates and detected with the indicated biotinylated anti-ZIKV or control (WNV E60 [flavivirus crossreactive] and WNV E16 [WNV type-specific]) mAbs by ELISA. Right: the relative avidity of binding was
calculated. Data are representative of five independent experiments, and the avidity values reflect the mean
of the five experiments. Error bars indicate SDs. (C) ADE studies. Serial dilutions of anti-ZIKV or control
(WNV E60 [flavivirus cross-reactive] and WNV E16 [WNV type-specific]) mAbs were mixed with (left)
ZIKV H/PF/2013 or (right) DENV-2 RVPs (which encode for GFP) prior to infection of
FcγRIIa+ human K562 cells and processing by flow cytometry. One representative experiment of two is
shown. Error bars indicate the range of duplicate technical replicates.
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Figure 2.3: BLI Binding Data
ZV-13 mAb binding to recombinant soluble ZIKV E protein was assayed by BLI. Randomly biotinylated
ZV-13 mAb was coated onto Streptavidin biosensor pins. The pins were equilibrated in binding buffer alone
(HBS-EP +1% BSA) before being plunged into wells containing various concentrations of recombinant
ZIKV E ectodomain protein. The association lasted ten minutes before the pins were placed back in binding
buffer to allow for dissociation. The real-time data were analyzed using Biaevaluation 4.1 (GE Healthcare).
Association and dissociation profiles, as well as steady-state equilibrium concentration curves, were fitted
assuming a 1:1 binding model.
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Figure 2.4: Structures of Anti-ZIKV Fabs and scFv Complexed with DIII
(A) Ribbon diagrams of four ZIKV DIII (H/PF/2013) complexes with antibody fragments. The crystal
structure of ZV-2 Fab (outer left, green), ZV-48 scFv (inner left, cyan), ZV-64 Fab (inner right, cyan), and
ZV-67 Fab (outer right, magenta) are shown with light chains rendered in paler colors. DIII is colored dark
blue with contact segments labeled. (B) Docking of the ZV-2, ZV-48, and ZV-64 complexes onto ZV-67DIII. DIII is rendered as a molecular surface with each mAb contact surface color coded. Simultaneous
docking of ZV-2 and ZV-67 with either ZV-48 or ZV-64 buries nearly half of the solvent surface of DIII
and creates no van der Waal contacts between adjacent mAbs. (C) Five mAbs were probed for competitive
and non-competitive binding against the DIII antigen by BLI. In one experiment, biotin-labeled ZV-67 was
captured on the streptavidinsensor, the antibody was then loaded with ZIKV DIII followed by either ZV54 or ZV-64, and finally, ZV-2 was added. In another experiment, ZV-48 was immobilized and ZV-64 or
ZV-67 was added after DIII followed by ZV-2. Additional BLI signal indicates an unoccupied epitope (noncompetitor), whereas no binding indicates epitope blocking (competition). In this experiment, ZV-48
competed with ZIKV-64 as expected given that they both bind nearly identical epitopes, while ZV-67
competed with its presumed sibling clone ZV-54. A dash (-) represents that no 2nd or 3rd antibody was
offered.
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Figure 2.5: mAb Sequence Alignments and Antigen Contacts
Amino acid sequence alignment of the variable heavy chain (VH) and light chain (VL) of the mAbs ZV-2
(A), ZV-48 and ZV-64 (B), and ZV-54 and ZV-67 (C) against the C57BL/6 germline. Nucleotide and amino
acid sequences were analyzed using NCBI/IgBlast and IMGT/V-Quest to identify the germline V, D and J
gene members with the highest sequence identity. The top sequence in each alignment is the presumptive
germline IgV, D, and J genes. Red stars indicate positions of somatic hypermutation. Red triangles mark
insertions at the junctions of rearrangement. The mAb-DIII contact residues are boxed in the color of
the epitope they bind: green for the ABDE epitope, cyan for the C-C’ loop epitope, and magenta for the LR
epitope. Absent residues are denoted with (.). Consensus variable domain numbering is given above the
aligned sequences, with insertions as described (Al-Lazikani et al., 1997). Complementarity determining
regions (CDR 1-3) are marked at the top of the alignment. The secondary structure elements are indicated
in blue (arrows for β sheet and coil for α helices). A table of the number of somatic mutations for
each antibody is provided at the bottom.
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Figure 2.6: Structural Definition of ZIKV-Specific DIII Epitopes
(A) Sequence alignment of DIII from our ZIKV immunizing stains (H/PF/2013 and MR-766), WNV,
DENV-1, DENV-2, DENV-3, and DENV-4 and highlighting of structurally defined DIII epitopes. The
ABDE sheet epitope of ZV-2 is shown in green, the C-C′ loop epitope of ZV-48 and ZV-64 is shown in
cyan, and the LR epitope of ZV-67 is shown in magenta. DIII residues are colored if they make van der
Waals contact of ≤3.90-Å distance, and the total number of contacts for each epitope residue are shown
below the ZIKV sequences. For comparison, the same structurally defined DIII epitopes of WNV E16
(magenta, LR), DV1-E106 (magenta, LR), DV1-E111 (cyan, C-C′ loop), DV2 1A1D-2 (pink, A-strand),
DV3 2H12 (light-green, A-B-loop), and DV4 4E11 (pink, A-strand) are displayed. The ZIKV β strands are
labeled and shown in dark blue above the sequences. (B) Delineation of the epitope contact regions on the
ZIKV DIII structures of ZV-2 (ABDE sheet), ZV-48 (C-C′ loop), ZV-64 (C-C′ loop) and ZV-67 (LR). DIII
epitope residues are colored as in (A), with side chains drawn as sticks and labeled if they make eight or
more van der Waals contacts.

74

Figure 2.7: Accessibility of ZIKV DIII Epitopes
(A) Mapping of the three distinct ZIKV DIII epitopes onto the mature virion (5IRE) (Sirohi et al., 2016).
The surface distribution of the ABDE sheet (green), C-C′ loop (cyan), and LR (magenta) epitopes are
rendered on the three symmetrically unique E proteins colored olive, wheat, and gray. While the ABDE
sheet and C-C′ loop epitopes are dominantly buried in all three symmetry environments, the LR epitope is
solvent accessible on the mature virion. (B) Docking of the ZV-2-DIII complex onto the crystal structure of
dimeric ZIKV (5JHM) (Dai et al., 2016). Shown above is the ZV-2 Fab docked to a soluble E monomer,
which indicates that the ABDE sheet epitope is occluded by DI with clashes by the VH domain. Below, the
ZIKV dimer is depicted, showing how it would sterically clash with the ZV-2 VLdomain. ZV-2 CDR loops
contact several of the same DIII residues that are contacted by the DII fusion loop in the dimer. (C) Docking
of the ZV-64-DIII and ZV-67-DIII complexes onto the cryoelectron microscopymodel of the M-E dimer
that forms the mature virion. ZV-67 binding to the LR epitope allows for the projection of the Fab away
from the viral membrane whereas ZV-64 binding to the C-C′ loop epitope positions the Fab in the plane of
the viral envelope and membrane. (D) Comparative docking of the DV1-E111 Fab-DIII complex (Austin
et al., 2012) onto the cryptic C-C′ loop epitope suggests similar steric clashes as predicted for ZV-64. (E)
Comparative docking of the WNV-E16 Fab-DIII complex (Nybakken et al., 2005) onto the exposed LR
epitope. (F) Comparative docking of the DV2-1A1D-2 Fab-DIII complex (Lok et al., 2008) and DV4-4E11
scFv-DIII complex (Cockburn et al., 2012) onto the exposed A-strand epitope.
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Figure 2.8: In Vivo Protection of Anti-ZIKV mAbs
4- to 5-week-old C57BL/6 mice were passively transferred 2 mg of anti-Ifnar1 mAb and 250 µg of the
indicated mAbs (CHK-166, ZV-54, or ZV-67) via an intraperitoneal injection1 day before
subcutaneous inoculation with 105 FFU of ZIKV Dakar 41519. (A and B) (A) On day 3 after
infection, serum was collected for analysis of viral RNA by qRT-PCR. (B) Daily weights were measured.
For (A) and (B), statistical significance was analyzed by a one-way ANOVA with a Dunnett’s multiple
comparisons test (∗∗p < 0.01; ∗∗∗p < 0.001). (C) ZV-54 and ZV-67 protected against ZIKV infection
compared to the control CHK-166 mAb (∗∗∗p < 0.001, log rank test). The results are pooled from two
independent experiments with n = 8–9 mice for each treatment condition.
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Chapter 3:
Neutralizing human antibodies prevent Zika virus replication and
fetal disease in mice
This chapter is adapted from a manuscript published in Nature:

Sapparapu G*, Fernandez E*, Kose N, Cao B, Fox JM, Bombardi RG, Zhao H, Nelson CA,
Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS,
Crowe JE. 2016. Neutralizing human antibodies prevent Zika virus replication and fetal
disease in mice. Nature. 2016 Nov 7; 540(7633): 443-447.
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obtained funding. All authors reviewed, edited and approved the paper.
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3.1

Summary
Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that can cause
severe disease, including congenital birth defects during pregnancy1. To develop
candidate therapeutic agents against ZIKV, we isolated a panel of human monoclonal
antibodies from subjects that were previously infected with ZIKV. We show that a subset
of antibodies recognize diverse epitopes on the envelope (E) protein and exhibit potent
neutralizing activity. One of the most inhibitory antibodies, ZIKV-117, broadly
neutralized infection of ZIKV strains corresponding to African and Asian-American
lineages. Epitope mapping studies revealed that ZIKV-117 recognized a unique
quaternary epitope on the E protein dimer–dimer interface. We evaluated the therapeutic
efficacy of ZIKV-117 in pregnant and non-pregnant mice. Monoclonal antibody
treatment markedly reduced tissue pathology, placental and fetal infection, and mortality
in mice. Thus, neutralizing human antibodies can protect against maternal–fetal
transmission, infection and disease, and reveal important determinants for structure-based
rational vaccine design efforts.
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3.2

Main
Recent ZIKV epidemics are linked to Guillain–Barré syndrome in adults and
microcephaly in fetuses and newborn infants2–5. Although ZIKV infection can potentially
cause severe disease, specific treatments and vaccines for ZIKV are not currently available.
We sought to isolate neutralizing human monoclonal antibodies (mAbs) with broad
specificity against all ZIKV strains and protective activity in vivo. We tested the serological
response of subjects who had previously been infected with ZIKV in diverse geographic
locations. Serum from each subject contained antibodies that were shown by ELISA assays
to react with ZIKV E protein and to neutralize infection of a contemporary Asian isolate
(H/PF/2013) from French Polynesia (Figures 3.1A and 3.1B). We studied the B cells of
subject 1001 in greater detail. Based on the results of replicate assays, the frequency of B
cells that secrete antibodies against ZIKV E protein in the peripheral blood was between
0.36% and 0.61% (Figures 3.1C and 3.1D). We next tested the reactivity of antibodies
with domain III (DIII) of the E protein from ZIKV or the related dengue (DENV) and West
Nile (WNV) viruses. Only a subset (6%) of the ZIKV-E-reactive antibodies bound to DIII,
and most were specific for ZIKV (Figure 3.1C). Comparative binding to a wild-type or
mutant ZIKV E protein lacking the conserved fusion loop epitope in DII (mutant denoted
hereafter as E-FLM) established immunodominance (binding around 70% of mAbs) of the
fusion loop.
We obtained 29 cloned hybridomas secreting mAbs that bound to ZIKV E protein
from the cells of three donors (mAb ZIKV-195 from subject 1011, mAb ZIKV-204 from
subject 973, and the remaining 27 mAbs from subject 1001). All of the mAbs except for
one belonged to the IgG1 isotype (two could not be determined), with an equal distribution
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of κ and λ light chains (Table 3.1); sequence analysis of cDNA of the antibody variable
gene regions revealed that each mAb represented an independent clone (Table 3.1). We
determined the half-maximal effective concentrations for binding to ZIKV E protein (EC50)
and neutralization (IC50) of infection (Figure 3.2A and 3.3); most of the mAbs bound to E
protein at low concentrations (EC50 < 100 ng ml−1), whereas only four of the 29 mAbs
exhibited strong neutralizing activity (IC50 = 5–420 ng ml−1). We next determined how
many antigenic sites on ZIKV E were recognized using quantitative competition binding.
We identified four major competition groups (designated A, B, C or D). Group A mAbs
had 23 members that were directed against the fusion loop in DII, as determined by
differential binding to E and E-FLM (Figure 3.3), and had only one clone (ZIKV-88) with
moderate neutralizing potency. The group B mAb ZIKV-116 neutralized ZIKV infection
and bound to E, DIII and E-FLM. Group C mAbs (ZIKV-19 and ZIKV-190) bound to E
and E-FLM weakly, but did not potently neutralize infection. The group D mAb ZIKV195 neutralized with moderate potency and was similar in binding to both E and E-FLM.
The most inhibitory group D mAb, ZIKV-117, bound to both E and E-FLM weakly.
We mapped the epitopes of representative mAbs using a shotgun alanine-scanning
mutagenesis library6 of ZIKV prM and E protein variants (Figure 3.2B and 3.4). Loss-ofbinding analysis confirmed that group A mAbs bound to the fusion loop in DII, whereas
the group B mAb bound to DIII. Group B mAb ZIKV-116 bound to an epitope involving
residues T309, E393 and K394 along the lateral ridge of DIII (DIII-LR), which was
confirmed in an ELISA that showed reduced binding to DIII with mutations A310E and
T335K in DIII-LR7. The epitope mapping studies suggest that the group D mAb ZIKV117 binds specifically to DII across two adjacent dimers at the ‘dimer–dimer’ interface
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(Figure 3.2C). We were unable to isolate virus neutralization escape mutant viruses for
ZIKV-117, despite six passages in cell culture under mAb selection pressure.
Because of their potency, we assessed whether group B mAb ZIKV-116 and group
D mAb ZIKV-117 could inhibit diverse ZIKV strains encompassing the African and AsianAmerican lineages. ZIKV-117 neutralized all of the ZIKV strains tested, including two
African (MR 766 and Dakar 41519), two Asian (Malaysia P6740 and H/PF/2013), and an
American (Brazil Paraiba 2015) strain with IC50 values of 5 to 25 ng ml−1 (Figures 3.2D
and 3.2E). ZIKV-116 inhibited four of the five strains efficiently, but was inactive against
MR 766, the original African strain (Figures 3.2D and 3.2E). Alignment of the sequences
of ZIKV H/PF/2013 and MR 766, with respect to residues in DIII-LR7 that ZIKV-116
binds, revealed only one difference (a conservative E393D change). Given these data, we
hypothesize that the DIII-LR epitope of ZIKV-116 is displayed differently on MR 766
owing to allosteric effects of changes in other parts of the E protein, which could regulate
epitope accessibility8,9.
As recent studies have suggested that cross-reactive ZIKV-specific human mAbs
can enhance DENV infection in vivo10, we tested whether these two ZIKV-neutralizing
mAbs could bind to DENV-infected cells. ZIKV-117 showed a restricted type-specific
binding pattern as it failed to stain cells infected with DENV-1, DENV-2, DENV-3 or
DENV-4, or bind to purified WNV E protein (Figure 3.5 and data not shown). In
comparison, ZIKV-116 bound to cells infected with DENV-1, DENV-2 or DENV-4, but
did not bind to DENV-2 DIII or WNV DIII in ELISA.
In vivo models of ZIKV pathogenesis and antibody prophylaxis have been
reported7,10,11 in mice deficient in type-I interferon signaling. To determine whether ZIKV-
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117 had therapeutic activity, we treated 4–5-week-old wild-type male C57BL/6 mice at
day −1 with anti-Ifnar1 mAbs, and then inoculated animals with 103 focus-forming units
(FFU) of a mouse-adapted African strain of ZIKV-Dakar7. Animals were treated with a
single dose of ZIKV-117 or non-binding isotype control (human (h)CHK-152)12, on day
+1 (100 µg; 6.7 mg kg−1) or day +5 (250 µg; 16.7 mg kg−1). Animals treated with hCHK152 sustained significant lethality compared to those receiving ZIKV-117 (Figure 3.6A),
which were protected even when administered only a single dose 5 days after virus
inoculation.
We and others have demonstrated placental injury and fetal demise following ZIKV
infection of pregnant mice with deficiencies in type-I interferon signalling13–15. To assess
the protective ability of ZIKV-117 during fetal development, we treated Ifnar1−/− pregnant
dams mated to wild-type male mice with a single 250 µg dose of ZIKV-117 or isotype
control mAb (hCHK-152) on embryo day 5.5 (E5.5), the day before ZIKV inoculation.
Whereas inoculation with ZIKV-Brazil at E6.5 following administration with hCHK-152
resulted in high levels of maternal infection and almost uniform fetal demise by E13.5,
treatment with ZIKV-117 improved fetal outcome (Figure 3.6B and 3.6C).
Because of the extent of demise at E13.5 after ZIKV infection of Ifnar1−/− dams,
we could not recover adequate numbers of fetuses to measure viral titerss. Accordingly,
we switched to a wild-type mouse model with an acquired type-I interferon deficiency
using the mouse-adapted African ZIKV-Dakar strain. Wild-type pregnant dams were
treated at day −1 (E5.5) with an anti-Ifnar1 mAbs. At the same time, these animals were
administered vehicle control (PBS), 250 µg isotype control hCHK-152, or 250 µg ZIKV117. One day later, dams were inoculated subcutaneously with 103 FFU of ZIKV-Dakar.
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Fetuses from dams treated with anti-Ifnar1 mAbs and given PBS or hCHK-152 showed
high levels (for example, around 105 to 107 FFU equivalents per gram) of viral RNA in the
placenta and fetal brain (Figure 3.6D). In comparison, mice treated with anti-Ifnar1 and
ZIKV-117 had reduced virus levels in the placenta and fetal brain (for example, around
10° to 103FFU equivalents per gram). This phenotype was associated with transport of
human ZIKV E-specific IgG across the maternal–fetal placental barrier (816 ± 53 ng
ml−1 for the placenta and 1,675 ± 203 ng ml−1 for the fetal head; Figure 3.7). As levels of
neonatal Fc receptor in the mouse placenta are lower than other mammalian species16,
reduced levels of transport of maternal or exogenous IgG into the fetus is expected17.
Although this factor could underestimate the therapeutic effect of exogenous anti-ZIKV
IgG or maternal antibodies, we nonetheless achieved levels in the placenta and fetal head
that were orders of magnitude above the IC50 neutralization value for ZIKV-117. Dams
treated with ZIKV-117 also had substantially lower levels of viral RNA in the maternal
brain and serum (Figure 3.6E).
Antibody-dependent enhancement of flavivirus infection occurs when type-specific
or cross-reactive antibodies fail to reach a stoichiometric threshold for neutralization and
instead facilitate infection of FcγR-expressing myeloid cells18. Because antibodies can
promote antibody-dependent enhancement of ZIKV in cell culture19,20, we evaluated the
protective efficacy of a recombinant form of ZIKV-117 IgG containing a leucine (L) to
alanine (A) substitution at positions 234 and 235 (LALA)21, which lacked efficient binding
to FcγR, retained interactions with FcRn22, and neutralized ZIKV in vitro equivalently
compared to the parent mAb (Figure 3.8). The LALA variant of ZIKV-117 showed similar
protective activity against infection of the placenta and fetus relative to the parent mAb
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(Figure 3.6F). As the protection conferred by ZIKV-117 in the pregnancy model is
probably due to neutralization and not Fc effector functions, LALA variants could be used
without a risk of antibody-dependent enhancement.
We next assessed the post-exposure efficacy of ZIKV-117 during pregnancy. Mice
treated with anti-Ifnar1 mAbs at E5.5 were inoculated with 103 FFU of ZIKV-Dakar at
E6.5 and then administered a single dose of PBS, 250 µg of hCHK-152, or 250 µg of ZIKV117 at E7.5. Compared to PBS or isotype control mAb treatment, administration of ZIKV117 markedly reduced the viral burden in the dams, the placenta and fetus when measured
at E13.5 (Figures 3.6G and 3.6H).
The reduction in viral load mediated by ZIKV-117 was associated with decreased
damage of the placenta (as judged by labyrinth layer and overall placenta area), less
trophoblast cell death, and increased body size of the fetus (Figure 3.9A- 3.9C) compared
to fetuses of PBS- or hCHK-152-treated dams. ZIKV-117 protected against ZIKV-induced
placental insufficiency, as the placental area and fetal size from infected dams treated with
anti-ZIKV mAbs were similar to that of uninfected placentas14. In situ hybridization
revealed an almost complete absence of viral RNA in the junctional zone and decidua of
the placenta in animals treated with ZIKV-117 compared to staining observed in PBS- or
hCHK-152-treated controls (Figures 3.9D and 3.10). We also observed vascular damage
associated with ZIKV infection of the placenta14, characterized as diminished vimentin
staining of fetal endothelial cells, which was rescued by ZIKV-117 to levels seen in
uninfected placentas (Figure 3.9E). The histopathological data suggests that ZIKV-117
treatment can reduce the ability of ZIKV to cross the fetal endothelial cell barrier, and
thereby prevent vertical transmission and improve fetal outcome.
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Our most potent neutralizing antibodies exhibited a breadth of inhibitory activity
against strains from Africa, Asia, and the Americas. Even a single ZIKV-117 dose given 5
days after infection protected mice against lethal infection, a timeline similar to the most
protective antibodies against other flaviviruses23. Prophylaxis or post-exposure therapy of
pregnant mice with ZIKV-117 reduced infection in mothers, and in placental and fetal
tissues. As the extent to which these observations in mice translate to humans remains
unclear, protection studies in non-human primates, which share a placental architecture
similar to humans, seem warranted. If the results were consistent, ZIKV-117 or human
antibodies with similar profiles10,19 could be developed as a treatment measure during
pregnancy for at-risk humans. By defining key epitopes on the E protein associated with
antibody-mediated protection, our studies also inform vaccine efforts to design new
immunogens that elicit highly protective antibody responses against ZIKV.
3.3

Methods
Research subjects. We studied eight subjects in the United States with previous or recent
ZIKV infection (Table 3.2). The studies were approved by the Institutional Review Board
of Vanderbilt University Medical Center; samples were obtained after informed consent
was obtained by the Vanderbilt Clinical Trials Center. Two subjects (972 and 973) were
infected with an African lineage strain in 2008 (one subject while working in Senegal, the
second acquired the infection by sexual transmission from the first, as previously
reported24). The other six subjects were infected during the current outbreak of an Asian
lineage strain, following exposure in Brazil, Mexico or Haiti.
Generation and quantification of human B-cell lines secreting ZIKV E protein
specific antibodies. Peripheral blood mononuclear cells (PBMCs) from heparinized blood
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were isolated with Ficoll-Histopaque by density gradient centrifugation. The cells were
used immediately or cryopreserved in the vapour phase of liquid nitrogen until use. Ten
million PBMCs were cultured in 384-well plates (Nunc) using culture medium (ClonaCellHY Medium A, StemCell Technologies) supplemented with 8 µg ml−1 of the TLR agonist
CpG (phosphorothioate-modified oligodeoxynucleotide ZOEZOEZZZZZOEEZOEZZZT,
Invitrogen), 3 µg ml−1 of Chk2 inhibitor (Sigma), 1 µg ml−1 of cyclosporine A (Sigma), and
clarified supernatants from cultures of B95.8 cells (ATCC) containing Epstein–Barr virus.
After 7 days, cells from each 384-well culture plate were expanded into four 96-well
culture plates (Falcon) using ClonaCell-HY Medium A containing 8 µg ml−1 of CpG, 3 µg
ml−1 of Chk2 inhibitor, and 107 irradiated heterologous human PBMCs (Nashville Red
Cross) and cultured for an additional 4 days. Supernatants were screened in ELISA
(described below) for reactivity with various ZIKV E proteins, which are described below.
The minimal frequency of ZIKV E-reactive B cells was estimated based on the number of
wells with E protein-reactive supernatants compared with the total number of
lymphoblastoid cell line colonies in the transformation plates (calculation: E-reactive Bcell frequency = (number of wells with E-reactive supernatants) divided by (number of
LCL colonies in the plate) × 100).
Protein expression and purification. The ectodomains of ZIKV E (H/PF/2013; GenBank
Accession KJ776791) and the fusion-loop mutant E-FLM (containing four mutations:
T76A, Q77G, W101R, L107R) were expressed transiently in Expi293F cells and purified
as described previously7. ZIKV DIII (residues 299–407 of strain H/PF/2013), WNV DIII
(residues 296–405 of strain New York 1999) and DENV-2 DIII (residues 299-410 of strain
16681) were expressed in BL21 (DE3) as inclusion bodies and refolded in vitro25. Briefly,
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inclusion bodies were denatured and refolded by gradual dilution into a refolding buffer
(400 mM L-arginine, 100 mM Tris (pH 8.3), 2 mM EDTA, 5 and 0.5 mM reduced and
oxidized glutathione) at 4 °C. Refolded proteins were purified by size-exclusion
chromatography using a Superdex 75, 16/60 (GE Healthcare).
Generation of human hybridomas. Cells from wells with transformed B cells containing
supernatants that exhibited reactivity to ZIKV E protein were fused with HMMA2.5
myeloma cells (gift from L. Cavacini) using an established electrofusion technique26. After
fusion, hybridomas were suspended in a selection medium containing 100 µM
hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine (HAT Media Supplement, Sigma),
and 7 µg ml−1 ouabain (Sigma) and cultured in 384-well plates for 18 days before screening
hybridomas for antibody production by ELISA. After fusion with HMMA2.5 myeloma
cells, hybridomas producing ZIKV E-specific antibodies were cloned biologically by
single-cell fluorescence-activated cell sorting. Hybridomas were expanded in post-fusion
medium (ClonaCell-HY Medium E, STEMCELL Technologies) until 50% confluent in
75-cm2 flasks (Corning).
For antibody production, cells from one 75-cm2 flask were collected with a cell
scraper and expanded to four 225-cm2 flasks (Corning) in serum-free medium (HybridomaSFM, Life Technologies). After 21 days, supernatants were clarified by centrifugation and
filtered using 0.45-µm pore size filter devices. HiTrap Protein G or HiTrap MAbSelectSure
columns (GE Healthcare Life Sciences) were used to purify antibodies from filtered
supernatants.
Sequence analysis of antibody variable region genes. Total cellular RNA was extracted
from pelleted cells from hybridoma clones, and an RT–PCR reaction was performed using
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mixtures of primers designed to amplify all heavy-chain or light-chain antibody variable
regions27. The generated PCR products were purified using AMPure XP magnetic beads
(Beckman Coulter) and sequenced directly using an ABI3700 automated DNA sequencer.
The variable region sequences of the heavy and light chains were analysed using the
IMGT/V-Quest program28,29.
ELISA and EC50 binding analysis. Wells of microtitre plates were coated with purified,
recombinant ectodomain of ZIKV E, DIII, DIII-LR mutants (DIII containing A310E and
T335K mutations) or DIII of related flaviviruses DENV-2 or WNV and incubated at 4 °C
overnight. In ELISA studies with purified mAbs, we used recombinant ZIKV E protein
ectodomain with His6 tag produced in Sf9 insect cells (Meridian Life Sciences R01635).
Plates were blocked with 5% skimmed milk in PBS-T for 1 h. B-cell culture supernatants
or purified antibodies were added to the wells and incubated for 1 h at ambient temperature.
The bound antibodies were detected using goat anti-human IgG (γ-specific) conjugated
with alkaline phosphatase (Southern Biotech) and pNPP disodium salt hexahydrate
substrate (Sigma). In ELISAs that assessed binding of mAbs to DIII and DIII LR mutants,
we used previously described murine mAbs ZV-2 and ZV-54 (ref. 7) as controls. A goat
anti-mouse IgG conjugated with alkaline phosphatase (Southern Biotech) was used for
detection of these antibodies. Colour development was monitored at 405 nm in a
spectrophotometer (Biotek). For determining EC50, microtitre plates were coated with
ZIKV E or E-FLM that eliminated interaction of fusion-loop specific antibodies. Purified
antibodies were diluted serially and applied to the plates. Bound antibodies were detected
as above. A nonlinear regression analysis was performed on the resulting curves using
Prism (GraphPad) to calculate EC50 values.
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ELISA for detection of human antibodies in murine tissues. Fetal head and placental
tissues were collected at E13.5 from groups treated with ZIKV-117 or PBS (as a negative
control), homogenized in PBS (250 µl) and stored at −20 °C. ELISA plates were coated
with ZIKV E protein, and thawed, clarified tissue homogenates were applied undiluted in
triplicate. Bound antibodies were detected using goat anti-human IgG (Fc-specific)
antibody conjugated with alkaline phosphatase. The quantity of antibody was determined
by comparison with a standard curve constructed using purified ZIKV-117 in a dilution
series.
Biolayer interferometry competition binding assay. His6-tagged ZIKV E protein was
immobilized on anti-His coated biosensor tips (Pall) for 2 min on an Octet Red biosensor
instrument. After measuring the baseline signal in kinetics buffer (PBS, 0.01% BSA, and
0.002% Tween 20) for 1 min, biosensor tips were immersed into the wells containing first
antibody at a concentration of 10 µg ml−1 for 7 min. Biosensors then were immersed into
wells containing a second mAb at a concentration of 10 µg ml−1 for 7 min. The signal
obtained for binding of the second antibody in the presence of the first antibody was
expressed as a percentage of the uncompeted binding of the second antibody that was
derived independently. The antibodies were considered competing if the presence of first
antibody reduced the signal of the second antibody to less than 30% of its maximal binding
and non-competing if the signal was greater than 70%. A level of 30–70% was considered
intermediate competition.
Shotgun mutagenesis epitope mapping. Epitope mapping was performed by shotgun
mutagenesis essentially as described previously6. A ZIKV prM/E protein expression
construct (based on ZIKV strain SPH2015) was subjected to high-throughput alanine
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scanning mutagenesis to generate a comprehensive mutation library. Each residue within
prM/E was changed to alanine, with alanine codons mutated to serine. In total, 672 ZIKV
prM/E mutants were generated (100% coverage), sequence confirmed, and arrayed into
384-well plates. Each ZIKV prM/E mutant was transfected into HEK-293T cells and
allowed to express for 22 h. Cells were fixed in 4% (v/v) paraformaldehyde (Electron
Microscopy Sciences), and permeabilized with 0.1% (w/v) saponin (Sigma-Aldrich) in
PBS plus calcium and magnesium (PBS++). Cells were incubated with purified mAbs
diluted in PBS++, 10% normal goat serum (Sigma), and 0.1% saponin. Primary antibody
screening concentrations were determined using an independent immunofluorescence
titration curve against wild-type ZIKV prM/E to ensure that signals were within the linear
range of detection. Antibodies were detected using 3.75 µg ml−1 of AlexaFluor488conjugated secondary antibody (Jackson ImmunoResearch Laboratories) in 10%
NGS/0.1% saponin. Cells were washed three times with PBS++/0.1% saponin followed by
two washes in PBS. Mean cellular fluorescence was detected using a high-throughput flow
cytometer (HTFC, Intellicyt). Antibody reactivity against each mutant prM/E clone was
calculated relative to wild-type prM/E protein reactivity by subtracting the signal from
mock-transfected controls and normalizing to the signal from wild-type prM/E-transfected
controls. Mutations within clones were identified as critical to the mAb epitope if they did
not support reactivity of the test MAb, but supported reactivity of other ZIKV antibodies.
This counter-screen strategy facilitates the exclusion of prM/E mutants that are locally
misfolded or have an expression defect.
Vertebrate animal studies ethics statement. This study was carried out in accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the
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National Institutes of Health. The protocols were approved by the Institutional Animal Care
and Use Committee at the Washington University School of Medicine (Assurance number
A3381-01). Inoculations were performed under anaesthesia induced and maintained with
ketamine hydrochloride and xylazine, and all efforts were made to minimize animal
suffering. No statistical methods were used to predetermine sample size. The experiments
were not randomized and the investigators were not blinded to allocation during
experiments and outcome assessment.
Viruses and cells. ZIKV strain H/PF/2013 (French Polynesia, 2013) was obtained from X.
de Lamballerie (Aix Marseille Université). ZIKV Brazil Paraiba 2015 was provided by S.
Whitehead (Bethesda) and originally obtained from P. F. C. Vasconcelos (Instituto
Evandro Cargas). ZIKV MR 766 (Uganda, 1947), Malaysia P6740 (1966), and Dakar
41519 (Senegal, 1982) were provided by the World Reference Center or Emerging Viruses
and Arboviruses (R. Tesh, University of Texas Medical Branch). Nicaraguan DENV
strains (DENV-1 1254-4, DENV-2 172-08, DENV-3 N2845-09, and DENV-4 N703-99)
were provided generously by E. Harris (University of California, Berkeley). Virus stocks
were propagated in C6/36 Aedes albopictus cells (DENV) or Vero cells (ZIKV). ZIKV
Dakar 41519 (ZIKV-Dakar) was passaged twice in vivo in Rag1−/− mice (M. Gorman and
M. Diamond, unpublished data) to create a mouse-adapted strain. Virus stocks were titrated
by focus-forming assay (FFA) on Vero cells. All cell lines were checked regularly for
mycoplasma contamination and were negative. Cell lines were authenticated at acquisition
with short tandem repeat method profiling; Vero cells, though commonly misidentified in
the field, were used as they are the standard cell line for flavivirus titration.
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Neutralization assays. Serial dilutions of mAbs were incubated with 102 FFU of different
ZIKV strains (MR 766, Dakar 41519, Malaysia P6740, H/PF/2013, or Brazil Paraiba 2015)
for 1 h at 37 °C. The mAb–virus complexes were added to Vero cell monolayers in 96-well
plates for 90 min at 37 °C. Subsequently, cells were overlaid with 1% (w/v)
methylcellulose in MEM supplemented with 4% heat-inactivated FBS. Plates were fixed
40 h later with 1% PFA in PBS for 1 h at room temperature. The plates were incubated
sequentially with 500 ng ml−1 mouse anti-ZIKV (ZV-16, E.F. and M.S.D., unpublished
data) and horseradish-peroxidase-conjugated goat anti-mouse IgG in PBS supplemented
with 0.1% (w/v) saponin (Sigma) and 0.1% BSA. ZIKV-infected cell foci were visualized
using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 5.0.37
macroanalyzer (Cellular Technologies).
mAb binding to ZIKV- or DENV-infected cells. C6/36 Aedes albopictus cells were
inoculated with a MOI 0.01 of ZIKV (H/PF/2013) or different DENV serotypes
(Nicaraguan strains DENV-1 1254-4, DENV-2 172-08, DENV-3 N2845-09, DENV-4
N703-99). At 120 h post infection, cells were fixed with 4% PFA diluted in PBS for 20 min
at room temperature and permeabilized with HBSS supplemented with 10 mM HEPES,
0.1% saponin and 0.025% NaN3 for 10 min at room temperature. 50,000 cells were
transferred to U-bottom plates and incubated for 30 min at 4 °C with 5 µg ml−1 of antiZIKV human mAbs or negative (hCHK-152)12, or positive (hE60)30 isotype controls. After
washing, cells were incubated with Alexa-Fluor-647-conjugated goat anti-human IgG
(Invitrogen) at 1:500, fixed in 1% PFA in PBS, processed on MACSQuant Analyzed
(Miltenyi Biotec), and analysed using FlowJo software (Tree Star).
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Recombinant antibody expression and purification. Total RNA was extracted from
hybridoma cells and genes encoding the VH and VL domains were amplified in RT–PCR
using IgExp primers31. The PCR products were directly cloned into antibody expression
vectors containing the constant domains of wild-type γ1 chain, LALA mutant (leucine (L)
to alanine (A) substitution at positions 234 and 235) γ1 chain for the VH domains, and
wild-type κ chain for the VL domain in an isothermal amplification reaction (Gibson
reaction)32. Plasmids encoding the heavy and light chain were transfected into 293F cells
and full-length recombinant IgG was secreted into transfected cell supernatants.
Supernatants were collected and IgG purified using Protein G chromatography and eluted
into PBS. The functional abrogation of the binding of the LALA variant IgG was confirmed
in an ELISA binding assay with recombinant human FcγRI. The binding of wild-type
ZIKV-117 or LALA antibody to FcγRI was evaluated, in comparison with the binding
pattern of control antibodies (human mAb CKV06333 LALA mutated IgG).
Adult mouse lethal protection experiments. C57BL/6 male mice (4–5-week-old,
Jackson Laboratories) were inoculated with 103 FFU of mouse-adapted ZIKV-Dakar by
subcutaneous route in the footpad. One-day before infection, mice were treated with 2 mg
anti-Ifnar1 mAb (MAR1-5A3, Leinco Technologies) by intraperitoneal injection. ZIKVspecific human mAb (ZIKV-117) or an isotype control (hCHK-152) was administered as
a single dose at day +1 (100 µg) or day +5 (250 µg) after infection through an
intraperitoneal route. Animals were monitored for 21 days.
Pregnant mouse protection experiments. Wild-type C57BL/6 mice were bred in a
specific pathogen-free facility at Washington University School of Medicine.
(1) Ifnar1−/− dams, prophylaxis studies: Ifnar1−/− female and wild-type male mice were
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mated; at E5.5, dams were treated with a single 250 µg dose of ZIKV mAb or isotype
control by intraperitoneal injection. At E6.5, mice were inoculated with 103 FFU of ZIKV
Brazil Paraiba 2015 by subcutaneous injection in the footpad. (2) Wild-type dams,
prophylaxis studies: wild-type female and male mice were mated; at embryonic days E5.5,
dams were treated with a single 250 µg dose of ZIKV mAb or isotype control by
intraperitoneal injection as well as a 1 mg injection of anti-Ifnar1 (MAR1-5A3). At E6.5,
mice were inoculated with 103 FFU of mouse-adapted ZIKV-Dakar by subcutaneous
injection in the footpad. At E7.5, dams received a second 1 mg dose of anti-Ifnar1 through
an intraperitoneal route. (3) Wild-type dams, therapy studies: wild-type female and male
mice were mated; at embryonic days E5.5, dams were treated with a 1 mg injection of antiIfnar1 (MAR1-5A3). At E6.5, mice were inoculated with mouse-adapted 103FFU of ZIKVDakar by subcutaneous injection in the footpad. At E7.5, dams received a second 1 mg
dose of anti-Ifnar1 as well as a single 250 µg dose of ZIKV mAb or isotype control through
an intraperitoneal route. All animals were euthanized at E13.5, and placentas, fetuses and
maternal tissues were collected. Fetus size was measured as the crown-rump length ×
occipitofrontal diameter of the head.
Measurement of viral burden. ZIKV-infected tissues were weighed and homogenized
with stainless steel beads in a Bullet Blender instrument (Next Advance) in 200 µl of PBS.
Samples were clarified by centrifugation (2,000g for 10 min). All homogenized tissues
from infected animals were stored at −20 °C. Tissue samples and serum from ZIKVinfected mice were extracted with RNeasy 96 Kit (tissues) or Viral RNA Mini Kit (serum)
(Qiagen). ZIKV RNA levels were determined by TaqMan one-step quantitative reverse
transcriptase PCR (qRT–PCR) on an ABI7500 Fast Instrument using published primers
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and conditions34. Viral burden was expressed on a log10 scale as viral RNA equivalents per
g or ml after comparison with a standard curve produced using serial tenfold dilutions of
ZIKV RNA.
Viral RNA in situ hybridization. RNA in situ hybridization was performed with
RNAscope 2.5 (Advanced Cell Diagnostics) according to the manufacturer’s instructions.
PFA-fixed paraffin embedded placental sections were deparaffinized by incubation for
60 min at 60 °C. Endogenous peroxidases were quenched with H2O2 for 10 min at room
temperature. Slides were boiled for 15 min in RNAscope Target Retrieval Reagents and
incubated for 30 min in RNAscope Protease Plus before probe hybridization. The probe
targeting ZIKV RNA was designed and synthesized by Advanced Cell Diagnostics
(catalogue number 467771). Negative (targeting bacterial gene dapB) control probes were
also obtained from Advanced Cell Diagnostics (catalogue number 310043). Tissues were
counterstained with Gill’s haematoxylin and visualized with standard bright-field
microscopy.
Histology and immunohistochemistry. Collected placentas were fixed in 10% neutral
buffered formalin at room temperature and embedded in paraffin. At least three placentas
from different litters with the indicated treatments were sectioned and stained with
haematoxylin and eosin to assess morphology. Surface area and thickness of placenta and
different layers were measured using Image J software. For immunofluorescence staining
on mouse placentas, deparaffinized tissues were blocked in blocking buffer (1% BSA,
0.3% Triton, PBS) for 2 h and incubated with anti-vimentin antibody (1:500, rabbit, Abcam
ab92547). Secondary antibody conjugated with Alexa 488 (1:500 in PBS) was applied for
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1 h at room temperature. Samples were counterstained with DAPI (4′6′-diamidino-2phenilindole, 1:1,000 dilution).
Statistical analysis. All virological data were analysed with GraphPad Prism software.
Kaplan–Meier survival curves were analysed by the log rank test, and viraemia was
compared using an ANOVA with a multiple comparisons test. P < 0.05 indicated
statistically significant differences.
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Figure 3.1: Human antibody and B-cell response to ZIKV infection
A, B, Serum samples from humans with a previous ZIKV infection were tested for binding to ZIKV E
protein in ELISA (A) (with two technical replicates) and neutralization of ZIKV (B) (at least two
independent repeats in triplicate). Subject 1001 had the highest endpoint titre in the binding assay and
displayed potent neutralizing activity. Subject 657 was a control without history of exposure to ZIKV. c,
Supernatants of Epstein–Barr virus (EBV)-transformed B-cell cultures from subject 1001 were tested for
binding to ZIKV E or DIII of ZIKV E or related flavivirus E proteins; the WNV-reactive clone and all but
one DENV-reactive B-cell line also reacted with ZIKV E protein. The frequency of antigen-specific cells
against each viral protein was determined with a threshold absorbance value at 405 nm (A405 nm) of 1.5 as
indicated. d, In four additional separate B-cell transformation experiments, the frequency of B cells reactive
with intact ZIKV E or E-FLM was determined.
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Figure 3.2: Characterization of anti-ZIKV mAbs
A) We tested 29 mAbs in binding, neutralization, and competition binding assays. The EC50 against ZIKV
E and the IC50 (by focus reduction neutralization test) against H/PF/2013 strain for neutralizing antibodies
(highlighted in blue) are shown. The mAbs are displayed in four groups (A, B, C or D) based on a
competition binding assay. The values are the percentage of binding that occurred during competition
compared to non-competed binding, which was normalized to 100% and the range of competition is
indicated by the box colours. Black filled boxes indicate strongly competing pairs (residual binding <30%),
grey filled boxes indicate intermediate competition (residual binding 30–69%), and white filled boxes
indicate non-competing pairs (residual binding ≥ 70%). The IC50 against H/PF/2013 strain for neutralizing
antibodies is shown with neutralizing clones highlighted in blue. B, A ribbon diagram of three protomers
of ZIKV E (DI in red, DII in yellow and DIII in blue) is shown with critical residues highlighted as spheres
from epitope mapping experiments for representative antibodies in each of the competition binding groups.
The colours of the critical residues correspond to the competition group designation as in A. The mutations
in the E-FLM and DIII-LR mutants are indicated by black and silver spheres, respectively. C,
Representative mAbs from each competition binding group are listed with the domains and residues critical
for binding. FL, fusion loop. D, Two mAbs were tested for neutralization of five strains of ZIKV. The
concentrations (ng ml−1) at which 50% or 90% neutralization occurred are listed in E. The neutralization
data are pooled from at least three independent experiments performed in triplicate.
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Figure 3.3: Binding of human mAbs to Zika E protein, E-DIII or E-FLM
mAbs are organized by competition binding groups A to D. Purified mAbs were tested for binding to
different antigens as indicated in ELISA as described in Methods. Non-linear regression analysis of the data
was performed, and the data plotted are the mean and s.d.
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Figure 3.4: High resolution epitope mapping of ZIKV mAbs
a, An alanine scanning mutation library for ZIKV envelope protein was constructed, in which each amino
acid of prM/E was mutated individually to alanine (and alanine to serine) and expression constructs arrayed
into 384-well plates, one mutation per well. Each clone in the ZIKV prM/E mutation library, expressed in
HEK-293T cells, was tested for immunoreactivity with five mAbs from competition groups A–D, measured
using an Intellicyt high-throughput flow cytometer. Shown here for each of the five mAbs is the reactivity
with the ZIKV E protein mutants that identified the epitope residues for these mAbs. mAb reactivity for
each alanine mutant are expressed as percent of the reactivity of mAb with wild-type ZIKV prM/E. Clones
with reactivity <30% relative to wild-type ZIKV prM/E were identified as critical for mAb binding. Bars
represent the mean and range of at least two replicate data points. Binding of group B mAbs, ZIKV-116 to
wild-type ZIKV E DIII (b) or DIII LR mutant (c) was compared with mouse mAbs ZV-2 and ZV-54.
Binding of ZIKV-116 was decreased by mutations in DIII-LR. Data plotted are mean ± s.d.
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Figure 3.5: Binding of human mAbs to permeabilized DENV-infected C6/36 cells
C6/36 cells were infected with DENV-1, DENV-2, DENV-3, DENV-4 or mock infected. Cells were stained
with the indicated anti-ZIKV mAbs, an isotype negative control (hCHK-152), or a positive control (a crossreactive antibody to DENV; chimeric human E60 (chE60)) and processed by flow cytometry. The data are
representative of two independent experiments. The numbers in the box indicate the fraction of cells that
stained positively.
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Figure 3.6: Protective activity of ZIKV-117 in adult male and pregnant female mice
A, We treated 4–5-week-old wild-type male mice with 2 mg of anti-Ifnar1 mAb followed by subcutaneous
inoculation with 103 FFU of mouse-adapted ZIKV-Dakar. Mice were treated with a single 100 µg or 250 µg
dose of isotype control mAb (hCHK-152) or ZIKV-117 on D+1 or D+5 (n = 10 per group from two
independent experiments), respectively. Significance was analysed by the log-rank test (*P < 0.05;
**P < 0.01). B,C, Ifnar1−/− female mice were mated with wild-type sires. At E5.5, dams were treated with
250 µg of either hCHK-152 isotype control mAb or ZIKV-117. Bars indicate the median values and reflect
data pooled from four independent experiments. Significance for fetal survival and viral RNA was analysed
by chi-square (B; ****P < 0.0001) and Mann–Whitney (C; *P < 0.05) tests, respectively. D-F, Wild-type
female mice were mated with wild-type sires. At E5.5, dams were treated with anti-Ifnar1 mAb and one of
the following: PBS (D,E), 250 µg (D-F) of hCHK-152 isotype control mAb, 250 µg of ZIKV-117 (D-F) or
250 µg of ZIKV-117 LALA (f). At E6.5, dams were inoculated with 103 FFU of ZIKV-Dakar. D-F, Fetuses
and placentas (D,F) and maternal brain and serum (e) were collected on E13.5 and viral RNA was measured
by qRT–PCR. Bars indicate the median values of samples collected from three biological replicates
(D, n = 20–36; E, n = 5–9; F, n = 23–28). Significance was analysed by ANOVA with a Dunn’s multiple
comparison test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). G,H, Wild-type female mice were
mated with wild-type sires. At E5.5, dams were treated with anti-Ifnar1 mAb. At E6.5, dams were
inoculated with 103 FFU of ZIKV-Dakar. At E7.5 (day +1 after infection), dams were treated with PBS,
250 µg of hCHK-152 isotype control mAb, or 250 µg of ZIKV-117. G, H, Fetuses and placentas (G) and
maternal brain and serum (H) were collected on E13.5 and viral RNA was measured by qRT–PCR. Bars
indicate the median values of samples collected from three biological replicates (G, n = 8–20; H, n = 3–7).
Significance was analysed by ANOVA with Dunn’s (G) or Tukey’s (H) multiple comparisons test
(*P < 0.05, ***P < 0.001, ****P < 0.0001). Dashed lines indicate the limit of detection of the assay.
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Figure 3.7: Detection of human IgG in placenta or fetal head tissues in ZIKV-117- or PBS-treated
pregnant mice
As described in Figure 3.6, wild-type female mice were mated with wild-type sires and monitored for
pregnancy. At E5.5, dams were treated with anti-Ifnar1 mAb and PBS or 250 µg of ZIKV-117. One day
later (E6.5), dams were inoculated with 103 FFU of ZIKV-Dakar. Fetuses and placentas (n = 4 each) were
collected on E13.5, homogenized, and tested for human IgG by ELISA. Human antibody in tissues was
captured on ELISA plates coated with ZIKV E protein and detected using goat anti-human IgG (Fc-specific)
antibody. The quantity of antibody was determined by comparison with a standard curve constructed using
purified ZIKV-117 in a dilution series. Four replicate measurements were performed for each mouse tissue
and the results were averaged. The graphs represent the mean + s.e.m. from 3 mice per group.
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Figure 3.8: Comparison of wild-type and LALA-mutated antibodies
A, Binding to recombinant human FcγR1. The functional abrogation of the binding of the LALA variant
IgG was confirmed in an ELISA binding assay with recombinant human FcγRI. ZIKV-117 wild-type bound
to FcγRI, whereas the ZIKV-117 LALA antibody did not. Wild-type and LALA versions of another human
mAb, CKV063, were used as controls. Binding to human FcγRI is one representative experiment of two,
and error bars indicate s.e.m. of triplicate technical replicates. B, Neutralization assays. Wild-type ZIKV117 and LALA antibodies exhibited equivalent neutralizing activity in vitro to each other and to the
hybridoma-derived antibody. Neutralization assays are representative of two independent experiments
completed in triplicate.
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Figure 3.9: Effect of ZIKV-117 treatment on the placenta and the fetus
A, Cartoon depicting murine placental structures and zones. B-E, Pregnant dams were treated with PBS,
hCHK-152, or ZIKV-117 as described in Fig. 3d–f before infection with ZIKV-Dakar or mock-infected. B,
Haematoxylin and eosin staining of placenta at E13.5. Placental labyrinth zone is marked with a solid line.
Low power (scale bar, 1 mm) and high power (scale bar, 50 µm) images are presented in sequence. Black
arrows indicate apoptotic trophoblasts in areas corresponding to regions of ZIKV infectivity (see panel D,
below). C, Measurements of thickness and indicated areas of placenta and fetus body size. Each symbol
represents data from an individual placenta or fetus. Significance was analysed by ANOVA with a Dunn’s
multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, P > 0.05, NS, not
significant). D, In situ hybridization. Low (scale bar, 500 µm) and high (scale bar, 50 µm) power images
are presented in sequence. Black arrows indicate cells positive for ZIKV RNA in the junctional zone of the
placenta. The images in panels are representative of several placentas from independent dams. E, Low
(scale bar, 50 µm) and high (scale bar, 10 µm) power magnified images of immunofluorescence staining of
placentas for vimentin (in green, which marks fetal capillary endothelium) from ZIKV-infected dams
treated with PBS or ZIKV-117 or from uninfected pregnant animals. Nuclei are counter-stained blue with
DAPI.
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Figure 3.10: In situ hybridization of Ifnar1+/- placenta after inoculation with ZIKV-Brazil and
treatment with ZIKV-117
As described in Figure 3.6Bs, Ifnar1−/− female mice were mated with wild-type sires and monitored for
pregnancy. At E5.5, dams were treated with 250 µg of either hCHK-152 isotype control or ZIKV-117. At
E6.5, dams were inoculated with 103 FFU of ZIKV-Brazil. Collected placentas were fixed in 10% neutral
buffered formalin at ambient temperature and embedded in paraffin. At least three placentas from different
litters with the indicated treatments were sectioned for in situ hybridization staining using negative or
ZIKV-specific RNA probes. Low (scale bar, 500 µm) and high (scale bar, 50 µm) power images are
presented in sequence.
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Human antibodies to the dengue virus E-dimer epitope have
therapeutic activity against Zika virus infection
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4.1

Summary
The Zika virus (ZIKV) epidemic has resulted in congenital abnormalities in fetuses and

neonates. Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance
ZIKV infection in mice, those recognizing the DENV E-dimer epitope (EDE) can neutralize ZIKV
infection in cell culture. We evaluated the therapeutic activity of human monoclonal antibodies to
DENV EDE for their ability to control ZIKV infection in the brains, testes, placentas, and fetuses
of mice. A single dose of the EDE1-B10 antibody given 3 d after ZIKV infection protected against
lethality, reduced ZIKV levels in brains and testes, and preserved sperm counts. In pregnant mice,
wild-type or engineered LALA variants of EDE1-B10, which cannot engage Fcg receptors,
diminished ZIKV burden in maternal and fetal tissues, and protected against fetal demise. Because
neutralizing antibodies to EDE have therapeutic potential against ZIKV, in addition to their
established inhibitory effects against DENV, it may be possible to develop therapies that control
disease caused by both viruses.
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4.2

Introduction
Zika virus (ZIKV) is an arthropod-transmitted, positive-sense RNA virus that is
closely related to viruses causing human disease, such as dengue (DENV), yellow fever
(YFV), West Nile (WNV), and Japanese encephalitis (JEV) viruses. Historically, ZIKV
infection in humans has been associated with a self-limiting mild, febrile illness1. Since its
epidemic emergence in 2007, ZIKV infection has become linked to more severe clinical
syndromes. For example, infection of pregnant women, particularly during the first
trimester, can result in congenital Zika syndrome, which includes microcephaly,
neurodevelopmental abnormalities, and fetal demise2–4. In adults, ZIKV infection is
associated with Guillain–Barré syndrome (GBS), an autoimmune disease characterized by
ascending paralysis and polyneuropathy5,6.
The ZIKV genome is organized as a single open reading frame that has genes
encoding three structural (capsid (C), pre-membrane/membrane (prM/M), and envelope
(E)) and seven nonstructural (NS) proteins. The ZIKV E protein is composed of three
domains: a central β-barrel domain (domain I; DI), an extended dimerization domain
containing a hydrophobic fusion loop (FL) epitope at the distal end (domain II; DII), and
an immunoglobulin-like segment implicated in receptor-binding and entry (domain III;
DIII)7. In the immature state of the virion, the prM and E proteins form 60 spiky
heterotrimers that protrude from the viral membrane surface8. Maturation during transit
through the trans-Golgi network results in furin-mediated cleavage of prM to M. After this
cleavage event, the E protein homodimers re-arrange in an anti-parallel orientation to form
a herringbone array and a smooth virion surface. The transitions undergone by the viral
particles expose different epitopes on the E protein that are essential for receptor-binding,
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entry, and fusion. The E protein is also the primary target for neutralizing antibody
responses.
ZIKV strains are classified into two genetic lineages, the African and the Asian–
American lineages. Because their neutralization by serum and monoclonal antibodies
(mAbs) is quite similar, ZIKV is categorized as a single serotype9. Genetic clustering
places ZIKV in close relationship to DENV, with the E proteins showing 54–59% amino
acid identity10,11.
The humoral response to ZIKV infection has been studied by several groups, with
advances made in our understanding of the epitopes engaged by protective mAbs12. MAbs
that target the conserved DII-FL epitope generally are poorly neutralizing against ZIKV;
despite this, passive transfer studies in mice have suggested that these mAbs can offer some
degree of protection against ZIKV infection, possibly because of 'virus breathing' and
further exposure of this epitope7,13,14. DII-FL-specific mAbs generated against DENV or
ZIKV also have the potential to induce reciprocal antibody-dependent enhancement (ADE)
of ZIKV or DENV infection in myeloid cells bearing transmembrane Fcγ receptors
(FcγRs)15,16 and in mice17. In comparison, strongly neutralizing and protective mouse and
human mAbs to ZIKV have been described that bind epitopes in DIII (lateral ridge or Astrand18–20), across adjacent dimers in DII19, or to sites in DI21. A distinct class of crossreactive mAbs that engage DII-FL are the EDE-specific mAbs. These mAbs were isolated
from DENV-infected patients, bind to an inter-dimer quaternary epitope with contact
residues in DI, DII, and DIII, and cross-react with ZIKV10,11,16,22. EDE-specific mAbs are
classified by their binding in the context of N-linked glycosylation at position Asn154 of
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the E protein. EDE1 mAbs, which bind in the absence of the N-linked glycan, inhibit ZIKV
more potently than do EDE2 mAbs10,16.
Studies in mice, nonhuman primates, and humans have shown that ZIKV can infect
and persist in several immune-privileged sites including the eye4,23,24, brain23,25,26,
testis27,28, and placenta25,29. Here we evaluated the therapeutic activity of EDE1 mAbs in
ZIKV infection. Although EDE1-B10 showed protective activity when administered
within 5 d of infection, it was less effective at clearing infection from immune-privileged
tissues after ZIKV disseminated to these sites. In the context of pregnancy, leucine and
alanine (LALA) variants of EDE1, which cannot bind FcγR, protected against ZIKV
infection, as did recombinant wild-type (WT) mAbs. Our studies suggest that it may be
possible to develop EDE1 LALA mAb therapeutics that prevent both ZIKV and DENV
infection without the possibility for pathological antibody-dependent immune
enhancement.
4.3

Results
Human mAbs to DENV inhibit ZIKV infection. Previous studies have established that
the EDE1-C8 and EDE1-C10 mAbs bind to and neutralize ZIKV with half-maximal
effective concentration (EC50) values ranging from 9 to 14 ng/ml10,30. We compared the
ability of another EDE1 mAb, EDE1-B10, to neutralize the four serotypes of DENV and
the two lineages of ZIKV. EDE1-B10 strongly neutralized virions of the DENV-1, DENV2, and DENV-3 serotypes (EC50 ~28–138 ng/ml) and showed weaker activity against
virions of the more distantly related DENV-4 serotype (Figure 4.1A). We tested EDE1B10 for its ability to inhibit virus strains that represented the African (HD78788) and
Asian–American (Brazil PE243) lineages of ZIKV and found that it had a stronger
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neutralization profile (EC50 ~2–4 ng/ml) than that of EDE1-C8 and other published EDEspecific mAbs10,16 (Figure 4.1B). As with other EDE-specific mAbs, EDE1-B10 engages
a quaternary epitope on the virion and does not bind monomeric E protein although the
epitope is restored on covalently linked E-dimers30,31. Like many other flavivirus-specific
antibodies, subneutralizing concentrations of EDE-specific mAbs can trigger ADE of
FcγR-expressing myeloid cells. To prevent possible ADE, we engineered LALA
substitutions into the Fc region of EDE1-B10 and EDE1-C8, which disrupted engagement
of the mAbs with Fc receptors and prevented ADE, but did not change neutralizing activity
against ZIKV (Figures 4.1C and 4.1D)32. Thus, mAbs to DENV EDE strongly neutralize
ZIKV infection, and LALA variants that do not promote ADE can be generated without a
loss of inhibitory activity in cell culture.
EDE1 mAb therapy controls ZIKV infection. We tested EDE-specific human mAbs for
their ability to protect mice against ZIKV-induced lethality when administered as a postexposure therapy. To create a lethal challenge model in 4- to 5 week-old C57BL/6 mice,
we passively transferred a blocking antibody specific for the type I interferon receptor
Ifnar1 1 d before infection with 103 focus-forming units (FFUs) of a mouse-adapted
African strain of ZIKV (ZIKV-Dakar)18,19. The mice were then treated with a single dose
of EDE1-B10, EDE1-C8 (EC50 = 2–15 ng/ml), EDE2-A11 (EC50 = 69–125 ng/ml)10, or an
isotype control mAb (Flu 28C) 1 d (day +1; 100 µg), 3 d (day +3; 250 µg), or 5 d (day +5;
250 µg) after infection and the weight and survival of the mice were monitored for 21 d
(Figures 4.2A and 4.3). The mice that were administered EDE1-B10, EDE1-C8, or EDE2A11 were protected against lethality when they were treated at 1 or 3 d after infection.
Furthermore, treatment with EDE1-B10 at 5 d after infection resulted in partial protection
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against lethality and weight loss (Figures 4.2A and 4.3). Given the greater neutralization
activity of EDE1-B10 in vitro, relative to that with the other EDE-specific mAbs, and its
ability to robustly protect against lethality, most of the subsequent in vivo studies were
performed with only EDE1-B10.
As a first step toward determining how EDE1 mAbs protect against disease, we
defined the kinetics of viral dissemination for the tissues of interest. Within 2 d of infection,
ZIKV RNA was readily detectable in the serum (1.7 × 105 FFU equivalents per ml; Figure
4.2B), brain (3.5 × 103 FFU equivalents per g tissue; Figure 4.2C), testis (4.8 × 103 FFU
equivalents per g tissue; Figure 4.2D), epididymis (5.0 × 102 FFU equivalents per g
tissue; Figure 4.2E), and eye (8.8 × 102 FFU equivalents per g tissue; Figure 4.2F). At the
last time point assessed (day +5), viral titers were still increasing in these organs.
We then evaluated the efficacy of EDE1-B10 therapy on the control of ZIKV
infection at different immune-privileged sites during the acute and persistent phases of
infection. Adult C57BL/6 male mice were pretreated with an Ifnar1-specific blocking
antibody and inoculated with 105 FFUs of mouse-adapted ZIKV-Dakar. The mice were
then administered a single dose of EDE1-B10 or an isotype control mAb at day +1 (100
µg), day +3 (250 µg), or day +5 (250 µg) after infection, and viral RNA levels were assessed
at day +5 (acute phase) or at day +21 (persistent phase) after infection. Treatment at day
+1 decreased the levels of ZIKV RNA in serum at day +5 (52-fold; P < 0.001; Figure
4.2G). Similarly, EDE1-B10 therapy at day +1 reduced viral RNA levels in the following
tissues at day +5 (Figures 4.2H-4.2J) and day +21 (Figures 4.2L-4.2N), relative to that
observed in mice treated with the isotype control mAb: brain (1,760-fold and 42-fold,
respectively; P < 0.001), testis (1,650-fold and 312-fold, respectively; P< 0.001), and
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epididymis (4,780- fold and 206-fold, respectively; P < 0.001). Whereas reduced levels
were observed in the eye at day +5 after EDE1-B10 therapy at day +1 (1,550-fold; P <
0.001; Figure 4.2K), ZIKV RNA levels were low at day +21 in EDE1-B10 and isotype
control mAb groups suggesting clearance occurred independently of mAb treatment
(Figure 4.2O).
In another set of experiments, we treated mice with EDE1-B10 at day +3 after
infection and evaluated viral burden in tissues at day +5 and day +21 after infection.
Treatment with EDE1-B10 at day +3 after infection had less of an effect on viral RNA
levels at day +5 than treatment with EDE1-B10 at day +1, with smaller reductions observed
in serum (fourfold; P < 0.05), brain (ninefold; P < 0.001), testis (threefold; P > 0.05),
epididymis (116-fold, P < 0.001), and eye (threefold; P < 0.05) (Figures 4.2G-4.2K). In
comparison, EDE1-B10 treatment at day +3 after infection resulted in decreased ZIKV
RNA levels in the testis (62-fold; P < 0.05) and epididymis (1,800-fold; P < 0.05) at day
+21 after infection, although levels in the brain were not affected, as compared to the
treatment with the isotype control mAb (Figures 4.2L-4.2N).
Finally, we evaluated EDE1-B10 therapy at day +5 after infection for its effect on
viral burden at day +21. However, treatment with EDE1-B10 beginning at day +5 after
infection failed to decrease ZIKV RNA levels at day +21 in any of the sites tested, as
compared to that after treatment with the isotype control mAb (Figures 4.2L-4.2O). To
begin to define why EDE1-B10 was protective at some sites but not others, we measured
mAb levels in tissues at day +5 after therapy was initiated at day +1 or day +3 after infection
(Figure 4.4). Although the levels of EDE1-B10 in serum at day +5 were relatively
equivalent, levels of the mAb in the brain and testis were lower (P < 0.01) when therapy
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was started at day +1 after infection than at day +3 after infection. This may reflect the
dimished systemic viral burden associated with treatment at day +1 after infection, which
we speculate limits pro-inflammatory immune responses that compromise the function of
the blood–brain barrier and the blood–testis barrier and allows EDE1-B10 access. Notably,
lower amounts of EDE1-B10 penetrated into the eye at day +5 after treatment regardless
of when the treatment was initiated, which may be due to a less permeable blood–retinal
barrier33. Because treatment at day +5 failed to reduce viral RNA levels at day +21, this
suggested that once immune-privileged sites were seeded, it may be difficult to accumulate
sufficient amounts of the EDE1-B10 mAb to control or clear the infection. In summary,
these experiments show that there is a narrow window of time after infection during which
treatment with the EDE1-B10 mAb is able to reduce ZIKV RNA levels in some, but not
other, immune-privileged sites once viral seeding had occurred.
To corroborate the protective effects observed with EDE1-B10 therapy, we
evaluated ZIKV infection in the male reproductive tract at day +21 using RNA in
situ hybridization (ISH). RNA ISH confirmed the absence of ZIKV RNA in the testis and
epididymis of mice treated with EDE1-B10 at day +1 after infection and showed reduced
viral RNA levels when treatment was initiated at day +3 after infection (Figures
4.5A and 4.6). By comparison, mice treated with the isotype control mAb had high viral
RNA levels, similar to those reported for untreated, infected mice27. Treatment with EDE1B10 at day +1 or day +3 after infection also protected against ZIKV-induced inflammation
and damage to the seminiferous tubules that was observed in mice treated with the isotype
control mAb (Figures 4.5B and 4.6) and described previously27,28. In contrast, treatment
that was initiated at day +5 after infection minimally protected against ZIKV infection or
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injury. We also evaluated the functional effect of EDE1-B10 treatment in the testis by
computer-assisted sperm analysis. Whereas ZIKV-infected mice treated with the isotype
control mAb showed low numbers of motile sperm, treatment with EDE1-B10 at day +1
or day +3 after infection but not at day +5 after infection resulted in higher numbers of
motile sperm (16-fold and 100-fold, respectively; P < 0.001) at day +21 after infection
(Figure 4.5C), which were similar to those observed in age-matched, uninfected male mice
(Figure 4.5C). These data suggest that EDE1-B10 treatment can reduce viral persistence
in select immune-privileged sites (for example, brain and testis) and protect against tissue
injury when administered within a few days of infection.
EDE1-B10 therapy in maternal and fetal tissues. In pregnant mice that are deficient in
type I interferon signaling, placental damage, and fetal infection and injury, occur after
ZIKV infection24,29,34,35. To assess the protective ability of EDE1-B10 treatment during
pregnancy, we mated Ifnar1−/− dams with WT C57BL/6 sires, and on embryonic day 6.5
(E6.5), we inoculated the dams subcutaneously with a Brazilian ZIKV strain (Paraiba
2015)19,34. One day after infection (at E7.5), we administered a single 250-µg dose of
EDE1-B10 or an isotype control mAb and monitored the effects on the Ifnar1−/− dam and
the Ifnar1+/− placenta and fetus. Seven days after ZIKV inoculation (at E13.5), we observed
a 90% rate of fetal demise in the group that was treated with the isotype control mAb versus
a 10% rate of fetal demise in the group that was treated with EDE1-B10 (P < 0.0001)
(Figure 4.7A, left). Histological analysis confirmed that the fetal demise caused by ZIKV
infection was prevented by the EDE1-B10 therapy (Figure 4.7A, right). Consistent with
these data, EDE1-B10 treatment at day +1 after infection reduced viral RNA burden in the
maternal serum (~71-fold; P < 0.01) and brain (~39,000-fold; P < 0.05) at day +7 after
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infection, as compared to that after treatment with the isotype control mAb (Figure 4.7B
and 4.7C). Analysis of the placentas by ISH showed ZIKV RNA in the maternal decidua
and the junctional layer of the placenta in the mice that were treated with the isotype control
mAb; in contrast, viral RNA staining was not observed in the dams that were treated with
EDE1-B10 (Figure 4.7D). Histological analysis after ZIKV infection showed reductions
in the size of the labyrinth layer of the placenta in the control-mAb-treated dams, but this
was not seen for the dams that were treated with EDE1-B10 at day +1 after infection
(Figure 4.7E).
The extent of fetal demise after ZIKV infection of Ifnar1−/− dams precluded
virological assessment of EDE1-B10 protection in the fetus. To obtain such data, we used
a second model of ZIKV infection in pregnancy with an acquired deficiency of type I
interferon signaling19,34. WT females that were mated with WT males were treated with an
Ifnar1-specific blocking mAb at E5.5. One day later (at E6.5), the dams were inoculated
subcutaneously with mouse-adapted ZIKV-Dakar, and 1 d (at E7.5) or 3 d (at E9.5) later
they were treated with EDE1-B10 or an isotype control mAb. Treatment of pregnant dams
with EDE1-B10 at day +1 after infection resulted in reduced levels of viral RNA in the
maternal serum (~240-fold; P < 0.001) and brain (~3,000-fold; P < 0.05), as compared to
that in the serum and brain of dams that were treated with the isotype control mAb (Figures
4.8A and 4.8B). When treatment was initiated at day +1 after infection, we observed
markedly less ZIKV RNA levels in the placenta and fetal head (660,000-fold and 4,900fold, respectively; P < 0.0001) of EDE1-B10-treated dams than in those of the controlmAb-treated dams (Figures 4.8C and 4.8D). Treatment of dams with EDE1-B10 at day +3
after infection also reduced ZIKV RNA levels in the maternal serum (22-fold; P < 0.05)
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and brain (114-fold; P < 0.001), as compared to that in the dams that were treated with the
isotype control mAb (Figures 4.8A and 4.8B). Although ZIKV levels in the placenta (23fold; P < 0.0001) and fetal head (19-fold; P < 0.0001) were lower in the EDE1-B10-treated
group than in the control-mAb-treated group, therapy administered at this time point did
not prevent virus seeding (Figures 4.8C and 4.8D).
We next evaluated whether antibody effector functions were required for EDE1B10-mediated protection. We generated a mutant version of the EDE1-B10 mAb (LALA
variant)32 that was unable to bind to FcγR and promote ADE (Figure 4.1C), and we tested
its efficacy in vivo during pregnancy. Like therapy with the recombinant WT EDE1-B10
mAb, treatment of dams with EDE1-B10 LALA at day +1 after infection resulted in
reduced viral RNA levels in the maternal serum (240-fold; P < 0.01), maternal brain
(3,000-fold; P < 0.05), placenta (633,000-fold; P < 0.0001), and fetal head (4,600-fold; P <
0.0001) (Figures 4.8A and 4.8B). Analogous experiments with paired recombinant WT
EDE1-C8 and EDE1-C8 LALA yielded similar results (Figure 4.9). Thus, in
utero protection mediated by EDE1 mAbs occurs independently of Fc effector functions
and is probably mediated by direct virus neutralization. The mutant mAbs that are unable
to bind FcγR could be safer immunotherapies, as they lack the potential to mediate ADE
and immunopathogenesis.
To corroborate the protective effects the EDE-B10 mAb in the placenta, we
analyzed tissue sections for virus infection and tissue injury. RNA ISH of placentas from
dams that were treated at day +1 after infection showed a virtual absence of ZIKV-infected
cells in the decidua and placenta, and mice that were treated at day +3 after infection also
showed reduced viral RNA staining in these tissues, as compared to that in the tissues of
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control-mAb-treated dams (Figure 4.8E). Histological measurements of the placental
layers showed that treatment at day +1 after infection, but not at day +3 after infection,
with EDE1-B10 restored the area and width of the junctional area, the total placental area,
and the overall fetal size (Figures 4.8F-4.8I), as compared to treatment with the isotype
control mAb. These data confirm a narrow therapeutic window for EDE1-B10 in
preventing ZIKV infection and injury to the developing placenta and fetus.
Sexual transmission is an established route of ZIKV infection36–41. Male-to-female
transmission of ZIKV has been modeled in pregnant mice through direct intravaginal
inoculation of virus29. Although recent vaccine studies indicate that adaptive immune
responses can protect against in utero transmission for ZIKV inoculated subcutaneously42,
no study has shown this in the context of vaginal transmission. We assessed whether
administration of EDE1-B10 through a peripheral route could prevent in utero transmission
following intravaginal inoculation of ZIKV (Figure 4.10). WT dams that were mated with
WT sires were then treated with the Ifnar1-specific blocking mAb and a single 250-µg dose
of EDE1-B10 or isotype control mAb at E5.5. At E6.5, the dams were inoculated with
mouse-adapted ZIKV-Dakar via the intravaginal route. At E7.5, the dams were given a
second dose of anti-Ifnar1. At E13.5, we determined the viral RNA burden in maternal and
fetal tissues, including those of the female reproductive tract. Treatment with EDE1-B10
reduced ZIKV RNA levels in the maternal serum (427-fold; P < 0.05) and brain (45,490fold; P < 0.01) (Figures 4.10A and 4.10B), as compared to those in the control-mAbtreated mice. In EDE1-B10-treated dams, ZIKV RNA levels were diminished, relative to
those in the control-mAb-treated mice, in all female reproductive-tract tissues, including
the vagina (106,840-fold; P < 0.01), cervix (12,450-fold; P < 0.01), and ovaries (341,300-
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fold; P < 0.01) (Figures 4.10C-4.10E). Because EDE1-B10 treatment also reduced ZIKV
RNA levels in the placenta (1,725,600-fold; P < 0.0001) and fetal head (3,020-fold; P <
0.0001) (Figures 4.10F and 4.10G), this indicated that circulating neutralizing antibodies
can prevent transvaginal transmission of ZIKV to the placenta and fetus. Consistent with
these data, staining by ISH showed a virtual absence of ZIKV RNA in the placenta and
decidua of EDE1-B10-treated dams, as compared to that in control-mAb-treated dams
(Figure 4.10H). Overall, these experiments establish that EDE1-B10 therapy can protect
against ZIKV infection and transmission to the fetus after subcutaneous or intravaginal
inoculation.
4.4

Discussion
A primary goal of this study was to identify human mAbs that could potently
neutralize ZIKV and provide post-exposure protection in vivo, including reduction of
infection in key immune-privileged sites. Prior studies had shown that EDE-specific mAbs
that had been isolated from DENV-infected subjects could neutralize DENV and ZIKV in
vitro10,11 and protect against ZIKV lethality in vivo when administered as prophylaxis22.
Studies with more ZIKV-specific human mAbs that do not cross-react with DENV also
have demonstrated post-exposure therapeutic activity in lethality models in mice17,19–21. On
the basis of in vitro neutralization studies, we defined EDE1-B10 as a candidate
immunotherapeutic because of its strong inhibitory activity against three virus strains that
encompass the genetic diversity of ZIKV, as well as its neutralizing activity against DENV1, DENV-2, and DENV-3. Of interest, EDE1-B10 failed to bind or neutralize DENV-4
efficiently; this phenotype was similar to that described for cross-reactive mouse mAbs to
DENV that react with the DII-FL epitope43.
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We compared EDE1-B10 with the previously published EDE-specific
mAbs10,11 EDE1-C8 and EDE2-A11 for their post-exposure therapeutic activity against
lethal ZIKV challenge. Although all three EDE-specific mAbs completely protected when
given 3 d after ZIKV inoculation, EDE1-B10 also reduced lethality when administered 5
d after infection. The combination of increased neutralizing and protective activity led us
to select EDE1-B10 for subsequent studies. We assessed how EDE1-B10 functioned at
immune-privileged sites, which were seeded within 2 d of virus inoculation. ZIKV
replication in immune sanctuary sites may contribute to its persistence in human and animal
body fluids, including semen, urine, and saliva27,28,44,45. During the acute phase of infection,
EDE1-B10 treatment markedly reduced viral RNA in multiple immune-privileged sites
when administered at day +1 after infection. However, the reductions were lower in
magnitude when EDE1-B10 treatment was initiated at day +3 after infection.
Correspondingly, persistence of ZIKV RNA at day 21 after inoculation was markedly
diminished at most immune-privileged sites when therapy was initiated at day +1 after
infection. However, when therapy was started at day +3 after infection, viral RNA persisted
at day +21 after infection at several immune-privileged sites (eye, brain, and testis). Thus,
the likely protective role of the EDE1 mAbs is to limit ZIKV dissemination, with antibodymediated clearance of already infected sites being substantially less efficient. Consistent
with this observation, protection of the placenta and fetuses by the WT and LALA variants
of EDE1-B10 and EDE1-C8 was equivalent in the dam model of infection and was not
dependent on Fc-dependent interactions. These results contrast with those in HIV32, Ebola
virus46, influenza A virus47, and respiratory syncytial virus48 studies in which antibody
effector functions enhanced protection. Fc effector functions may contribute to antibody-
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mediated protection of these viruses because, unlike ZIKV, they bud from the plasma
membrane and express structural proteins on the cell surface, which can serve as targets
for antibody-dependent cellular cytotoxicity and phagocytosis.
Sexual transmission is an established route of ZIKV spread and of concern to
individuals within and traveling to endemic regions, particularly for those of child-bearing
age. Our study shows that systemic mAb administration can protect against intravaginal
transmission of ZIKV infection in the context of pregnancy. This observation is relevant,
as studies in macaques suggest that ZIKV replication in the female reproductive tract
precedes infection of peripheral organ tissues that contribute to viremia49. Our passive
antibody-transfer experiments in mice suggest that ZIKV vaccines that induce robust
neutralizing antibody responses and protect against in utero transmission after
subcutaneous virus challenge42 may also prevent sexual transmission.
ZIKV epidemics in the Americas now occur in DENV-endemic regions. Crossreactive

antibodies

against

ZIKV

and

DENV

could

protect

or

mediate

pathogenesis50 depending on the stoichiometry of binding and mechanism of action31. Our
preclinical studies with LALA variants of EDE1-B10 and EDE1-C8 provide a first step
toward developing a safe and effective therapeutic antibody against both ZIKV and DENV,
without the possibility for pathogenic immune enhancement. Nonetheless, as the extent to
which these findings in mice translate to humans remains unclear, protection studies with
EDE1 mAbs in nonhuman primate models of ZIKV infection in pregnancy are warranted.
If these data are promising, then human clinical trials will be required to show efficacy.
The design of such trials will be challenging given the ephemeral nature of mosquito-
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transmitted virus epidemics in a given locale and the absolute need for safety in the context
of transmission studies with pregnant women.
4.5

Methods
Viruses. ZIKV-Brazil (Paraiba, 2015) was provided by S. Whitehead (US National
Institutes of Health) and was originally obtained from P.F.C. Vasconcuelos (Instituto
Evandro Chagas). Mouse-adapted ZIKV-Dakar 41519 was passaged twice in vivo in
immunodeficient Rag1−/− mice (M.S.D., unpublished data) and grown in Vero cells. The
DENV-2 strain D2S20 was a gift from S. Shresta) and was grown in the C6/36 Aedes
albopictus cell line. Primary isolates of DENV-1 (02-0435; GenBank accession
number JQ740878), DENV-3 (2-1969; GenBank accession number JQ740881), and
DENV-4 (1-0093; GenBank accession number JQ740883) were obtained from DENVinfected patients in Thailand (provided by P. Malasit and S. Noisakran). DENV-2 strain
DF-699 (GenBank accession number FM210221) was isolated from a patient in Vietnam
(provided by C. Simmons). DENV-2 strain 16681 was a gift from the Armed Forces
Research Institute of Medical Sciences (AFRIMS), Thailand. Additional ZIKV strains
from Brazil (PE243, provided by A. Kohl, R.F. de Oliveira Freitas, and L.J. Pena) and
Africa (HD78788, provided by A. Sakuntabhai) were used for neutralization assays. Virus
stocks were titered by the focus-forming assay (FFA) on Vero cells, as previously
described51.
Antibody generation. Activated antibody-secreting cells (CD19+, CD3−, CD20lo or
CD20−, CD27hi and CD138hi) were sorted by flow cytometry. To amplify the VH- and VLencoding genes, one-step RT–PCR (Qiagen) and nested PCR (Qiagen) were performed.
The nested PCR products were cloned into expression vectors encoding the human IgG1
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constant region or the LALA-variant IgG1 (leucine-to-alanine substitutions at positions
116 and 117) for the VH gene and the human Igκ constant region for the VL gene. Plasmids
encoding the heavy and light chains were co-transfected into HEK 293T cells by the
polyethylenimine method (Sigma). WT and LALA-variant IgG1 were purified by Protein
G plus/Protein A agarose (Merck).
Neutralization assays. Serial dilutions of mAbs were incubated with 102 FFU of the
different DENV serotypes or ZIKV strains for 1 h at 37 °C. The mAb–virus complexes
were added to Vero cell monolayers in 96-well plates for 2 h at 37 °C. Subsequently, the
cells were overlaid with 1.5% (wt/vol) carboxymethyl cellulose in modified Eagle's
medium (MEM) supplemented with 3% heat-inactivated FBS. Plates were fixed 72h later
for DENV and 48 h later for ZIKV with 4% paraformaldehyde (PFA) in PBS for 10 min
and then permeabilized with 2% Triton X-100 in PBS for 10 min at room temperature.
Plates were stained with mAb 4G2 (cross-reactive mouse mAb to the FL epitope of
flaviviruses) at 37 °C for 1 h followed by incubation with peroxidase-conjugated goat antimouse-immunoglobulin (Sigma) at a dilution of 1:1,000 in 0.05% Tween–PBS for 1 h at
37 °C. Foci were visualized by adding DAB substrate (Sigma) at a concentration of 0.6
mg/ml.
ADE assay. Serial dilutions of mAbs were incubated with virus at a multiplicity of
infection (MOI) of 5 at 37 °C for 1 h before adding them to U937 myelomonocytic
leukemia cells. After 24 h of incubation at 37 °C, cells were harvested and washed with
FACS buffer (2% FBS, 0.5% BSA, and 0.1% NaN3 in PBS). Cells were fixed and
permeabilized for 10 min at room temperature with 4% PFA in PBS and 0.5% (wt/vol)
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saponin in FACS buffer, respectively. Finally, the cells were stained with Alexa-Fluor647-conjugated 4G2 mAb and analyzed using a BD LSRFORTESSA X-20 flow cytometer.
Mouse experiments. Mouse studies were performed in accordance with the
recommendations of the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health and were approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine (assurance number A338101). Mice were inoculated with ZIKV after anesthetizing them with ketamine
hydrochloride and xylazine, and all efforts were made to minimize pain and suffering.
Antibody-protection studies were performed in the following models: a lethal challenge
model in which WT C57BL/6 mice (4–5 weeks old; Jackson Laboratories) were
administered 2 mg anti-Ifnar1 mAb (MAR1-5A3, Leinco Technologies) by an
intraperitoneal (i.p.) injection 1 d before inoculation with 103 FFU of mouse-adapted
ZIKV-Dakar by the s.c. route in the footpad. Cross-reactive EDE mAbs (EDE1-C8, EDE1B10, or EDE2-A11) or isotype control (Flu 28C) human mAbs were administered by the
i.p. route as a single dose at day +1 (100 µg, 5 mg per kg body weight (mg/kg)), day +3
(250 µg, 12.5 mg/kg), or day +5 (250 µg, 12.5 mg/kg) after infection. All of the mice were
monitored for lethality for 21 d. Time course studies in which WT C57BL/6 mice (8–9
weeks old; Jackson Laboratories) were treated with 0.5 mg of anti-Ifnar1 mAb by
intraperitoneal injection 1 d before inoculation with 105 FFU of mouse-adapted ZIKVDakar by the subcutaneous route. Mice were euthanized at day +1, day +2, day +3, day +4,
or day +5 after infection. Acute-phase mAb protection studies in which WT C57BL/6 mice
(8–9 weeks old; Jackson Laboratories) were treated with 0.5 mg anti-Ifnar1 mAb by
intraperitoneal injection 1 d before inoculation with 105 FFU of mouse-adapted ZIKV-

128

Dakar by the subcutaneous route. Cross-reactive EDE1-B10 or an isotype control mAb
(Flu 28C) was administered by the administered route as a single dose at day +1 or day +3
after infection as described above. All of the mice were euthanized at day +5 after infection,
and tissues were harvested following extensive perfusion with PBS. Persistence-phase
mAb protection studies in which WT C57BL/6 mice (8–9 weeks old; Jackson Laboratories)
were treated with 0.5 mg anti-Ifnar1 mAb by intraperitoneal injection 1 d before
inoculation with 105 FFU of mouse-adapted ZIKV-Dakar by the subcutaneous route.
Cross-reactive EDE1-B10 or an isotype control mAb (Flu 28C) was administered by the
intraperitoneal route as a single dose at day +1, day +3, or day +5 after infection as
described above. All animals were euthanized at day +21 after infection, and tissues were
harvested.
Pregnancy studies were done in WT C57BL/6 mice that were bred in a specificpathogen-free facility at Washington University School of Medicine. In some
experiments, Ifnar1−/− females and WT males were mated. At embryonic day E6.5, dams
were inoculated with 103 FFU of ZIKV-Brazil (Paraiba 2015) by the s.c. route. At E7.5,
dams were treated by the intraperitoneal. route with a single 250-µg dose of EDE1-B10 or
an isotype control mAb. In another series of experiments, WT female and male mice were
mated. At E5.5, dams were treated with 1 mg of anti-Ifnar1 by the intraperitoneal route. At
E6.5, the mice were inoculated with 103 FFU mouse-adapted ZIKV-Dakar by the
subcutaneous route. At E7.5, all of the mice received a second 1-mg dose of anti-Ifnar1
mAb through an intraperitoneal route. For treatment, mice received a single 250-µg dose
of EDE1-B10, EDE1-B10 LALA, EDE1-C8, EDE1-C8 LALA, or isotype control mAb by
the intraperitoneal route on E7.5 (day +1 after infection) or E9.5 (day +3 after infection,
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excluding the LALA mutants). All of the mice were euthanized at E13.5, and placentas,
fetuses, and maternal tissues were collected. Finally, in another series of studies, WT
female and male mice were mated. At E5.5, dams were treated via an intraperitoneal route
with 1.5 mg of anti-Ifnar1 mAb and a single 250-µg dose of EDE1-B10 or isotype control
mAb. At E6.5, mice were inoculated with 105 FFU mouse-adapted ZIKV-Dakar in 10 µl
by the intravaginal route. At E7.5, all of the mice received a second 1-mg dose of antiIfnar1. At E13.5, the mice were euthanized, and placentas, fetuses, and maternal tissues
were collected.
Measurement of viral burden. Tissues from ZIKV-infected mice were weighed and
homogenized with stainless steel beads in a Bullet Blender instrument (Next Advance) in
600 µl (brain) or 200 µl (testis, epididymis, eye, vagina, cervix, and ovaries) of PBS.
Samples were clarified by centrifugation (2,000g for 10 min). All of the homogenized
tissues from the infected mice were stored at −80 °C. Tissue samples and serum from
ZIKV-infected mice were extracted with the RNeasy 96 Kit (for tissues) or Viral RNA
Mini kit (for serum) (Qiagen). ZIKV RNA levels were determined by Taqman one-step
qRT–PCR on an ABI7500 Fast Instrument using published primers and conditions52. Viral
burden was expressed on a log10 scale as viral RNA equivalents per g or ml after
comparison with a standard curve produced using serial tenfold dilutions of ZIKV RNA.
Measurement of EDE1-B10 in tissues. Tissues of ZIKV-infected mice that were perfused
were weighed and homogenized with stainless steel beads in a Bullet Blender instrument
(Next Advance) in 600 µl (brain) or 300 µl (testis, epididymis, and eye) of PBS. Samples
were clarified by centrifugation (2,000g for 10 min). All of the homogenized tissues from
infected animals were stored at −80 °C. Flat-bottom 96-well MaxiSorp (ThermoFisher)
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plates were coated with goat anti–human (IgG H+L chain) antibody (KPL) and then
blocked with PBS + 2% BSA (Sigma) for 1 h at 37 °C. Tissue homogenates were diluted
in PBS + 2% BSA and incubated for 1 h at 4 °C. Plates were washed six times and then
incubated with AffiniPure horseradish peroxidase (HRP)-conjugated goat-antihuman-IgG
(Jackson Immuno) for 1 h at 4 °C and developed with TMB substrate. The reaction was
stopped by addition of 2N H2SO4, and emission (450 nm) was read using a TriStar LB 941
reader (Berthold Technologies). EDE1-B10 levels are shown in 'µg/ml' after comparison
with a standard curve and logistical regression produced using serial threefold dilutions of
EDE1-B10 in corresponding homogenates of tissues from naive mice.
Viral RNA in situ hybridization (ISH). RNA ISH was performed with RNAscope 2.5
(Advanced Cell Diagnostics) according to the manufacturer's instructions. PFA-fixed
paraffin-embedded placental sections were deparaffinized by incubation for 60 min at 60
°C. Endogenous peroxidases were quenched by treatment with H2O2 for 10 min at room
temperature. Slides were boiled for 15 min in RNAscope Target Retrieval Reagent and
incubated for 30 min in RNAscope Protease Plus before probe hybridization. The probe
targeting ZIKV RNA was designed and synthesized by Advanced Cell Diagnostics (catalog
number 467771). A negative control probe (targeting bacterial gene dapB) was also
obtained from Advanced Cell Diagnostics (catalog number 310043). Tissues were
counterstained with Gill's haematoxylin and visualized with standard bright-field
microscopy.
Histology. Testis and epididymis were collected and fixed overnight in 4% PFA in PBS.
Subsequently, 5-µm-thick sections from EDE1-B10-treated or isotype-control-mAbtreated mice were processed for histology by H&E staining. Collected placentas were fixed
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in 10% neutral-buffered formalin at room temperature and embedded in paraffin. Placentas
were sectioned and stained with H&E to assess morphology. Surface area and thickness of
the placenta and of the different layers were measured using ImageJ software.
Computer-assisted sperm analysis. Mature sperm from the cauda epididymis of EDE1B10-treated or isotype-control-mAb-treated mice at day +21 after infection were collected
immediately after euthanasia as reported53. The sperm suspension, in vitro fert medium
(Cook Medical), was analyzed using the HTM-IVOS Vs12 integrated visual optical system
motility

analyzer

(Hamilton-Thorne

Research)

as

described

previously54.

All

measurements of motile sperm were made within 60 min of dissection of the cauda
epididymis.
Statistical analysis. All data were analyzed with GraphPad Prism software. Kaplan–Meier
survival curves were analyzed by the log-rank test. Viral burden and viremia were analyzed
by the Mann–Whitney test. Motile sperm and placental and fetal measurements were
analyzed by ANOVA using either a Kruskal–Wallis or Holm–Sidak test with a multiplecomparisons correction. Fetal outcome was assessed by Fisher's exact test.
4.6

Acknowledgments
We thank Haina Shin for advice on the intravaginal infection experiments, S.
Whitehead (US National Institutes of Health (NIH)) for ZIKV-Brazil (Paraiba, 2015), S.
Shresta(La Jolla Institute of Allergy and Immunology) for DENV-2 strain D2S20, P.
Malasit and S. Noisakran (Mahidol University) for DENV-1, DENV-3, and DENV-4
isolates from patients, C. Simmons (University of Melbourne) for DENV-2 strain DF-699,
A. Kohl, R.F. de Oliveira Freitas, and L.J. Pena (University of Glasgow) for ZIKV-Brazil
PE243, and A. Sakuntabhai (Institut Pasteur) for ZIKV-Africa HD78788. Supported by

132

grants and contracts from the NIH (R01 AI073755 (M.S.D.), R01 AI127828 (M.S.D.), R01
HD091218 (I.U.M. and M.S.D.), HHSN272201400018C (M.S.D.), T32 AI007163 (E.F.)),
the Wellcome Trust (G.R.S.), MRC-NEWTON UK (J.M.), and the National Institute for
Health Research Biomedical Research Centre funding scheme UK (G.R.S.).

133

4.7
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.

References
Weaver, S. C. et al. Zika virus: History, emergence, biology, and prospects for control.
Antiviral Res. 130, 69–80 (2016).
Brasil, P. P. et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N. Engl. J.
Med. 375, 2321–2334 (2016).
Schaub, B. et al. Analysis of blood from Zika virus-infected fetuses: a prospective case
series. Lancet Infect. Dis. 17, 520–527 (2017).
Honein, M. A. et al. Birth Defects Among Fetuses and Infants of US Women With
Evidence of Possible Zika Virus Infection During Pregnancy. JAMA 317, 59 (2017).
Cao-Lormeau, V.-M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus
infection in French Polynesia: a case-control study. Lancet 387, 1531–1539 (2016).
Parra, B. et al. Guillain- Barre Syndrome Associated with Zika Virus Infection in
Colombia. N. Engl. J. Med. 373, 1513–1523 (2016).
Dai, L. et al. Structures of the Zika Virus Envelope Protein and Its Complex with a
Flavivirus Broadly Protective Antibody. Cell Host Microbe 19, 696–704 (2016).
Kuhn, R. J. et al. Structure of dengue virus: Implications for flavivirus organization,
maturation, and fusion. Cell 108, 717–725 (2002).
Dowd, K. A. et al. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a
Single Viral Serotype. Cell Rep. 16, 1485–1491 (2016).
Barba-Spaeth, G. et al. Structural basis of potent Zika–dengue virus antibody crossneutralization. Nature 536, 48–53 (2016).
Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies
isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177
(2014).
Fernandez, E. & Diamond, M. S. Vaccination strategies against Zika virus. Curr. Opin.
Virol. 23, 59–67 (2017).
Nelson, S. et al. Maturation of West Nile Virus Modulates Sensitivity to AntibodyMediated Neutralization. PLoS Pathog. 4, e1000060 (2008).
Kam, Y.-W. et al. Cross-reactive dengue human monoclonal antibody prevents severe
pathologies and death from Zika virus infections. JCI Insight 2, (2017).
Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S. & Mosser, D. M. Intrinsic
antibody-dependent enhancement of microbial infection in macrophages: disease
regulation by immune complexes. Lancet Infect. Dis. 10, 712–722 (2010).
Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent
enhancement of infection with zika virus. Nat. Immunol. 17, 1102–1108 (2016).
Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika
virus infection. Science (80-. ). 353, 823–826 (2016).
Zhao, H. et al. Structural Basis of Zika Virus-Specific Antibody Protection. Cell 166,
1016–1027 (2016).
Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and
fetal disease in mice. Nature 540, 443–447 (2016).
Robbiani, D. F. et al. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in
Brazil and Mexico. Cell 169, 597–609.e11 (2017).
Wang, Q. et al. Molecular determinants of human neutralizing antibodies isolated from a
patient infected with Zika virus. Sci. Transl. Med. 8, 369ra179-369ra179 (2016).
134

22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.

Swanstrom, J. A. et al. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies
Isolated from Dengue Patients Are Protective against Zika Virus. MBio 7, e01123-16
(2016).
Hirsch, A. J. et al. Zika Virus infection of rhesus macaques leads to viral persistence in
multiple tissues. PLoS Pathog. 13, (2017).
Miner, J. J. et al. Zika Virus Infection in Mice Causes Panuveitis with Shedding of Virus
in Tears. Cell Rep. 16, 3208–3218 (2016).
Bhatnagar, J. et al. Zika virus RNA replication and persistence in brain and placental
tissue. Emerg. Infect. Dis. 23, 405–414 (2017).
Aid, M. et al. Zika Virus Persistence in the Central Nervous System and Lymph Nodes of
Rhesus Monkeys. Cell 169, 610–620.e14 (2017).
Govero, J. et al. Zika virus infection damages the testes in mice. Nature 540, 438–442
(2016).
Ma, W. et al. Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice.
Cell 167, 1511–1524.e10 (2016).
Yockey, L. J. et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain
infection. Cell 166, 1247–1256.e4 (2016).
Rouvinski, A. et al. Covalently linked dengue virus envelope glycoprotein dimers reduce
exposure of the immunodominant fusion loop epitope. Nat. Commun. 8, 15411 (2017).
Pierson, T. C. & Diamond, M. S. A game of numbers: The stoichiometry of antibodymediated neutralization of flavivirus infection. Progress in Molecular Biology and
Translational Science 129, 141–166 (2015).
Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody
protection against HIV. Nature 449, 101–104 (2007).
Magdelaine-Beuzelin, C., Pinault, C., Paintaud, G. & Watier, H. Therapeutic antibodies in
ophthalmology: Old is new again. MAbs 2, 176–180 (2010).
Miner, J. J. et al. Zika virus infection during pregnancy in mice causes placental damage
and fetal demise. Cell 165, 1081–1091 (2016).
Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental
models. Nature 534, (2016).
Foy, B. D. et al. Probable Non-Vector-borne Transmission of Zika Virus, Colorado, USA.
Emerg. Infect. Dis. 17, 880–882 (2011).
Musso, D. et al. Potential sexual transmission of zika virus. Emerg. Infect. Dis. 21, 359–
361 (2015).
Russell, K. et al. Male-to-Female Sexual Transmission of Zika Virus — United States,
January–April 2016. Clin. Infect. Dis. 64, ciw692 (2016).
Davidson, A., Slavinski, S., Komoto, K., Rakeman, J. & Weiss, D. Suspected Female-toMale Sexual Transmission of Zika Virus — New York City, 2016. MMWR. Morb. Mortal.
Wkly. Rep. 65, 716–717 (2016).
Deckard, D. T. et al. Male-to-Male Sexual Transmission of Zika Virus — Texas, January
2016. MMWR. Morb. Mortal. Wkly. Rep. 65, 372–374 (2016).
Barzon, L. et al. Infection dynamics in a traveller with persistent shedding of Zika virus
RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro
Surveill. 21, (2016).
Richner, J. M. et al. Vaccine Mediated Protection Against Zika Virus-Induced Congenital
Disease. Cell 170, 273–283.e12 (2017).

135

43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.

Sukupolvi-Petty, S. et al. Functional Analysis of Antibodies against Dengue Virus Type 4
Reveals Strain-Dependent Epitope Exposure That Impacts Neutralization and Protection.
J. Virol. 87, 8826–8842 (2013).
Mansuy, J. M. et al. Zika virus: High infectious viral load in semen, a new sexually
transmitted pathogen? Lancet Infect. Dis. 16, 405 (2016).
Murray, K. O. et al. Prolonged Detection of Zika Virus in Vaginal Secretions and Whole
Blood. Emerg. Infect. Dis. 23, 99–101 (2017).
Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed
as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. 108, 20690–20694 (2011).
DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing antiinfluenza antibodies require Fc receptor engagement for in vivo protection. Journal of
Clinical Investigation 126, 605–610 (2016).
Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced
effector function and in vivo efficacy. Proc. Natl. Acad. Sci. U. S. A. 111, 5992–7 (2014).
Carroll, T. et al. Zika virus preferentially replicates in the female reproductive tract after
vaginal inoculation of rhesus macaques. PLoS Pathog. 13, e1006537 (2017).
Halstead, S. B. Biologic evidence required for zika disease enhancement by dengue
antibodies. Emerg. Infect. Dis. 23, 569–573 (2017).
Brien, J. D., Lazear, H. M. & Diamond, M. S. Propagation, Quantification, Detection, and
Storage of West Nile Virus. in Current Protocols in Microbiology 15D.3.1-15D.3.18
(John Wiley & Sons, Inc., 2013). doi:10.1002/9780471729259.mc15d03s31
Lanciotti, R. S. Genetic and serologic properties of Zika virus associated with an
epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232–1239 (2008).
Hansen, D. A., Esakky, P., Drury, A., Lamb, L. & Moley, K. H. The Aryl Hydrocarbon
Receptor Is Important for Proper Seminiferous Tubule Architecture and Sperm
Development in Mice. Biol. Reprod. 908, 1–12 (2014).
Goodson, S. G., Zhang, Z., Tsuruta, J. K., Wang, W. & O’Brien, D. A. Classification of
Mouse Sperm Motility Patterns Using an Automated Multiclass Support Vector Machines
Model1. Biol. Reprod. 84, 1207–1215 (2011).

136

Figure 4.1: EDE1-B10 is a human mAb to DENV that cross-neutralizes ZIKV infection
(a) Serial dilutions of EDE1-B10 were tested for neutralization of DENV-1, DENV-2, DENV-3, and
DENV-4 serotypes using a focus-reduction neutralization test. (b) EDE1-B10 was tested for
neutralization of ZIKV strains from Africa (HD78788) and Brazil (PE243). The data in a,b are expressed
as the percentage of neutralized virus. (c,d) ADE (c) and neutralization (d) studies with WT and LALA
recombinant variants of EDE1-B10 and EDE1-C8 with DENV-2 (16681) and ZIKV (HD78788).
Infection of U937 cells (c) in the presence of mAbs EDE1-B10, EDE1-C8, or their LALA mutants is
presented as the percentage of infection. Data are representative of three independent experiments (a–
d).
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Figure 4.2: EDE1-B10 protects against ZIKV-induced lethality and viral burden
(a) Four- to five-week-old male WT mice were treated with anti-Ifnar1 followed by s.c. infection with
mouse-adapted ZIKV-Dakar. Mice were then treated with isotype control mAb or EDE1-B10 at day +1
(100 µg, left), day +3 (250 µg, middle), or day +5 (250 µg, right) after infection. Weight and survival
data were pooled from two (EDE1-B10) or three (isotype) independent experiments (isotype-mAbtreated, n = 19 mice per group; EDE1-B10-treated, n = 10 mice per group). (b–f) Eight- to nine-weekold male WT mice were treated with anti-Ifnar1 followed by s.c. inoculation with mouse-adapted ZIKVDakar. Viral RNA was measured in serum (b), brain (c), testis (d), epididymis (e), and eye (f) by qRT–
PCR at 1 d (D+1), 3 d (D+3), or 5 d (D+5) after infection. Bars indicate median values from two
experimental replicates (n = 8 mice per group). (g–k) Eight- to nine-week-old male WT mice were
treated with anti-Ifnar1 followed by subcutaneous inoculation with mouse-adapted ZIKV-Dakar. Mice
were treated with isotype control mAb or EDE1-B10 at day +1 (100 µg) or day +3 (250 µg) after
infection. At day +5 after infection, viral RNA was measured in serum (g), brain (h), testis (i),
epididymis (j), and eye (k). Bars indicate median values collected from two experimental replicates (n =
8 mice per group). (l–o) Eight- to nine-week-old male WT mice were treated with anti-Ifnar1 followed
by s.c. inoculation with mouse-adapted ZIKV-Dakar. Mice were treated with isotype control mAb or
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EDE1-B10 at day +1 (100 µg; isotype, n = 9; EDE1-B10, n = 10), day +3 (250 µg; isotype, n = 10;
EDE1-B10, n = 15), or day +5 (250 µg; isotype, n = 8; EDE1-B10, n = 9) after infection. At day +21
after infection, viral RNA was measured in the brain (l), testis (m), epididymis (n), and eye (o). Bars
indicate median values collected from three experimental replicates. Throughout, the dashed lines
indicate the limit of detection of the assay. *P < 0.05, **P < 0.001, and ***P < 0.0001 (log-rank (a) or
Mann–Whitney (g–n) test). Data from two (a, b–k) or three (a, l–o) independent experiments (a: mean
± s.d.).
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Figure 4.3: EDE-specific mAbs protect against ZIKV-induced lethality
Four to five week-old WT male mice were treated with anti-Ifnar1 mAb followed by subcutaneous
infection with 103 FFU of mouse-adapted ZIKV-Dakar. Mice then were treated with isotype-control,
EDE1-C8, or EDE2-A11 mAbs at day +1 (100 µg, left) or day +3 (250 µg, right). Data were pooled
from two (isotype-control mAb) or three (EDE1-C8 and EDE2-A11) independent experiments (isotypecontrol mAb, n = 19; EDE1-C8, n = 10; EDE2-A11, n = 10). Statistical significance was analyzed (logrank test: ****, P < 0.0001).
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Figure 4.4: Levels of EDE1-B10 mAb in tissues at day +5 after infection.
Eight to nine week old WT male mice were treated with a single dose of EDE1-B10 mAb at day +1 or
+3 as described in Figure 4.2. a. At D+5, tissues were harvested and EDE1-B10 levels were assessed
by ELISA using a standard curve. Bars indicate median values. Data were pooled from two independent
experiments, and symbols correspond to individual mice (n = 8 per group). Statistical analysis was
determined (Mann-Whitney test: **, P < 0.01; ***, P < 0.001).
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Figure 4.5: EDE1-B10 protects against testis infection and injury.
Eight- to nine-week old male WT mice were treated with isotype control or EDE1-B10 mAb at day +1
(n = 6 mice per group), day +3 (n = 4 mice per group), or day +5 (n = 8 mice per group) after infection,
as described in Figure 4.2. (a) Low-magnification (top) and high-magnification (bottom) images after
RNA ISH staining of testis at day +21 after infection using ZIKV-specific RNA probes. (b) Lowmagnification (top) and high-magnification (bottom) images of hematoxylin and eosin (H&E)-stained
samples of testis from mice that were treated with isotype control or EDE1-B10 mAbs at day +1 (n = 4
mice per group), day +3 (n = 4 mice per group), or day +5 (n = 7 mice per group). (c) The number of
motile sperm from each mouse, as determined by computer-assisted sperm analysis (uninfected: n = 10;
day +1: isotype, n = 8; EDE-B10, n = 10; day +3: isotype, n = 10; EDE-B10, n = 15; day +5: isotype, n =
9 per group). Bars indicate median values. In a,b, scale bars, 500 µm (top) and 20 µm (bottom). *P <
0.01; n.s., not significant (ANOVA with a Dunn's multiple-comparison test). Data are representative of
two (a,b) or three (c) independent experiments.
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Figure 4.6: ISH and histological analysis of epididymis from mice treated with EDE1-B10.
Eight- to nine- week old male WT mice were treated with isotype control or EDE1-B10 mAb at day +1
(n=6 mice), day +3 (n=4 mice), day +5 (n=8 mice) after infection, as described in Figure 4.2. a. RNA in
situ hybridization (ISH) staining of epididymis at day +21 using ZIKV-specific RNA probes. Low power
(scale bar = 500 µm) and high power (scale bar = 20 µm) images are presented in sequence. The images
in the panels are representative of sections from 4 to 6 mice. b. H & E staining of epididymis. Low
power (scale bar = 500 µm) and high power (scale bar = 20 µm) images are shown in sequence. The
images are representative of sections from 3 to 5 mice.

143

Figure 4.7: EDE1-B10 protects Ifnar1-/- pregnant dams.
Ifnar1−/− female mice were mated with WT sires. At E6.5, dams were infected with ZIKV-Brazil and
treated on E7.5 with 250 µg of an isotype control mAb or EDE1-B10. Dams were harvested on E13.5
to assess fetal survival and maternal viral burden. (a) Left, fetal outcome, presented as intact versus
resorbed fetuses at the time of harvest. Middle and right, images of fetal histology; black arrow indicates
a partially resorbed fetus in the uterus. Scale bars, 1 mm. (b,c) Viral burden in the maternal brain (b)
and serum (c). Horizontal bars indicates median values, and dashed lines indicate limit of detection for
the assay. (d) Low-magnification (top) and high-magnification (bottom) images after RNA ISH staining
of placentas at E13.5. Scale bars, 500 µm (top) and 20 µm (bottom). The images are representative of
placenta from one (isotype control mAb) or three (EBE-B10) dams. (e) Low-magnification (top) and
high-magnification (bottom) H&E-stained images of a placenta at E13.5. Placental labyrinth zone is
marked with a solid line. The images are representative of placenta from one (isotype control mAb) or
three (EDE1-B10) dams. Scale bars, 1 mm (top) and 100 µm (bottom). Blue arrows indicate apoptotic
trophoblasts in the labyrinth zone. *P < 0.05, **P < 0.01, and ***P < 0.0001 (Fisher's exact test (a) or
Mann–Whitney test (b,c)). Data were pooled from two independent experiments (a–c) or are
representative of one (d,e), two (a), and three (d,e) experiments.
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Figure 4.8: Therapeutic effect of EDE1-B10 in WT pregnant dams.
WT female mice were mated with WT sires. At E5.5, dams were treated with anti-Ifnar1. At E6.5, dams
were infected subcutaneously with 103 FFU of mouse-adapted ZIKV-Dakar. At E7.5 (day +1 after
infection) or E9.5 (day +3 after infection), dams were treated with 250 µg of either isotype control (day
+1, n = 9 mice; day +3, n = 6 mice), EDE1-B10 (day +1, n = 12 mice; day +3, n = 12 mice), or EDE1B10 LALA (day +1, n = 5 mice) mAbs. (a–d) At E13.5, viral RNA was assessed by qRT–PCR in the
maternal serum (a), maternal brain (b), placenta (c), and fetal head (d). Bars indicate median values.
Dashed lines indicate the limit of detection for the assay. (e) Low-magnification (top) and highmagnification (bottom) images after RNA ISH staining of placenta at E13.5. Scale bars, 500 µm (top)
and 20 µm (bottom). (f–i) Measurements of the placenta (f–h) and fetal body size (i) from isotypetreated (n = 7 per group) or EDE1-B10-treated (day +1, n = 7; day +3, n = 5) dams. Bars indicate median
values. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (Kruskal–Wallis or Holm–Sidak's
multiple-comparisons test (a–d, day +1 samples), Mann–Whitney test (a–d, day +3 samples), or
Kruskal–Wallis test with a Dunn's multiple-comparison test (f–h)). Data were pooled from eight (a–d)
or three (f–i) independent experiments or are representative of three (e) independent experiments.
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Figure 4.9: Protection of pregnant mice with WT and LALA EDE1-C8 mAbs
WT female mice were mated with WT sires. At E5.5, dams were treated with anti-Ifnar1 mAb. At E6.5,
dams were infected subcutaneously with 103 FFU of mouse-adapted ZIKV-Dakar. At E7.5 (day +1),
dams were treated with 250 µg of either isotype-control mAb or EDE1-C8 (wild-type or LALA variant).
At E13.5, placentas and fetal heads were harvested, and viral RNA was assessed by qRT-PCR. Bars
indicate median values. Data were pooled from two independent experiments, and symbols correspond
to individual mice (isotype mAb, n = 16; EDE1-C8, n = 20; EDE1-C8 LALA, n = 12). Statistical
significance was determined (Kruskal-Wallis test: ***, P < 0.001; ****, P < 0.0001). Dashed line
indicates the limit of detection for the assay.
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Figure 4.10: Treatment with EDE1-B10 prevents maternal and fetal ZIKV infection after
intravaginal inoculation of pregnant dams
WT female mice were mated with WT sires. At E5.5 (day −1 before infection), dams were treated with
anti-Ifnar1 and a single 250-µg dose of either isotype control mAb (n = 5) or EDE1-B10 (n = 8). At
E6.5, dams were inoculated intravaginally with 105FFU of mouse-adapted ZIKV-Dakar. (a–d) At E13.5,
viral RNA was assessed by qRT–PCR of maternal serum (a), maternal brain (b), vagina (c), cervix (d),
ovary (e), placenta (f), and fetal head (g). Bars indicate median values. Dashed line indicates limit of
detection for the assay. (h) Low-magnification (top) and high-magnification (bottom) images after RNA
ISH staining of placenta at E13.5 from uninfected (n = 3) or from infected and mAb-treated (n = 4 per
group) dams. Scale bars, 500 µm (top) and 20 µm (bottom). *P < 0.05, **P < 0.01, and ***P < 0.0001
(Mann–Whitney test (a–g)). Data were pooled from three independent experiments (a–g) or are
representative of three (h) independent experiments.
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Chapter 5:
Mouse and human monoclonal antibodies protect against infection
of multiple genotypes of Japanese encephalitis virus

This chapter is adapted from a manuscript published in Nature Immunology:
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5.1

Summary
Japanese encephalitis virus (JEV) remains a leading cause of viral encephalitis
worldwide. Although JEV-specific antibodies have been described, an assessment of their
ability to neutralize multiple genotypes of JEV has been limited. Here, we describe the
development of a panel of mouse and human neutralizing monoclonal antibodies (mAbs)
that inhibit infection in cell culture of four different JEV genotypes tested. Mechanism-ofaction studies showed that many of these mAbs inhibited infection at a postattachment step,
including blockade of virus fusion. Mapping studies using site-directed mutagenesis and
hydrogen-deuterium exchange with mass spectrometry revealed that the lateral ridge on
domain III of the envelope protein was a primary recognition epitope for our panel of
strongly neutralizing MAbs. Therapeutic studies in mice demonstrated protection against
lethality caused by genotype I and III strains when mAbs were administered as a single
dose even 5 days after infection. This information may inform the development of vaccines
and therapeutic antibodies as emerging strains and genotypic shifts become more prevalent.
Although Japanese encephalitis virus (JEV) is a vaccine-preventable cause of viral
encephalitis, the inactivated and live attenuated platforms available are derived from strains
belonging to a single genotype (GIII) due to its historical prevalence in areas of JEV
epidemics. Related to this, studies with vaccines and antibodies have focused on assessing
the in vitro and in vivo protective responses to homologous or heterologous GIII strains.
An epidemiological shift in JEV genotype distribution warrants the induction of broadly
neutralizing antibody responses that inhibit infection of multiple JEV genotypes. Here, we
generated a panel of mouse and human neutralizing monoclonal antibodies and evaluated
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their inhibitory activity, epitope location, and capacity for protection against multiple JEV
genotypes in mice.
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5.2

Introduction
Despite the existence of inactivated and live attenuated vaccine platforms, Japanese
encephalitis virus (JEV) remains a primary cause of viral encephalitis. It is particularly
prevalent in Asia, with approximately 68,000 clinical cases (1, 2) and an estimated 10,000
to 15,000 deaths per year (1). JEV circulation is endemic in southern tropical and
subtropical areas (e.g., Australia, Indonesia, and Singapore), with epidemics occurring in
northern temperate regions (e.g., Japan, Bhutan, and Nepal) (3, 4). JEV is transmitted
primarily by the Culex tritaeniorhynchus mosquito and is maintained in an enzootic cycle
with pigs and wading birds. In contrast, humans are infected as incidental dead-end hosts
(5, 6). The high incidence of JEV in rural areas has been attributed to the presence of open
water sources, the preferred breeding grounds for Culex mosquitoes (7). Approximately 5
to 15 days after mosquito inoculation of JEV, a nonspecific febrile illness develops,
characterized by malaise, headache, and general discomfort (2). Symptomatic JEV
infection is observed most commonly in children in areas of endemicity, children and
adults in areas with JEV epidemics, and travelers to areas of endemicity and epidemics (3,
8). Severe clinical JEV disease occurs in about 1% of infected humans, with progression
to encephalitis, seizures, or neurological deficits (9, 10). Beyond death, which occurs in 20
to 30% of clinical cases, severe long-term complications include paralysis, dystonia, and
cognitive deficits (10–12). JEV is a flavivirus of the Flaviviridae family and is related to
other viruses that cause human disease, including Zika (ZIKV), West Nile (WNV), dengue
(DENV), tick-borne encephalitis (TBEV), and yellow fever (YFV) viruses. JEV is an ~50nm enveloped, positive-stranded RNA virus with an ~11-kb genome flanked by 5 = and 3
= untranslated regions. The genome encodes a single open reading frame that is co- and
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posttranslationally cleaved by viral and host proteases into three structural proteins (capsid
[C], premembrane [prM], and envelope [E]) and seven nonstructural proteins. The E
protein is necessary for virus binding, entry, and fusion in host cells (13) and the
ectodomain is divided into three domains: domain I (E-DI) is the central -barrel domain,
domain II (E-DII) is an extended dimerization domain with a distal hydrophobic fusion
loop (FL), and domain III (E-DIII) is an immunoglobulin-like fold (14). Structural analysis
of the JEV E protein shows a smaller dimer interface with increased contacts at the E-DIDIII pocket compared to those of related flaviviruses (15). Although most phylogenetic
analyses define four JEV genotypes based on sequence variation of the E protein, multiple
strains belonging to a fifth genotype were recently identified in Malaysia and South Korea
(16–18). The genotypes cluster within particular geographic distributions: for example,
genotype I (GI) and GIII strains are more common in temperate regions, whereas GII and
GIV strains are more common in tropical climates (19–21). GIII has been the predominant
genotype historically, and as such, existing vaccines against JEV are derived from
prototypical GIII strains such as JEV-Nakayama and JEV-SA14 (21). Recent reports have
noted a substantial increase in GI infections in Asian countries, including China and Japan
(22, 23). The humoral response to JEV, like that of other flaviviruses, is considered
necessary for limiting infection, and neutralizing antibody titers often serve as a correlate
of protection (24). Indeed, JEV type-specific mouse monoclonal antibodies (mAbs) with
protective activity (e.g., E3.3) have been identified and were derived against GIII strains
(25–28). Moreover, a humanized mAb (B2) that was derived from a chimpanzee
immunized with JE-VAX also protected mice against JEV-Nakayama, a strain of the
homologous JEV genotype (GIII) (29). Other neutralizing mAbs (e.g., 2H4 and 2F2) in
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goat and monkey models of infection (30) protected against JEV strains from the
homologous genotype to which they were raised. Notwithstanding these data, no study has
comprehensively profiled the inhibitory activity of anti-JEV mAbs against multiple
genotypes in vitro and in vivo, and no fully human anti-JEV mAbs have been described.
The shift in prevalence from GIII to GI may require a different antibody repertoire for
protection against infection and thus has implications for the efficacy of existing vaccines
that were derived from GIII strains. Here, we generated a panel of mouse and human mAbs
against JEV after immunizing mice and humans with a GIII vaccine strain (JEV-SA14-142) or mice with pathogenic GII and GIII strains of JEV. Six of the mouse mAbs (JEV-31,
JEV-106, JEV-128, JEV-131, JEV-143, and JEV-169) neutralized infection of strains
representative of the four JEV genotypes (GI, GII, GIII, and GIV) that we tested to various
degrees. Site-directed mutagenesis and hydrogen-deuterium exchange mass spectrometry
(HDX-MS) mapping data identified sites within E-DI (JEV-169), E-DIII (JEV-31, JEV106, JEV-128, JEV-131, JEV-143, and hJEV-69), and additional regions of the E
ectodomain (JEV-117 and hJEV-75) as key epitopes for neutralization. Passive transfer
studies in lethal JEV challenge mouse models showed protective efficacy for some mouse
and human mAbs even when administered up to 5 days after GI or GIII infection. These
data may be relevant for the development of antibody-based therapeutics or anti-JEV
vaccines with broader protective activity, which may be important as the predominant
genotypes shift over time.
5.3

Results
Anti-JEV mAbs. We generated a panel of neutralizing murine mAbs against JEV to begin
to address the impact of shifting genotype epidemiology on antibody-mediated protection.
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We inoculated and boosted adult C57BL/6 mice deficient for interferon (IFN) regulatory
factor 3 (Irf3-/-) with 102 focus-forming units (FFU) of a vaccine strain of JEV (JEV-SA1414-2). Additionally, we inoculated Irf7-/- mice with JEV-Nakayama (GIII), boosted with
JEV-Bennett (GII), and administered a final intravenous boost with JEV-Nakayama before
splenocyte-myeloma cell fusion. We immunized Irf3-/- and Irf7-/- rather than wild-type
(WT) mice, as JEV replicated to higher titers and induced stronger neutralizing antibody
responses in these animals (data not shown). We screened ~3,800 hybridoma supernatants
from five independent fusions for binding to JEV-infected cells by flow cytometry and
direct virus binding by enzyme-linked immunosorbent assay (ELISA) and cloned 13 JEV
mAbs by limiting dilution for further characterization. Using a single-endpoint
neutralization assay, we identified 8 mAbs with 95% neutralizing activity against infection
of JEV-SA14-14-2 in Vero cells (data not shown). We then tested these mouse mAbs for
their ability to bind recombinant JEV E ectodomain, JEV E-DI, JEV E-DIII, WNV E
ectodomain, or ZIKV E ectodomain by ELISA (Table 5.1). JEV-169 bound E-DI, and the
remaining mAbs recognized E-DIII, with the exception of JEV-117, which recognized JEV
E ectodomain but not the domain fragments. JEV-31 and JEV-117 showed cross-reactivity
to WNV E protein, whereas JEV-143 cross-reacted with ZIKV E protein.
To generate human mAbs against JEV, we screened neutralization profiles from
donors immunized with a two-dose regimen of a commercially available inactivated JEV
vaccine, IXIARO, that was based on a genotype III strain (Figure 5.1A). We obtained
hybridoma supernatants derived from donors that bound to JEV-SA14-14-2, determined
the single-endpoint neutralization titer (data not shown), and cloned 4 anti-JEV mAbs.
Three of the human mAbs bound to E-DIII, whereas hJEV-75 bound to the E ectodomain
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but not to E-DI or E-DIII (Table 5.1). hJEV-11 and hJEV-80 cross-reacted with WNV E
protein, whereas hJEV-69 and hJEV-75 appeared specific to JEV and did not bind either
WNV or ZIKV E proteins.
Breadth of neutralization of mAbs. We performed focus reduction neutralization tests
(FRNTs) on Vero cells to assess the inhibitory capacity of our anti-JEV mAbs against the
vaccine strain, JEV-SA14-14-2, and available prototype strains representative of multiple
genotypes. We did not test a representative genotype V strain of JEV, as one was not
available from the World Arbovirus Reference Collection. We determined the mAb
concentration that reduced the number of foci of infection by 50% (50% effective
concentration [EC50]) (Figure 5.1B and C; Table 5.1). JEV-31 and JEV-169 had the
strongest neutralization activity against the four genotypes tested (GI, GII, GIII, and GIV),
with EC50 values between 84 and 365 ng/ml and 49 and 315 ng/ml, respectively. JEV-106,
JEV-128, JEV-131, and JEV-143 had intermediate neutralizing activity, with EC50 values
between 147 and 548 ng/ml, 102 and 1,629 ng/ml, 95 and 509 ng/ml, and 346 and 818
ng/ml, respectively, against strains of the four genotypes. As expected, the JEV-SA14-142 vaccine and JEV-SA14 parental strain were neutralized to similar levels by most mAbs,
with the exception of JEV-117, which showed a remarkable ~1,000-fold shift in EC50
values. In general, JEV-27 and JEV-117 had the weakest neutralizing activity, with EC50
values between 1,441 and 4,830 ng/ml and 10,000 ng/ml, respectively.
We identified four human mAbs with neutralizing activity against JEV-SA14-142, which we characterized in greater detail. hJEV-11 and hJEV-80 exhibited relatively
weak neutralizing activity (1,509 to 10,000 ng/ml and 857 to 10,000 ng/ml, respectively)
against the other strains tested (Figure 5.1C; Table 5.1). In comparison, hJEV-69 and
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hJEV-75 inhibited infection of multiple JEV strains more potently. hJEV-69 had greater
activity against the GI strains (2372/79 and MAR 859; EC50, 335 to 1,102 ng/ml) than
against the GIV strain (JKT 7887; EC50, 3,111 ng/ml), whereas hJEV-75 had the strongest
neutralizing activity against GI, GII, and GIII strains (EC50, 9 to 457 ng/ml) but did not
inhibit the GIV strain (JKT 7887; EC50, 10,000 ng/ml). Overall, the mouse-derived mAbs
had greater breadth of neutralization against multiple genotypes of JEV than the humanderived mAbs. This finding could reflect the different immunogens used (live versus
inactivated viruses for mice or humans, respectively), species-specific differences in the
antibody repertoire, or the limited size of the panel of mAbs that we obtained.
Mechanism of neutralization. Antibody neutralization of flaviviruses can occur by
inhibiting attachment, internalization, and/or fusion (31). To determine how the
neutralizing mAbs inhibited infection in cell culture, we performed pre- and postattachment neutralization assays (32–34). MAbs were incubated with JEV-SA14-14-2
before or after virus binding to cells, and infection was measured by FRNT (32–34). As
expected, all mAbs efficiently neutralized infection when premixed with virus (Figure
5.2A and 5.3 [solid lines]). All mouse mAbs also inhibited JEV infection when added after
virus adsorption to the cell surface, although to a lesser extent, suggesting that at least part
of their blocking activity was at a post-attachment step (Figure 5.2A; Figure 5.3, dashed
lines). Similarly, hJEV-69 and hJEV-75 neutralized in both pre- and post-attachment
assays (Figure 5.2B).
We next determined whether the neutralizing mouse and human mAbs could block
fusion by adapting a virus fusion from without (FFWO) assay at the plasma membrane (32,
33). JEV-SA14 was adsorbed to a monolayer of Vero cells on ice and subsequently
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incubated with the mAbs. Fusion at the plasma membrane was induced by brief exposure
to low-pH-buffered medium at 37°C. After washing, cells were incubated overnight in the
presence of 10 nM concanamycin A1 to prevent canonical endosomal fusion and allow
viral replication. As described for other flaviviruses (33), in the absence of mAb treatment,
~20% of cells produced viral antigen that was measurable by flow cytometry; in contrast,
minimal viral antigen (~2 to 3% of cells) was detected when fusion was induced under
neutral-pH conditions (Figure 5.2C and D). All neutralizing mouse mAbs tested inhibited
plasma membrane fusion under acidic conditions and subsequent viral antigen expression.
In contrast, hJEV-69 and hJEV-75 inhibited fusion at the plasma membrane less efficiently
(Figure 5.2C and D).
Epitope mapping. To begin to assess the basis for differential inhibition by the
neutralizing mAbs, we mapped their epitopes. We defined key peptide regions and amino
acid residues required for mAb binding by using both hydrogen-deuterium exchange mass
spectrometry (HDX-MS) (35) and alanine-scanning site-directed mutagenesis (36) of the
E protein of JEV-SA14-14-2.
(i) HDX-MS. As HDX-MS should show slower exchange at mAb binding sites (increased
protection), we analyzed five mouse mAbs (JEV-31, JEV-106, JEV-128, JEV131, and
JEV-143) that engaged E-DIII. The mAbs were mixed in a 1:1 ratio with E-DIII, and HDX
was performed for 10, 30, 60, 120, 900, 3,600, and 14,400 s. The quenching and protein
digestion conditions were optimized to obtain 32 different peptides that spanned the 11kDa JEV E-DIII protein (Figure 5.4A). All five mAbs showed changes in deuterium
uptake compared to unliganded E-DIII. Representative kinetic plots are shown for eight of
the peptides spanning E-DIII in the presence of JEV-31 (Figure 5.5A). The deuterium

157

uptake studies showed that binding of JEV-31, JEV-106, JEV-128, JEV-131, and JEV-143
protected regions in the N-terminal region and A strand (residues 304 to 310), BC loop
(residues 326 to 342), and DE loop (residues 355 to 371) of E-DIII (Figure 5.5B; Figure
5.4B), regions that correspond to the well-defined lateral ridge (LR) epitope (37) (E-DIIILR).
(ii) Alanine-scanning mutagenesis. The amino acid binding sites of neutralizing mouse
and human anti-JEV mAbs also were mapped by alanine-scanning mutagenesis and
mammalian cell expression (36) of the JEV prM-E protein. Residues in the E protein
ectodomain were replaced with alanine with two exceptions: alanine residues were mutated
to serine, and cysteines were not mutated to prevent protein misfolding (data not shown).
We characterized a residue as critical for mAb binding if the mutation resulted in less than
25% binding compared to the wild-type protein (Figure 5.5C and 5.6). We found that
alanine substitution of certain amino acids (e.g., T321, D332, and I383), which correspond
to sites in E-DIII-LR, caused loss of binding of most of the neutralizing murine and human
mAbs tested, especially JEV-31, JEV-131, JEV-143, and hJEV-69 (Figure 5.6A and B).
JEV-131 showed a broader binding footprint, as loss of binding was observed for alanine
substitution of additional residues, including G299, L345, P376, and V384. JEV-117 and
hJEV-75 demonstrated loss of binding following mutations in other regions of the E
ectodomain (Figure 5.6C) that correspond to previously defined epitopes for related
flaviviruses, including residues in the E-DI-DII-hinge region (K136 for JEV-117 and S275
for hJEV-75), E-DI-LR (L180 for hJEV-75), E-DII-hinge (E49), E-DII-LR (N82 for hJEV75), and E-DII-central interface (W217 for hJEV-75) (15, 38). The loss of binding observed
within E-DIII for alanine substitutions of residues F308 (JEV-117 and hJEV-75) and F310
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(JEV-117) corresponds to sites within the previously described A-strand epitope (39) (data
not shown). This pattern of mutagenesis and binding also correlates with the inability of
JEV-117 and hJEV-75 to recognize isolated domains by ELISA (Table 5.1). JEV-169
demonstrated loss of binding with three different mutations in DI (L25, G184, and L285)
and a single mutation in DII (M204), although these residues do not correspond to any
published epitope. Because alanine substitutions can have only moderate structural
differences compared to other residues, we also made charge substitutions in amino acids
at different E-DIII epitopes, including the A strand (S309K, K312E, and H395K), DIII-LR
(S331K, S364K, N367K, and K369E), C-C’ loop (T349K), and FG loop (R387E and
D389K). Loss of binding in the E-DIII-LR epitope (S331K and S364K) but not in other EDIII regions was observed for the murine mAbs JEV-31, JEV-106, JEV-128, JEV-131,
and JEV-143 (data not shown). Unexpectedly, we did not observe loss of binding for hJEV69, suggesting it may recognize E-DIII somewhat differently than the neutralizing mAbs
of mouse origin.
In vivo protection studies. To evaluate whether neutralizing mAbs could protect against
JEV infection in vivo, we developed challenge models of JEV-induced lethality in mice by
using GIII (Nakayama) and GI (MAR 859 and 2372/79) strains. Once models were
established, we treated 4- to 5-week-old male WT C57BL/6 mice on day 1 with a single
10- µg (0.5-mg/kg) prophylactic dose of seven different anti-JEV mAbs or an isotypecontrol mAb and then inoculated animals on day 0 with different pathogenic JEV strains.
(i)

Nakayama (GIII). Whereas JEV-31, JEV-106, JEV-143, and JEV-169 protected
all mice from lethal infection (Figure 5.7A), JEV-27, JEV-128, and JEV-131
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conferred partial (25 to 89%) protection. We also observed protection (60 to 80%)
with similar doses of hJEV-69 and hJEV-75 (Figure 5.7B).
(ii)

MAR 859 (GI). JEV-31, JEV-128, JEV-131, and JEV-169 conferred partial
protection, ranging from 40 to 55% (Figure 5.7C).

(iii)

2372/79 (GI). JEV-31, JEV-131, and JEV-169 provided complete protection
against lethality, whereas JEV-106 and JEV-128 provided more limited (25 to 30%)
protection (Figure 5.7D).

To define the therapeutic potential of our most protective mAbs, a single 250-µg (15mg/kg) dose was administered to mice 5 days after infection (Figure 5.7E and F). Whereas
JEV-31 and JEV-169 completely protected against lethality induced by JEV-Nakayama
(GIII), these mAbs showed more limited therapeutic activity against JEV-2372/79 (GI), as
they protected 50 to 60% of mice, respectively. Administration of hJEV-75 at 5 days after
infection also had significant protection against both JEV-Nakayama (GIII) and JEV2372/79 (GI) strains. Overall, our data show that a single mAb that broadly neutralizes
multiple JEV genotypes can provide therapeutic activity in vivo against multiple strains.
5.4

Discussion
We sought to identify murine and human mAbs that broadly neutralize infection of
JEV strains corresponding to most genotypes. We inoculated mice with attenuated or
infectious strains of JEV to generate a panel of eight anti-JEV mAbs and characterized
them at the functional and structural levels. From our analyses, we identified three classes
of antibodies based on neutralization profile, epitope binding, and in vivo efficacy. The
two mAbs JEV-27 and JEV-117 had the weakest inhibitory profiles. Four mAbs (JEV-106,
JEV-128, JEV-131, and JEV-143) had intermediate neutralization abilities, and two mAbs
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(JEV-31 and JEV-169) were strongly and broadly neutralizing. Binding analysis revealed
two mouse mAbs (JEV-31 and JEV-117) that were cross-reactive with WNV. JEV-143
cross-reacted with ZIKV, and five other mouse mAbs (JEV-27, JEV-106, JEV-128, JEV131, and JEV-169) appeared more type specific. JEV-31, which cross-reacted with WNV
and was one of the most strongly neutralizing mAbs in our panel, recognized an epitope in
the E-DIII-LR. A single JEV-specific neutralizing murine mAb, JEV-169, mapped to EDI. We also generated the first human mAbs for JEV isolated from B cells of recipients of
a chemically inactivated JEV vaccine; to our knowledge, this also is the first isolation of
human mAbs from an individual immunized with an inactivated flavivirus vaccine. We
identified two strongly neutralizing JEV-specific human mAbs: one (hJEV-69) that
recognized E-DIII-LR and another (hJEV-75) that mapped to residues in the E-DI-LR, EDI-DII-hinge, E-DII-LR, and E-DII-hinge. Future studies will need to assess the inhibitory
potential of the anti-JEV humoral response against contemporary strains of JEV of all
genotypes, including GV strains. Type-specific and cross-reactive neutralizing mAbs have
been identified against JEV. Although others have identified E-DIII-specific anti-JEV
mAbs from mice (25, 27, 28), this class of antibodies appears less immunodominant in
humans, at least against some (40–44) but not all (45, 46) flaviviruses. Murine-derived EDIII-specific mAbs (2H4, A3, and E3.3) against JEV had stronger neutralizing activity in
vitro than E-DII-specific mAbs (25, 30, 47, 48). Humanization of chimpanzee-derived EDI (A3 and B2)- and E-DIII (E3)-specific mAbs demonstrated equivalent in vitro
neutralization compared to the parental mAbs, and this finding correlated with protection
against JEV infection in mice by the homologous genotype (GIII) (29). We performed
epitope-mapping studies on our mouse mAbs by using complementary approaches: HDX-
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MS and alanine-scanning mutagenesis. Epitope mapping by HDX-MS identified a series
of short peptides that were recognized by our strongest neutralizing E-DIII-specific mAbs
(JEV-31, JEV-128, JEV-131, and JEV-143). Subsequent analysis by alanine-scanning
mutagenesis confirmed and extended these findings by defining individual amino acid
residues in E-DIII-LR (T321, D332, and I383) required for optimal mAb binding (JEV-31,
JEV-131, JEV-143, and hJEV-69). HDX provided information on mAb reactivity with a
peptide segment but lacked residue-level specificity. Reciprocally, alanine-scanning
mutagenesis defined specific amino acids required for optimal binding but is of limited
utility if mutation of more than one residue is required for significant loss of binding. Lossof-binding analysis of the neutralizing hJEV-75 mAb identified residues across E-DI and
E-DII, particularly within the previously defined E-DI-LR, E-DII-LR, and E-DI-DII-hinge
epitopes. JEV-117, a mouse mAb that was poorly neutralizing, exhibited a similar loss-ofbinding profile to hJEV-75. Although further studies are warranted, the differential
functional activities of JEV-117 and hJEV-75 may be due to differences in accessibility of
their epitopes or affinity of binding. Higher resolution studies, including X-ray
crystallography and cryo-electron microscopy, are necessary to determine the precise
geometry of binding and a complete footprint of interacting residues. We observed some
variation in neutralizing activity of some mAbs against different JEV strains and
genotypes. This piece of data is analogous to that observed with mAbs against different
DENV-3 genotypes (49, 50). The inter-genotypic amino acid sequence divergence in the
E protein among genotypes ranges from 0.6% (GII versus GIII) to 5.6% (GIII versus GIV)
(51). Infection with one JEV genotype is believed to confer long-term immunity against
both homologous and heterologous genotypes. We assumed it might be straightforward to
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generate mouse and human mAbs that neutralized all JEV genotypes available to us.
Indeed, there are limited amino acid changes in E-DIII among the JEV strains that we
tested, with only 5 amino acid differences (residues 315, 327, 333, 336, and 366);
accordingly, the variation in neutralization of different JEV genotypes by E-DIII-specific
mAbs was limited (~10-fold). Two mAbs (JEV-117 and hJEV-75) effectively neutralized
the JEV-SA14-14-2 vaccine strain but remarkably lost inhibitory activity against the
parental JEV-SA14 strain. These mAbs mapped to epitopes that also contained residues
outside E-DIII, in E-DI and E-DII. An alignment of the genotypic variation in JEV
sequences (Figure 5.8) failed to show a direct correlation with the residues identified in
loss-of-binding studies for JEV-117 and hJEV-75. Although the sites of genotypic
variation between JEV-SA14-14-2 and JEV-SA14 are not coincident with JEV-117 or
hJEV-75 epitope residues, there are several residues in close proximity. For JEV-117, the
H/Q264 genotypic variation is within 5 Å of the epitope residue at position 262; M/K279
also is within 5 Å of epitope residue 49, and the K/E138 site of genotypic variation is within
10 Å of epitope residue 136. For hJEV-75, the M/K279 genotypic variation is within 5 Å
of epitope residue 49 or within 10 Å of epitope residues 273 and 275. Similarly, the K/E138
site of genotypic variation is within 10 Å of epitope residue 49, and the H/Q264 site of
genotypic variation is also within 10 Å of the epitope residue 262. As an alternative
explanation, differences in strain and genotype residues allosterically could affect the
display of JEV-117 and hJEV-75 epitopes. This idea has been described as a basis for
differential neutralization of flavivirus genotypes by other antibodies (52, 53). Clearly,
further studies with higher-resolution epitope mapping of the JEV-117 and hJEV-75 mAbs
(e.g., atomic resolution structures of the Fab-E complexes) may resolve this question of
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differential neutralization of JEV strains. Overall, our results have potential implications
for assessing the breadth of the protective efficacy of existing and new JEV vaccines. It
may be critical to assess whether antibody responses against the vaccine strain of a given
JEV efficiently neutralize infection of heterologous genotypes that may emerge.
Mechanism-of-action studies showed that all neutralizing murine E-DIII-LR mAbs
could block virus fusion, as was observed previously for E16, a WNV-specific mAb (33).
Although hJEV-69 exhibited a loss-of-binding profile similar to those of E-DIII-LRspecific mouse mAbs, charge substitutions in this region (S331K and S364K) did not affect
hJEV-69 binding, suggesting a somewhat unique epitope. Consistent with this observation,
FFWO studies of hJEV-69 indicated that although it inhibited at a post-attachment stage,
it did not efficiently block pH-dependent fusion. Although further studies are required, the
neutralizing human mAbs could block at a post-entry step before fusion. Alternatively, the
FFWO, which is a measure of viral fusion at the plasma membrane, may not fully
recapitulate the events occurring in the late endosome. We performed protection studies in
vivo with our mouse and human mAbs and JEV strains corresponding to the two most
commonly circulating genotypes (GI and GIII). To our knowledge, the protective effect of
JEV mAbs against genotype I strains in vivo has not been studied previously. Several of
our neutralizing mAbs (JEV-31, JEV-106, JEV-131, JEV143, JEV-169, and hJEV-75)
completely protected against lethal JEV-Nakayama (GIII) infection when administered as
prophylaxis. A subgroup of mAbs (JEV-31, JEV-131, and JEV-169) also completely
protected against JEV-2372/79, a GI strain, with all mAbs tested partially preventing lethal
infection by a highly homologous second GI strain, JEV-MAR 859, with 99% amino acid
identity at the E protein. Remarkably, post-exposure therapeutic administration of a single
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dose of JEV-31 or JEV-169 at 5 days after infection also conferred complete or partial
protection against GIII or GI strains, respectively. A single post-exposure dose of hJEV75 also provided high levels of protection against GI or GIII strains. Although prior studies
have reported in vivo efficacy of murine and humanized E-DIII mAbs against JEV (26, 29,
30), these challenge studies were performed with single, homologous JEV genotypes, and
protection was limited to prophylaxis, with the exception of a single study (30). The postexposure protection we observed is similar to that seen previously for other E-DIII-LR
mAbs, including E16 and WNV (54) and E106 and DENV-1 (55). One caveat of our study
is that administration of anti-JEV antibody at day 5 preceded the development of central
nervous system symptoms (e.g., seizures, tremors, paralysis, or lethargy). More detailed
window-of-treatment analysis is needed to determine which mAbs retain protective
efficacy after the development of disease onset. In summary, we identified a panel of antiJEV mAbs that map to epitopes in E-DI and E-DIII with broadly neutralizing activity
against multiple JEV genotypes. Although both mouse and human neutralizing mAbs can
block infection at a post-attachment stage, the mouse mAbs appear to have a greater
capacity to block pH-dependent viral fusion. Studies using liposome-based fusion
experiments (32, 33, 56) and cell entry assays (33) will be required to corroborate these
findings. Overall, our combination of in vitro mAb neutralization analyses with mechanism
of action, epitope mapping, and in vivo activity provides insight into developing and
refining vaccine and therapeutic countermeasures against emerging JEV strains and
genotypes.
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5.5

Methods
Viruses. JEV strains 2372/79 (Thailand 1979, GenBank accession no. U70401), MAR 859
(Cambodia 1967, accession no. U70410), Bennett (Korea 1951, accession no. HQ223285),
Nakayama (Japan 1935, accession no. EF571853), SA14-14-2 (China 1954, accession no.
JN604986), SA14 (China 1954, accession no. M55506), and JKT 7887 (Indonesia 1981;
accession no. L42160) were provided by the World Reference Center for Emerging Viruses
and Arboviruses (K. Plante, S. Weaver, and R. Tesh, Galveston, TX). Virus stocks were
propagated in C6/36 Aedes albopictus cells for 5 days prior to collection, and their titers
were determined by focus-forming assay (FFA) on Vero cell monolayers, as described
previously (57).
MAb generation.
(i) Mouse mAbs. Irf3-/- mice were infected and boosted with 102 FFU of JEV-SA14-14-2
and given a final intravenous boost with 106 FFU of JEV-SA14-14-2 3 days prior to fusion
with P3X63.Ag.6.5.3 myeloma cells. Irf7-/- mice were infected and boosted with 102 FFU
of JEV-Nakayama and JEV-Bennett, respectively, and given a final boost with 103 FFU of
JEV-Nakayama 3 days prior to fusion. Antibodies from hybridomas that bound to JEVinfected Vero cells by flow cytometry and JEV-SA14-14-2 by direct ELISA were cloned
by limiting dilution. All hybridomas were screened initially with a single-endpoint
neutralization assay using neat hybridoma supernatant incubated with 102 FFU of JEVSA14-14-2 for 1 h at 37°C. MAb-virus complexes were added to Vero cell monolayers for
1 h at 37°C followed by 1% (wt/vol) methylcellulose in modified Eagle medium (MEM)
supplemented with 4% fetal bovine serum (FBS). Plates were fixed with 2%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) 30 h later and sequentially
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stained with 500 ng/ml WNV E60 (cross-reactive mAb) (38) and horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG in PBS supplemented with 0.1% saponin and
0.02% Tween 20. JEV-infected foci were visualized using TrueBlue peroxidase substrate
(KPL) and quantitated on an ImmunoSpot 5.0.37 macroanalyzer (Cellular Technologies).
Hybridoma supernatants with greater than 85% neutralization were purified commercially
(Bio-X Cell) after adaptation for growth under serum-free conditions.
(ii) Human mAbs. The human donors used in this study were born in the United States
and Colombia and had not experienced prior JEV infection. However, they were not tested
for prior exposure to other flaviviruses (e.g., WNV or DENV). Donors were immunized
voluntarily with a two-dose regimen of a commercially available inactivated JEV vaccine,
IXIARO, as part of an occupational exposure program. Peripheral blood was obtained for
research purposes after informed consent approximately 1 month after boosting, with prior
Institutional Review Board approval from Vanderbilt University Medical Center.
Peripheral blood mononuclear cells (PBMCs) from heparinized blood were isolated using
Ficoll-Histopaque and density gradient centrifugation. The cells were cryopreserved in the
vapor phase of liquid nitrogen until use. Ten million PBMCs were cultured in 384-well
plates (Nunc) using culture medium (ClonaCell-HY medium A; StemCell Technologies)
supplemented with 8 µg/ml 1 of the Toll-like receptor (TLR) agonist CpG
(phosphorothioate- modified oligodeoxynucleotide

ZOEZOEZZZZZOEEZOEZ ZZT;

Invitrogen), 3 µg/ml of Chk2 inhibitor (Sigma), 1 µg/ml of cyclosporine (Sigma), and
clarified supernatants from cultures of B95.8 cells (ATCC) containing Epstein-Barr virus.
After 7 days, cells from each 384-well culture plate were expanded into four 96-well
culture plates (Falcon) using ClonaCell-HY medium A containing 8 µg/ml 1 of CpG, 3
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µg/ml of Chk2 inhibitor, and 107 irradiated heterologous human PBMCs (Nashville Red
Cross) and cultured for an additional 4 days. Supernatants were screened by ELISA
(described below) for reactivity with JEV-SA14-14-2. Hybridoma cell lines were cloned
by single-cell flow cytometric sorting in a sterile FACSAria III cytometer (BD
Biosciences).
Neutralization assays. Serial dilutions of mAbs were incubated with 102 FFU of different
JEV strains for 1 h at 37°C as described previously (57). MAb-virus complexes were added
to Vero cell monolayers for 1 h at 37°C followed by 1% (wt/vol) methylcellulose in
modified Eagle medium (MEM) supplemented with 4% FBS. Plates were fixed and
processed as described above. Nonlinear regression analysis was performed, and EC50
values were calculated after comparison to wells infected with JEV in the absence of mAb.
Flavivirus E ectodomain and JEV E-DI and JEV E-DIII expression and purification.
JEV E protein (residues 1 to 399 corresponding to the E ectodomain of the JEV-SA14-142 strain) was prepared as previously described (15). A JEV E-DI synthetic gene was
designed based on a DENV-4 DI construct (58) with modifications such that JEV E
residues 1 to 50 were linked to residues 135 to 195 by a glycine dipeptide, and residues
135 to 195 were connected by a serine residue to residues 281 to 298. This fragment was
cloned into the pFM1.2 mammalian expression vector (59) downstream of a pHLsec signal
sequence and terminated with a C-terminal tobacco etch virus (TEV) protease and
hexahistidine affinity tag. Transient expression and purification were completed using
established protocols (60). JEV E-DIII (residues 299 to 399) was cloned into the NdeI and
XhoI restriction enzyme sites of pET21a for expression in BL21(DE3) Codon Plus
Escherichia coli cells by autoinduction (61). The protein was refolded from inclusion
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bodies and purified by size exclusion essentially as described previously (62). WNV (63)
and ZIKV (60) E ectodomain proteins were produced and purified based on established
protocols.
JEV mAb domain mapping. MaxiSorp 96-well plates (Thermo, Fisher) were coated with
50 µl of 4 µg/ml of recombinant JEV E (15), JEV E-DI, JEV E-DIII, WNV E, or ZIKV E
overnight at 4°C. Plates were washed three times with PBS with 0.02% Tween 20 followed
by incubation with PBS and 2% bovine serum albumin (BSA) for 1 h at 37°C. MAbs were
added (1 µg/ml) for 1 h at room temperature. Plates were washed again and sequentially
incubated with biotin-conjugated anti-mouse IgG, streptavidin-HRP, and 3,3’, 5,5’tetramethylbenzidine (TMB) substrate. The reaction was stopped by addition of 2 M H2SO
4,

and emission (450 nm) was read using a TriStar LB 941 reader (Berthold Technologies).

Pre- and postattachment neutralization assays. For preattachment assays, serial
dilutions of MAbs were prepared at 4°C in Dulbecco’s modified Eagle medium (DMEM)
with 2% FBS and preincubated with 102 FFU of JEV-SA14-14-2 for 1 h at 4°C. MAbvirus complexes were added to a monolayer of Vero cells for 1 h at 4°C. Unbound virus
was removed with three washes of chilled DMEM, and adsorbed virus was allowed to
internalize during a 37°C incubation for 1 h. Cells were overlaid with 1% (wt/vol)
methylcellulose in MEM supplemented with 4% FBS. For postattachment assays, 102 FFU
of JEV-SA14-14-2 was adsorbed onto a monolayer of Vero cells for 1 h at 4°C. After
removal of unbound virus, serial dilutions of MAbs were added to virus-adsorbed cells for
1 h at 4°C. Virus then was allowed to internalize for 1 h at 37°C, and subsequently cells
were overlaid with methylcellulose as described above. Thirty hours later, the plates were
fixed with 2% PFA and analyzed for antigen-specific foci as described above.
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Fusion blockade assay. The assay for plasma membrane fusion inhibition with flavivirus
mAbs was described previously (32–34). Briefly, Vero cells (2 x 104 per well) were seeded
in flat-bottom 96-well plates overnight at 37°C. The following day, cells were preincubated
with 10 nM concanamycin A (Sigma catalog no. C9705), which blocks acidification of
endosomes and viral fusion, for 30 min on ice and subsequently incubated with JEV-SA14
(multiplicity of infection [MOI] of 50) for 2 h. Cells were washed twice with chilled PBS
followed by incubation with 100 µg/ml (murine) or 50 µg/ml (human) MAbs for 30 min
on ice. Cells were pH shifted with warmed DMEM (buffered to pH 5.5 or control pH 7.5)
at 37°C for ~7 min. The cells were rinsed and incubated for 24 h at 37°C in DMEM with
10 nM concanamycin A. Subsequently, cells were rinsed, fixed, permeabilized, and
sequentially stained for 1 h at 4°C with JEV-13 (1 µg/ml) and goat anti-mouse Alexa Fluor
647-conjugated secondary antibody (1:2,000). Samples were processed by flow cytometry
(MacsQuant), and data were analyzed using FlowJo software.
Hydrogen-deuterium exchange. Continuous HDX labeling of JEV E-DIII with or
without the mAbs was performed at 25°C for 0, 10, 30, 60, 120, 900, 3,600, and 14,400 s
as previously described with the following modifications (64). Briefly, stock solutions of
JEV E-DIII both with and without the mAbs were prepared in PBS (pH 7.4) and incubated
at 25°C for at least 1 h. Continuous labeling with deuterium was initiated by diluting the
stock samples 10-fold in deuterated PBS buffer (Sigma-Aldrich). HDX control samples
(nondeuterated) were prepared in the same way with H2O. Quenching was performed under
reducing conditions by adding a solution of 500 mM Tris (2-carboxyethyl)phosphine
hydrochloride (TCEP HCl) and 4 M guanidine hydrochloride in PBS buffer (pH 7.4
[adjusted using sodium hydroxide]) to the reaction vial at a 1:1 vol/vol ratio. The sample

170

was mixed and incubated for a minute at 25°C before being loaded onto our custom-built
HDX platform for desalting, online pepsin digestion, and reversed-phase separation and
directly injected into the mass spectrometer for analysis.
The sample was passed over a custom-packed 2- by 20-mm pepsin column at 200 µl/min;
immobilized pepsin was prepared according to a published protocol (65). The peptides
resulting from digestion were captured by a 2.1- by 20-mm Zorbax Eclipse XDB-C 8 trap
column (Agilent) and desalted at 200 µl/min 1 of H2O containing 0.1% trifluoroacetic acid
for 3 min. The peptides were separated by a 2.1 x 50 mm C18 column (2.5- µm XSelect
CSH C18; Waters) with a 9.5-min gradient of 5 to 100% acetonitrile in 0.1% formic acid
at a flow rate of 100 µl/min delivered by a LEAP 3 x Ti pump (Leap Technologies, NC).
The linear part of the gradient from 0.3 min to 5.5 min raised the acetonitrile content from
15% to 50%, during which time most of the peptides eluted from the C18 column. The
entire fluidic system was kept in an ice bath, except for the pepsin column, to minimize
back exchange. Duplicate measurements were carried out for each of the time points.
HDX data analysis and epitope assignment. Acquired spectra were analyzed using HDX
workbench software (66) against a peptide set generated as described below. The deuterium
level was normalized to the maximum deuterium concentration (80%) contained in the
reaction vial. The peptide list used to search the HDX data was identified first by a tandemMS experiment in a data-dependent mode on a linear trap quadrupole-Fourier transform
(LTQ-FT) mass spectrometer (Thermo). The six most abundant ions were submitted to
collision-induced dissociation fragmentation. Product-ion spectra were then submitted to
MassMatrix (version 2.4.2) for identification (67) and manually inspected, and the
validated peptides were used for the HDX analysis. The epitopes were identified as
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regions/sequences of amino acids (not single residues) that show a significant difference
in HDX for the bound versus unbound states, as determined from the peptide-level HDXMS data. Criteria for the selection of peptides as potential epitopes are explained further in
the Immune Epitope Database (IEDB) submission mentioned below in the “Accession
number(s)” section.
Site-directed mutagenesis epitope mapping. Epitope mapping was performed by alanine
scanning mutagenesis as described previously (36). A JEV prM-E protein expression
construct (based on JEV-SA14-14-2) was subjected to commercial alanine-scanning
mutagenesis (Genewiz) to generate a mutant library. Each residue within the JEV E protein
was changed to alanine, with alanine codons mutated to serine and cysteine residues left
unchanged. In total, 400 mutants were generated and sequence confirmed. Each JEV E
protein mutant was transfected into human 293T cells and allowed to express for 24 h and
then fixed and permeabilized with Foxp3 transcription factor staining buffer (Thermo
catalog no. 00-5523-00). Cells were incubated sequentially with purified MAbs at
concentrations optimized for staining (range, 30 to 1,000 ng/ml) and Alexa Fluor 647conjugated secondary antibody (Invitrogen) in permeabilization buffer. Fluorescence
signal was detected by flow cytometry (MacsQuant) and analyzed using FlowJo software.
Antibody reactivity against each mutant was compared to that of the WT prM-E protein
after subtracting the signal from mock-transfected controls and normalizing to the signal
from WT prM-E transfected controls. Mutations were identified as critical to the MAb
epitope if the mutants showed less than 25% binding compared to the wild type. For charge
mutants, we substituted residues in the A strand (S309K, K312E, and H395K), DIII-LR
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(S331K, S364K, N367K, and K369E), C-C’ loop (T349K), and FG loop (R387E and
D389K) and transfected and stained as described above.
Mouse experiments. Animal studies were carried in accordance with the
recommendations of the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health and were approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine (assurance no. A3381-01).
Mice were inoculated with JEV after induction of anesthesia using ketamine hydrochloride
and xylazine, and all efforts were made to minimize pain and suffering. Antibody
protection studies were performed according to the models described below.
(i)

Genotype I. WT C57BL/6 male mice (3 weeks old; Jackson Laboratories) were
inoculated with 103 FFU of JEV-MAR 859 or JEV-2372/79 subcutaneously in the
footpad. Anti-JEV or isotype control (CHK-152) mAbs were administered
intraperitoneally as a single dose on day 1 (10 µg, 0.5 mg/kg) or day 5 (250 µg,
12.5 mg/kg) after infection. Animals were monitored for lethality for 28 days.

(ii)

Genotype III. WT C57BL/6 male mice (4 to 5 weeks old; Jackson Laboratories)
were inoculated with 102 FFU of JEV-Nakayama subcutaneously in the footpad.
Anti-JEV or isotype control (CHK-152) mAbs were administered intraperitoneally
as a single dose on day 1 (10 µg, 0.5 mg/kg) or day 5 (250 µg, 12.5 mg/kg) after
infection. Animals were monitored for lethality for 28 days.

Statistical analysis. Statistical significance of FFWO was determined by one-way
ANOVA with Dunnett’s multiple comparisons to an isotype control mAb. Statistical
significance of alanine shotgun mutagenesis was determined by one-way ANOVA with
Holm-Sidak’s multiple comparisons of each mutant to V315 for each MAb. Kaplan-Meier
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survival curves were analyzed by the log rank test for each mAb compared to an isotype
control mAb.
Accession number(s). The epitopes of the five JEV-specific mAbs (E31, E106, E128,
E131, and E143) have been deposited in the Immune Epitope Database (IEDB) under
submission no. 1000721.
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Table 5.1: Binding and neutralization of inhibitory anti-JEV mAbs
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Figure 5.1: Neutralization activity of anti-JEV mAbs.
(A) Serum samples from humans previously immunized against JEV with an inactivated virion vaccine
were tested against a panel of JEV strains (2372/79 [GI], MAR 859 [GI], Bennett [GII], SA14 [GIII], SA1414-2 [GIII], Nakayama [GIII], and JKT 7887 [GIV]) by focus-forming assay (FFA) for neutralization
activity. Serial serum dilutions were incubated with 102 FFU for 1 h at 37°C, and Vero cells were
subsequently infected and stained. (B) Neutralization curves of eight mouse anti-JEV mAbs (JEV-27, JEV31, JEV-106, JEV-117, JEV-131, JEV-128, JEV-143, and JEV-169) against the indicated strains. (C)
Neutralization curves of human-derived anti-JEV mAbs (hJEV-11, hJEV-69, hJEV-75, and hJEV-80)
against the indicated strains. All data are representative of three independent experiments performed in
triplicate.
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Figure 5.2: Mechanism of neutralization by anti-JEV mAbs.
(A and B) The preattachment inhibition assay (solid lines) was performed by incubating 102 FFU of JEVSA14-14-2 with serial dilutions of mAbs starting at 10 µg/ml for 1 h at 4°C before addition to prechilled
Vero cells at 4°C and subsequently following the FFA protocol. The postattachment assay (dashed lines)
was performed by adding 102 FFU of JEV-SA14-14-2 to cells for 1 h at 4°C. After extensive washing to
remove unbound virus, serial dilutions of mAbs were added, starting at 10 µg/ml, and incubated for 1 h at
4°C, and the FFA then was completed at 37°C. Data are representative of three experiments performed in
triplicate. (C) The fusion-from-without (FFWO) assay was performed after incubating Vero cells at 4°C
with JEV-SA14 (MOI of 50) for 2 h. For these experiments, we used JEV-SA14 instead of JEV-SA14-14-
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2 because it could be grown to a higher titer. Cells were washed extensively, and the indicated mAbs were
added for 30 min. Plasma membrane fusion was induced by exposing the cells briefly (~7 min) to an acidic
pH buffer. After pH normalization, cells were incubated with 10 nM concanamycin for 24 h to inhibit
infection via the endosomal pathway and collected, fixed, permeabilized, and stained for E protein
expression. The treatment and percentage of positive cells are shown. (D) The data are pooled from three
independent experiments, each performed in triplicate, with error bars (standard deviation) and were
analyzed using one-way ANOVA with Dunnett’s multiple comparisons to the isotype control condition.
****, P < 0.0001; ns, not significant.
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Figure 5.3: Mechanism of neutralization by JEV neutralizing mAbs.
Shown are the pre- and postattachment assays for mouse MAbs (JEV-31, JEV-106, JEV-128, and JEV131) against JEV-SA14-14-2, as described in Figure 2. Data are representative of three experiments, each
performed in triplicate.
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Figure 5.4: Sequence coverage map of peptic digestion of JEV E-DIII.
(A) A total of 32 peptides were identified with complete sequence coverage for JEV E-DIII. Each bar
indicates a peptide identified by mass spectrometry. The colored bars represent the average deuterium
uptake percentage (D%) for the duplicate analysis of seven exchange time points. (The warmer the color,
the higher the deuterium uptake is.) The deuterium uptake percentages for the duplicate analyses are
indicated inside the bars, along with the standard deviation and the charge states of the peptide in
parentheses. (B) Comparison of the kinetics of HDX for eight different peptides covering the entire E-DIII
in the absence (E-DIII alone, black lines) or presence (E-DIII plus mAbs) of various mAbs (colored lines).
Each region (column) is represented by a peptic peptide, as measured by mass spectrometry. Each row
represents a state bound with a mAb (JEV-106, orange; JEV-128, maroon; JEV-131, green; JEV-143, light
blue); the antibody is listed on the left. Regions showing reduced rates of exchange for the sample of EDIII with MAbs (non-black lines) are considered to contain the epitopes. Regions with no difference are
examples of regions that do not contain the epitopes and can be viewed as controls.
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Figure 5.5: Epitope mapping by hydrogen-deuterium exchange and alanine-scanning
mutagenesis.
(A) Representative HDX kinetic plots for eight different peptides spanning JEV E-DIII in the presence
(blue lines) or absence (black lines) of JEV-31. Regions showing reduced rates or extents of exchange are
considered to contain the binding epitopes. All experiments were performed in duplicate, and data are
representative of two independent experiments. (B) Heat map depicting the average difference of deuterium
incorporation between E-DIII alone and the corresponding E-DIII-mAb complex states across all seven
time points (ΔD%). Negative values of ΔD% indicate less deuterium incorporation in the DIII-mAb state.
The regions with significant protection are shown in red. Peptides with no or little change in deuterium
uptake are indicated by white and green. (C) Representative alanine-scanning mutagenesis. 293T cells were
transfected with 1 µg of the indicated plasmid and incubated overnight prior to fixation, permeabilization,
and staining with JEV-31, JEV-106, JEV-117, JEV-128, JEV-131, and JEV-143. Loss of binding was
detected by flow cytometry. Data are representative of three independent experiments, with error bars
(standard error of the mean [SEM]) and were analyzed by one-way ANOVA with Holm-Sidak’s multiple
comparisons of each mutant compared to V315 for each mAb. Superscript letters indicate significance:
a, P < 0.05; b, P < 0.01; c, P < 0.001; d, P < 0.0001.
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Figure 5.6: Structural representation of JEV E epitopes defined by alanine-scanning mutagenesis
and HDX.
(A) JEV E-DIII epitopes for each of the eight mouse and human JEV mAbs were defined by alaninescanning mutagenesis (shaded gray boxes) and HDX (boldface letters). Genotypic differences from the
JEV-SA14-14-2 strain (GIII) are highlighted by a star: V315 is A in the JEV-2372/79 (GI), JEV-MAR 859
(GI), JEV-Bennett (GII), and JEV-Nakayama (GIII) strains; S327 is T in the JEV-2372/79 (GI), JEV-MAR
859 (GI), and JEV-Bennett (GIII) strains; K336 is N in the JEV-2372/79 (GI) and JEV-MAR 859 (GI)
strains; and A366 is S in the JEV-2372/79 (GI), JEV-MAR 859 (GI), and JEV-Bennett (GIII) strains. For
comparison to the JEV E-DIII epitopes, immediately below we show the structurally defined E-DIII
epitopes of ZIKV in complex with ZV-2 (green, ABDE epitope), ZV-48 (cyan, C-C') and ZV-67 (magenta,
lateral ridge [LR]), WNV E16 (magenta, LR), DV1-E106 (magenta, LR), DV1-E111 (cyan, C-C′ loop),
DV2-1A1D-2 (pink, A strand), DV3-2H12 (light green, AB loop), and DV4-4E11 (pink, A strand). (B)
JEV E-DIII epitopes defined by alanine-scanning mutagenesis are depicted on the JEV E-DIII structure
(based on the full-length JEV E structure, PDB accession no. 3P54). (C) JEV epitopes defined by alaninescanning mutagenesis, HDX mapping, and surface exposure are shown in the context of the full-length JEV
E structure.
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Figure 5.7: Protective efficacy of anti-JEV mAbs in mice.
(A and B) Four- to 5-week-old male C57BL/6 mice were passively administered 10 µg of the indicated (A)
mouse or (B) human MAb via intraperitoneal injection 1 day prior to inoculation with 102 FFU of JEVNakayama via the subcutaneous route. JEV-31 (n = 9), JEV-106 (n = 8), JEV-143 (n = 8), and JEV-169
(n = 10) provided complete protection against lethality. JEV-27 (n = 8), JEV-128 (n = 9), and JEV-131 (n =
9) provided partial protection compared to the isotype control mAbs. (C and D) Three-week-old male
C57BL/6 mice were passively administered 10 µg of the indicated mAb as described above 1 day prior to
inoculation with 103 FFU of (C) JEV-MAR 859 (JEV-31, n = 8; JEV-131, n = 9; JEV-169, n = 8) or (D)
JEV-2372/79 (JEV-31, n = 9; JEV-106, n = 9; JEV-131, n = 9; JEV-169, n = 9). (E and F) Two hundred
fifty micrograms of the indicated mAb was administered 5 days postinfection to (E) 4- to 5-week-old mice
infected with 102 FFU of JEV-Nakayama (JEV-31, n = 9; JEV-106, n = 9; JEV-143, n = 9; JEV-169, n= 9;
hJEV-75, n = 8) or (F) 3-week-old mice infected with 103 FFU of JEV-2372/79 (JEV-31, n = 10; JEV131, n = 9; JEV-143, n = 9; JEV-169, n = 10; hJEV-75, n = 9). Data are pooled from at least two independent
experiments. Survival was analyzed for each MAb compared to the isotype control mAb by the log rank
test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
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Figure 5.8: Alignment of sequences of different JEV strains.
Genotypic differences from the JEV-SA14-14-2 strain (GIII) are highlighted as shaded black residues.
The secondary structure elements above the alignment are derived from the structure of JEV E protein
(PDB accession no. 3P54). The GenBank identification numbers for each viral sequence are described in
Materials and Methods. The JEV-Nakayama strain includes an unknown amino acid at position 209
(denoted by an X).

189

Chapter 6:
Conclusions and Future Directions

190

6.1

Summary and Future Directions: mAb-defined ZIKV epitopes
We initially mapped a panel of human- and murine-derived ZIKV neutralizing and nonneutralizing mAbs1. These studies identified two epitopes bound by non-neutralizing mAbs
and multiple epitopes bound by mAbs that neutralize with variable efficacy.
Cross-reactive mAbs to flavivirus infections have been largely mapped to the fusion
loop epitope of DII (DII-FL)2–4. The DII-FL is highly conserved across flaviviruses and
although bound by type-specific mAbs, these tend to be weakly neutralizing5. We isolated
one murine (ZV-13) and two human (ZIKV-12 and ZIKV-15) mAbs that recognize the
DII-FL. Binding studies with ZV-13 identified cross-reactivity with flaviviruses, including
all DENV serotypes that share 54-59% homology by alignment of the E protein amino acid
sequence6 and the more distantly related JEV, with 53% homology by E protein. Previous
studies have shown variable in vitro neutralization efficacy of DII-FL specific mAbs. For
example, DV2-305 and WNV-E534 neutralized their respective viruses while DV2-36 and
WNV-E28 were unable to neutralize their indicated flaviviruses. Neutralization studies
with ZV-13 demonstrate an inability to inhibit infection against any of the ZIKV strains
tested. Conversely, DENV-derived cross-reactive 2A10G62 neutralized ZIKV in vitro and
provided complete protection against ZIKV in a murine lethality model7. A consequence
of DII-FL specific mAbs is the potential for antibody-dependent enhancement (ADE),
where previous cross-reactive mAbs are present but fail to neutralize a secondary infection
and instead augment infection in FcR-bearing myeloid cells8. This phenomenon has been
observed in vitro and in vivo in the context of sequential DENV infection of differing
serotypes. We described the ability of ZV-13 to enhance secondary DENV and ZIKV
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infection in vitro. Recently, convalescent plasma from DENV- or WNV-infected patients
was shown to enhance secondary ZIKV infection in vitro and in vivo as shown by increased
lethality and disease score, particularly for those receiving the plasma from DENV-infected
patients9. An important consideration is the predominance of the human immune response
to the cross-reactive epitopes instead of the type-specific immune response10. Future
studies should focus on identifying features of the cross-reactive mAbs that are promote
protection in order to skew the humoral immune response toward a broadly-neutralizing
response. Vaccine design will need to take this into consideration in order to avoid
sensitizing recipients to subsequent augmented disease, especially if vaccines will be
implemented in regions where DENV and ZIKV co-circulate.
The antibodies that bound E-DIII were specific to ZIKV and were the most strongly
neutralizing. Within DIII, the lateral ridge (DIII-LR) specific mAbs (ZV-54 and ZV-67)
reduced in vitro infection of four strains of ZIKV representative of the two current lineages.
Similarly, ZIKV-116, a human mAb isolated from an infected patient was also a potent
neutralizer of ZIKV in vitro, with reduced inhibitory activity against the historical strain
MR 766. Administration of ZV-54 or ZV-67 one day prior to infection was able to confer
complete protection in a murine lethal model of infection. Previous studies on related
flaviviruses have shown a similar protective in vivo effect of DIII-LR specific mAbs
against lethality by WNV11, DENV-112, and DENV-25. The mechanism of neutralization
of the human and murine mAbs is undertermined but studies with a comparable mAb (E16)
against WNV13 indicates inhibition at a post-attachment step, potentially by inhibiting
fusion at the plasma membrane. The ability of DIII-LR mAbs against ZIKV to bind and
neutralize may be potentiated by the accessibility of the epitope on the mature virion, as
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was observed by docking ZV-67 onto a previously published cryo-EM structure of a mature
ZIKV virion14,15.
A second E-DIII epitope bound by neutralizing ZIKV mAbs (ZV-48 and ZV-64) is the
C-C’ loop, a cryptic epitope found to also be important in related flaviviruses16. Previous
studies conducted with DV1-E111 found the C-C’ loop residues bound by mAb to be
important for E-dimer associations on the mature virion indicating that exposure of this
epitope may require structural reorganization. The variability in neutralization of DV1E111 against different DV1 strains also highlights potential structural organization
variation that impacts mAb binding and therefore neutralization. This group of mAbs were
unable to neutralize heterologous strains of ZIKV in vitro and compared with ZV-54 and
ZV-67 had higher EC50 values against the ZIKV strains against which they were derived
(H/PF/2013). The last E-DIII epitope bound by ZIKV-specific mAb (ZV-2) was the ABDE
sheet, a site exposed on the mature virion, conserved between ZIKV strains, but is highly
divergent across flaviviruses and is therefore not cross-reactive. An analogous mAb against
DENV, 2H12, was found to bind six of the same residue positions17. However, 2H12 does
neutralize multiple serotypes of DENV and may only bind in the context of extensive
conformational changes implying that it may only exist as a cryptic epitope. Future studies
may interrogate whether there are variations in E-dimer associations between flaviviruses
that may permit the same site to be exposed in one virus (as in ZIKV) but cryptic in another
(DENV). Differential binding analysis by biolayer interferometry further confirmed the
neutralization profiles as the most potent, DIII-LR specific, neutralizing mAbs (ZV-54 and
ZV-67) had greater binding affinity and slower dissociation rates compared to the C-C’
loop (ZV-48 and ZV-64) and ABDE (ZV-2) mAbs.
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Lastly, mAbs against structural epitopes in ZIKV were found to be potently
neutralizing in vitro and protective in adult and pregnant models of infection. ZIKV-117
was isolated from a ZIKV-infected patient and potently neutralized all five strains of ZIKV
against which it was tested in vitro. Therapeutic administration of ZIKV-117 one or five
days post-infection conferred complete protection against ZIKV lethality in adult male
mice. Administration of ZIKV-117 in three models of infection early in pregnancy (E6.5)
demonstrated 1) Ifnar+/- pups had 90% protection against ZIKV induced lethality when
ZIKV-117 was administered one day prior to infection 2) wild-type (WT) dams and the
pups had reduced viral load in the placenta and fetal when ZIKV-117 was administered
one day prior to infection and 3) WT dams and pups had reduced viral load in the placenta
and fetal heads when ZIKV-117 was administered one day after infection. Dams and pups
were assessed seven days post-infection including maternal tissues to determine viral
distribution and we observed that prophylactic administration prevented virus from
entering maternal brain while therapeutic administration only decreased the viral load
present in the brain. Epitope mapping by alanine scanning mutagenesis identified residues
within E-DII but not those comprising the DII-FL. Subsequent cryo-EM studies
demonstrated that ZIKV-117 cross-links the E monomers within a dimer also identified a
novel binding pattern in which ZIKV-117 can also cross-link the E monomers across the
E dimer18. This pattern of binding may sterically impede mAb binding and thus saturation
can be achieved at lower concentration.
The E-dimer epitope (EDE) was introduced in Chapter 1 as eliciting protective mAbs
against DENV and ZIKV19,20. The EDE epitope is made up of residues present in all three
domains within the E protein and as such, can only be found in the whole virion. In vitro
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studies with a panel of EDE1 and EDE2 mAbs found the ability to neutralize multiple
strains of ZIKV representative of the Asian and American lineages. EDE1-B10 was able
to bind and neutralize multiple strains of ZIKV in vitro. We first determined the kinetics
of viral seeding of immune privileged sites in an adult murine model following infection
and found that by two days post-infection, the brain, testis, epididymis, and eye had become
infected with ZIKV. We next assessed the ability of EDE1-B10 to protect immune
privileged sites from viral seeding when administered at different time points following
infection in the acute and long-term stages. When administered one day post infection,
EDE1-B10 was able to reduce viral seeding significantly suggesting that it was preventing
viral entrance into the immune privileged sites. Administration of EDE1-B10 at three days
post infection showed limited protection in the acute phase of infection (day +5) but more
marked reduction when assessed long-term (day +21) indicating that while it may reduce
viral burden in immune privileged sites, it was not completely able to prevent seeding.
Follow up studies demonstrated that EDE1-B10 was able to reach immune privileged sites.
Treatment with EDE1-B10 five days post infection was unable to reduce infection
indicating that viral seeding had occurred and viral replication had exceeded the potential
for mAb neutralization. Two additional important findings from the study in male mice
were 1) the eye was negative for viral RNA by 21 days post-infection for the isotype- and
EDE1-B10 treated mice indicating that it is naturally cleared and 2) EDE1-B10
administration up to three days post-infection was able to rescue testicular damage and
sperm motility. In the pregnancy model of infection, systemic prophylactic EDE1-B10
administration was able to reduce viral RNA burden in maternal tissues (brain and female
reproductive tract) and fetal tissues following intravaginal infection.
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The potential for immune enhancement following secondary infection has been
previously discussed. Briefly, sub-neutralizing levels of mAb from a primary infection may
bind virus and allow for viral internalization by Fc-receptor mediated pathways. The
internalization of virus can subsequently permit viral replication for release on infection
progeny. In order to address this concern, studies using the structural mAbs (ZIKV-117
and EDE1-B10) modified at the Fc-receptor binding region (LALA) were completed. In
vitro studies demonstrated equivalent neutralization against multiple strains of ZIKV by
ZIKV-117 LALA and EDE1-B10 LALA as well as an inability to cause antibodydependent enhancement (ADE) in myeloid cells. Administration of ZIKV-117 LALA
prophylactically or EDE1-B10 LALA one day following infection showed equivalent
reduction in viral RNA burden following subcutaneous infection. This result indicates that
LALA variants of strongly neutralizing mAbs ZIKV-117 and EDE1-B10 may be
considered as prophylactic or for acute administration following infection without risk of
severe disease resulting from enhancement.
Our studies have focused on single mAb therapy administration for reduction of viral
burden which may limit the window at which protection can be observed. Future studies
should look into combination mAb therapy at later time points post-infection. Furthermore,
our studies in wild-type mice were completed with a mouse-adapted strain of ZIKV that
may vary from contemporary, circulating strains. In vitro assays indicate that in vivo
protective efficacy will be observed but our mAbs will need to be evaluated in other models
of infection as they continue to arise. It will be important to test our panel of mAbs,
particularly the human-derived mAbs, in non-human primate models of infection.
6.2

Summary and Future Directions: mAb inhibition of JEV
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We generated a panel of eight anti-JEV mAbs from mice immunized with the
vaccine (JEV-SA 14-14-2) or virulent strains (JEV-Nakayama and JEV-Bennett) of JEV.
We identified six mAbs to be directed at DIII, one mAb against DI (JEV-169), and one
mAb (JEV-117) to unable to bind either domain by ELISA but able to bind the full-length
E protein. In vitro neutralization studies against a panel of JEV strains representative of the
four lineages indicates a wide breadth of neutralization efficacy against the different
genotypes and between strains of the same genotype. We tested individuals mAbs in vivo
against JEV-2372/79 (GI) or JEV-Nakayana (GIII) in a murine lethal model of infection
and noted that the strongest neutralizing mAb in vitro, JEV-169, was not consistently the
most protective mAb. Future studies should identify residue-level mapping of JEV-169 to
determine if the site is variably exposed during viral maturation which may explain
discrepancy observed in vitro and in vivo data.
We also identified two human-derived mAbs from vaccinated individuals that are
able to neutralize the panel of JEV representative of the four genotypes. hJEV-69 bound
E-DIII by ELISA and alanine scan mutagenesis indicated loss of binding at various
residues, however, a pattern consistent with an epitope is yet to be determined. hJEV-75
was strongly neutralizing against JEV-SA 14-14-2 and significantly decreased
neutralization potential against JEV-JKT 7884 (GIV). Domain mapping by ELISA was
unable to identify binding of hJEV-75 to a specific domain and alanine scan mutagenesis
of E-DIII indicated a single residue, E373, for loss of binding. In vivo studies with
prophylactic administration of human-derived JEV mAbs indicated 80% and 100%
protection by hJEV-69 and hJEV-75, respectively.

197

The time course to lethality varies across flaviviruses and while the kinetics of viral
dissemination has been extensively studied in realted viruses, such as DENV, WNV, and
ZIKV, similar studies have been limited in JEV. Future studies should aim to understand
the kinetics of viral entry to the central nervous system as that usually precipitates lethality.
Particularly, it should be determined whether there are differences in viral dissemination
kinetics between strains of JEV that may alter the window of therapy between strains of
JEV. Lastly, the emergence of a GV strain raises the concern of efficacy of current
vaccination on emerging strains, therefore currently available panels of mAbs should be
tested in vitro and in vivo against JEV-Muar (GV) to determine further breadth of humoral
response.
6.3

Conclusions
The rapid rise of ZIKV infections and the associated clinical manifestations that
occurred in 2014 suggests that there is potential for emerging arboviruses to cause sudden
distress. Similarly, the emergence of new genotypes of existing flaviviruses, such as JEV,
suggests that current flaviviruses have the potential to alter their current infectious
capability by further altering their genome. The work presented in this dissertation provides
insight into how current vaccination strategies may be optimized to improve breadth of
protection by epitope analysis and the potential for acute management of emerging
flaviviruses.
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